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ABSTRACT
The effect of guanethidine (1.20 mg/kg, i.p.) or reserpine (0.2
mg/kg, i.p.) has been compared on various indices of pituitary-adrenal
stimulation in rats subjected to chronic forced restraint for 24 days.
This was accomplished by analyzing the serum corticosterone, the adrenal
ascorbic acid (AAA) and various organ weights such as the adrenals, brain
and heart.

Peripheral and central norepinephrine (NE) was also measured.

Chronically stressed, control rats or those treated with guanethidine
demonstrated both behavioral and neurochemical adaptation.

Initial exci-

tation associated with restraint was related to changes in NE in the brain
and heart.

As the experiment progressed, the stressed, guanethidine-

treated animals showed changes in peripheral NE that were similar to those
of the stressed, vehicle-treated animals; whereas, the non-stressed guanethidine-treated animals showed a progressive decline in peripheral NE
over the 24 day study.

This change in the peripheral NE in the stressed,

guanethidine-treated animals was attributed to increased production of
NE, perhaps by the adrenals, since low doses of guanethidine do not
affect adrenal catecholamines.
Reserpine-treated, stressed animals showed 40% mortality over the
24 day period, thus indicating non-adaptation.

This increased mortality

was not due to starvation or decreased water intake.

It is suggested

that non-adaptation in these animals may be due to a chemical sympathectomy, and the animals were unable to respond to severe · changes · in the
environment.
Changes in behavior, in the different groups of animals, were correlated with changes in brain NE.

Evidence is also presented indicating

that reserpine and guanethidine do not deplete heart NE by the same
mechanism(s).
iv
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I.

INTRODUCTION

The life of an animal depends upon its ability to adapt to changes
in both internal and external environment; for example, one of Claude
Bernard's classical experiments demonstrated that adaption to cold
exposure involved heat production from two main sources:

muscular

activity and chemical processes other than those concerned with muscular activity.

Research in this field has shown· that adaptation to

changes in environment or to a stimulus (stressor) involves an interplay between the central nervous system (CNS), the autonomic nervous
system (ANS) and the endocrine system.

In many species, including man,

every type of stress activates the anterior pituitary-adrenocortical
system (Tepperman, 1962).

A discharge of sympathin, thought to be a

mixture of epinephrine (E) and norepinephrine (NE), from adrenergic
nerve endings, has also been shown to occur during systemic stress.

In-

asmuch as adaptation involves nervous activity, numerous studies have
been carried out to determine the effects of various drugs on the central
and peripheral nervous systems.
The major function of NE in the body is as the dominant transmitter
released from sympathetic adrenergic neurons of mammals (von Euler, 1956).
In view of the presence of both NE and dopamine in brain neurons having
the same characteristics as sympathetic adrenergic neurons, it is probable that NE also serves as the transmitter in the CNS (Hillarp et al.,
1966a).

Maynert and Klingman (1961) discussed the possibility that brain

NE functions as part of the sympathetic nervous system and that its
release is accompanied by arousal or excitement.

Trendelenburg (1963)

reported that the nerve terminals of adrenergic fibers have functions

l
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other than just those concerned with the synthesis and release of NE.
The NE stores are important sites of action for various drugs, and the
ability of the stores to take up various sympathomimetic agents has been
the subject of much important physiological and pharmacological research.
Leblanc and Nadeau (1961) and Leduc (1961) showed that exposure of
an animal to cold produced a significant and immediate increase in urinary excretion of NE.

These observations drew attention to the important

role of both the adrenergic nervous system and the adrenal glands in cold
adaptation and survival.

Others have shown that catecholamine (CA)-

depleting drugs, such as reserpine, prevented the normal physiological
responses to cold, leading to poor adaptation and death (Zilberstein,
1960; Taylor, 1961); a close relationship between cold resistance and
urinary excretion of NE was obtained in such treated animals (Johnson,
1963).

Previous work in this laboratory (Rosecrans and DeFeo, 1965)

showed first, that reserpinized animals subjected to chronic restraint
stress (CRS) had a 50% greater mortality than did similarly treated rats
which were not stressed, and second, that the reserpinized animals subjected to stress showed a decreased food and water intake.

The question

therefore arose whether this increased mortality might be due either to
depletion of the central and/or peripheral NE or to starvation.

Since

non-adaptation may be associated with interference with some physiological
mechanism(s), the question was further refined to include a study of the
relationship between the apparent exhaustion of NE with non-adaptation
(Rosecrans, 1963).
These reports and others indicated the importance of NE in the
survival of rats subjected to stress.

However, it is difficult from

studies such as these to determine whether the decreased resistance was

3
due mainly to a peripheral or central action of reserpine, since this
drug has important depleting effects on both brain CA and indolamines
(Sheppard and Zirrnnerman, 1960a), on peripheral CA (Orlans

et~.,

1960),

and produces marked sedation.
In the present study guanethidine was selected to evaluate the
importance of the peripheral liberation of CA.

Guanethidine is a potent

sympatholytic drug, which blocks nervous transmission in the noradrenergic
postgangl i onic fibers (Maxwell et al., 1960a) and depletes various peripheral organs of their CA content without affecting amine stores in the
brain (Kuntzman et al., 1962).

This drug does not cross the blood-brain

barrier to any appreciable extent (Kuntzman et al., 1962).

Further,

guanethidine, contrary to reserpine, does not impair the resistance of
rats exposed to very low temperatures (Pouliot and Leblanc, 1963).
An additional purpose of the present investigation was to evaluate

more precisely the importance of peripheral secretion and action of NE
vs the central secretion and action of NE in the defense against stress
and the involvement in adaptation.
In summary, this work was designed to test the following hypotheses:
1.

Increased mortality of reserpine-treated rats subjected to
chronic restraint may be due to :

2.

a.

depletion of central NE,

b.

depletion of peripheral NE,

c.

depletion of both central and peripheral NE,

d.

starvation.

Non-adaptation of rats subjected to chronic restraint is due at
least in part to exhaustion of central and/or peripheral NE.

II.

LITERATURE SURVEY
A)

1.

STRESS

Introduction
The term "stress" is undoubtedly one of the most impressive terms

in the lexicon of science; but like many words, it means different
things to different people.

The term probably originated in the field

of engineering; and to the engineer it means an external force directed
at some physical object, with the result of "strain" and temporary or
permanent alteration in the structure of the object.

The word has also

been borrowed for use in literature and conversation to indicate a
special force or emphasis exerted on some word or idea in speaking or
writing.
The concept of stress was first introduced into the life sciences
by Hans Selye in 1936 and elaborated in successive papers, leading to
a full theoretical statement in book form in 1950.

Today, many writers

in physiology and psychology have adapted the engineering convention;
stress being the external agent or stimulus and strain being the resultant.

This usage is probably appealing because of the ease with which

it seems to fit into the concept of homeostasis.
From the homeostatic point of view, a stress is some stimulus
condition that results in the disruption of equilibrium in a system
and produces changes in that system against which mechanisms of equilibrium are activated.

One example of such mechanisms at the physiological

level is Selye's adaptation syndrome, which is an elaborate series of
neural-hormonal reactions against the effects of noxious agents on the
tissue system.

However, Selye (1956) has been instrumental in

4
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stimulating a reversal of the engineering convention for the language
of stress.

He refers to the "noxious" stimulating condition which pro-

duces stress reactions as the "stressor"; and the reaction is called
the stress.

Sometimes Selye uses the term "stress" to refer to the

initial impact of the stressor on the tissue, sometimes to the adap tive mechanisms whose function it is to restore homeostasis, and
sometimes to the wear and tear, damage, or disease consequences of prolonged homeostatic processes.

There are at least three meanings here

to the term "stress", even though the word always refers to the state
or reaction of the animal's tissue systems to the stressor or noxious
stimulus.
It makes little difference, however, if the external force is
called a stress or stressor, or whether the effect on the animal is
called stress or strain.

It is important that we are consistent in

our terminology, that the definition of terms is clear, and that the
connotations of terms come as close as possible to the analogy intended
by theory .

For example, "strai n" is a poor analogy to adaptive or

homeostatic mechanisms, but "adaptive syndrome" is more suitable.
2.

History
It would be impossible to do justice to Selye's concept of stress

in the few short paragraphs to follow.

His own work on this subject

has extended over four decades and has resulted i.n over a thousand publications.

Selye (1936) found antecedents for his work in the concept

of Hippocrates, that disease is not only suffering but also toil; that
is , the fight of the body to restore itself to normal.

Claude Bernard's

(1859) description, that one of the most characteristic features of all

6

living beings is their ability to "maintain the constancy of their
internal milieu", despite changes in the surroundings, was an acknowledged base for Selye (1950) and also for Cannon (1932) in the development of his concept of homeostasis.
Cannon suggested that the ANS is the initiator of adaptive
mechanisms.

He proposed that under environmental changes, ANS

stimulation, especially plasma adrenalin, could initiate cellular preparedness and permit adaptation.

His main experimental approach was

total or partial sympathectomy where homeostatic responses were observed under normal and stress conditions.
Selye, dissatisfied with Cannon's theory, did a series of experiments demonstrating that any animal presented with a noxious stressor
would respond in a very characteristic manner elicited by adrenalcortical hyperfunction due to stimulation of the anterior pituitary.
The theories of Cannon and Selye do not necessarily conflict but
together tend to present the overall picture of the concept of stress.
While the classical observations of Cannon clearly pointed to the
adrenal medulla as an important reactor in response to disturbing
factors, Selye studied the adrenal cortex and placed more emphasis on
the pituitary-adrenocortical system.

However, both of these systems

are operating in stress conditions, and the type of reaction depends
on the nature of the stressing factors.
There is little doubt of the central position of the pituitaryadrenal axis in adaptation; however, ANS activity is also important.
George Sayers (1950) compared these relationships.

He stated that the

adrenal-cortical hormones play a generally supportive role rather than
an initiating role in bodily processes; whereas the adrenal medulla

7

initiates cellular and metabolic changes in response to an emergency.
Also, the adrenal cortex plays a passive role and makes it possible for
various regulatory systems to expend the additional effort necessary
for homeostatic adjustment.
3.

General Adaptation Syndrome
Selye pointed out that, although different disease syndromes have

unique properties and symptoms, they have many features in corrnnon, and
it is these common features that constitute stress .

Disease is not just

suffering, but a fight to maintain the homeostatic balance of our tissues,
despite damage.

Se lye's definition of stress is as follows:

"Stress

is a state manifested by a specific syndrome, which consists of all the
non-specifically induced changes within a biological system."

Thus

stress has its own characteristic form and composition but no particular
cause.

It may be described more simply as the rate of wear and tear in

the body.

It is increased during nervous tension, physical injury,

infection, muscular exertion or any other strenuous activity, and is
connected with a nonspecific defense mechanism which increases resistance to stressor agents.

An important part of this defense mechanism

is the increased secretion by the hypophysis of adrenocorticotrophic
hormone (ACTH), which in turn stimulates the adrenal cortex to produce
corticoids (gluco- and mineralocorticoids).
Selye postulated that organisms subjected to alarming stimuli will
respond in a given manner, which he termed the "stress syndrome" or
"general adaptation syndrome" (GAS).

The GAS evolves in three stages:

the initial stage, or the "alarm reaction" (AR) during which defensive
forces are mobilized; a secondary stage, the

11

stage of resistance",
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which reflects full adaptation to the stressor; and, finally, the "stage
of exhaustion" which follows when the stressor is severe and applied for
a prolonged period.

The AR is associated with the discharge of ACTH, cortical steroids
(CS), and CA, plus various other physiological changes such as autonomic
excitability, heart rate, muscle tone, blood content changes and gastrointestinal ulceration.

During the second stage, there is an adaptation

to the stressor which results in a diminished reaction and thus increased
resistance.

Depending on the nature and intensity of the stressor and

the condition of the organism at the time of exposure, the period of
resistance may be short or prolonged.

Finally, when the animal can no

longer adapt to or compensate for the prolonged overexposure to the stressor, it will pass into the exhaustive stage and death ensues.
Berry and Buckley (1966) reviewed the physiological responses to
stress as suggested by Selye (1955).

The responses are as follows:

the stressor acts on the body or some part of it directly by way of the
pituitary and adrenals.

An immediate discharge of ACTH stimulates the

release of corticoids from the adrenal cortex.

If the stress is ex-

tremely severe, the adrenal cortex shows morphological changes characteristic of hyperactivity.

Simultaneously, the animal's corticoid

requirement markedly increases, and there is an increase in the blood
concentration and urinary excretion of corticoids and their metabolites.
There is a general stimulation of the sympathetic division of the ANS;
and the splanchnics induce the adrenal medulla to discharge E and NE,
thus increasing the discharge of NE at various peripheral receptor sites
and causing the cardiovascular responses of vasoconstriction and hypertension.

Other physiological changes include alterations in water and

9

electrolyte metabolism, gluconeogenesis and increased blood sugar levels,
alteration in both red and white blood cell counts, and · increased renin
production by the kidney.
Selye (1950) reported that alm~;

aU

the changes caused by systemic

stressors follow a characteristic triphasic course, in which the direction of the deviation from the normal is the same in the AR (stage one)
and the stage of exhaustion (stage three) but is reversed in the stage
of resistance (stage two).

For example, the adrenals lose lipids in

stages one and three, but store lipids in stage two; the thymus discharges thymocytes in stages one and three, but stores them in stage
two; there are hypoglycemia and hypochloremia in stages one and three,
but hyperglycemia and hyperchl.oremia in stage two.

This explains many

of the apparently contradictory findings reported in the literature concerning the effects of exposure to systemic stressor agents.

Hence, the

changes produced by stressors in the various targets cannot be discussed
without consideration of the time-relations as stated above.

There are

also organ weight changes which characterize each particular stage of
the stress syndrome.

In general, there is adrenalcortical enlargement

and hyperactivity; there is atrophy of the thymus, the spleen and lymph
nodes and of other lymphatic structures in the body during the AR.
Gonadal weight is also decreased during this stage.

In the latter

stages of the syndrome these changes will persist or return to the
normal.
Throughout the stress syndrome, numerous biochemical patterns
change, an indication of specific homeostatic adjustments.

Changes in

adrenal weight provide some information on endogenous ACTH secretion;
however, adrenal weight alone does not reflect rapid modifications in
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ACTH secretion.
ACTH are :

Other changes that are attributed to the release of

a fall in adrenal ascorbic acid (AAA); a rise in plasma

corticosterone; an increase in livertrypt~~~ pyrrolase (TP) activity; and an excessive mobilization of free fatty acids (FFA) from
body fat depots (Westermann, 1962).

Increases of adrenocorticosteroid

output and decreases in adrenal cholesterol (Fortier

et~ . ,

1950) and

ascorbic acid (Sayers and Sayers, 1947) have been reported as good indexes of adrenocortical hyperact i vity.

Within the past decade numerous

analytical methods have been developed for the direct measurement of
ACTH (Lipscomb and Nels on, 1962; Munson and Toepel, 1958) and for the
direct analyses of plasma and adrenal corticosteroids (Guillemin
1958; Zenker and Bernstein, 1958) .

~ ~!·•

These methods have greatly enhanced

recent investigations concerning the pituitary-adrenal axis.
4.

Pituitary-Adrenal Axis and Stress
Selye (1950) reported that , before a stressor will elicit a normal

GAS response, it must first reach the centers of the two coordinat ing
systems

responsible for set t ing this defense reaction into motion .

These are the hypothalamus, as a center of the ANS, and the anterior
pituitary , as the chief coordinator of the endocrine glands .

Smith

(1927), one of the first researchers in this area to study the relationship between adrenocorti c al act i vity and the pituitary gland, demonstrated
a rapid adrenal cortical atrophy due to hypophysectomy.

Selye (1936)

reported that a number of "nocuous" treatments, which varied greatly in
their nature and specific effects, possessed a common property :
ability

the

to produce hypertrophy of the adrenals and involution of the

thymus in the intact rat .

Following hypophysec tomy, however, although
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the specific effects were again produced, the nonspecific effects on
the adrenals and thymus failed to appear.

Since that time, it has been

demonstrated that, every type of stressor activates the anterior pituitary-adrenocortical system .
Selye (1950) reported that, upon exposure to numerous types of
stress, the anterior pituitary responds with an increased production of
ACTH, thus causing a release of the adrenal cortical hormones.

He also

reported that there is some evidence to indicate that certain stressors
may affect the anterior pituitary by way of the hypothalamic center.
Selye's discovery initiated a great deal of research in the many aspects
of endocrinology of the anterior pituitary-adrenocortical axis.

One of

the most important aspects, which is still being investigated, is the
CNS control of the anterior pituitary function .

Because the activation

of the anterior pituitary-adrenocortical axis occurs in response to
practically all experimental procedures in intact animals, it has been
extremely difficult to analyze the mechanism of activation .

This pro-

blem became more complex after it was demonstrated that the secretion
of ACTH from the anterior pituitary is increased by neurohumors from
hypothalamic areas (DeGroot and Harris, 1950) .

This development was

preceded by a large number of publications assigning the role of
"activator" of anterior pituitary to many substances occuring in the
body.

However, the work of Guillemin (1958; 1959b), Saffran (1959a;

1959b) and others, demonstrated that the hypothalamus exerts its effect
on the pituitary via a hormonal substance, which when brought to the
anterior pituitary through the hypophyseal portal vessels, stimulated
the secretion of ACTH .

This polypeptide, which is probably related to

vasopressin, has been named the corticotrophin releasing factor (CRF).

12
Another physiological possibility involved in the anterior
pituitary regulation is that the CNS exerts some chronic inhibitory
influence over the hypothalamic mechanisms which st i mulate ACTH release (Porter, 1954; Egdahl, 1961).

The basic role played by stress in

the act i vation of the pituitary-adrenal axis has been reviewed by numerous investigators, such as Fortier (1962) and Reichlin ( 1963) .

The

mechanism of ac tivation of ACTH is di scussed in detail by Hilf (1965).
A more detail ed di s cussion on the synthes i s and control of ACTH secretion in normal and stress conditions is given by Ganong (1963) and
Mangil i

~~

al. (1966) .

Ganong (1 963) concluded that there is an increase in ACTH
secret ion to meet emergency situations .

The ACTH is carried along the

pathways that funnel through the median eminence .

He states that there

is a basal level of ACTH secretion that is independent of these pathways
but not necessarily independent of neural control.

He further states

that the hypot halamus and the pitu it ary function as a unit in the response to stress and that the ACTH secretion rate in stressed animals
is determined by the balance struck between the hypothalamic
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drive 11

and the degree to which circulating cor ticoid levels inhibit ACTH secretion.

Corticoids inhibit ACTH secretion by an effect on its syn-

thesis and probably by an additional acute blocking effect .
conclusions were reported by Chowers et al . (1 967) .

Similar

They stated that

corticosteroids act directly on the hypothalamus to decrease CRF release and content and to influence storage and release of ACTH.

Their

findings support the view that, under certain conditions, corticosteroids
exert an inhib itory effect on the hypothalamus as well as on the anterior
pituitary .

Mangili et al . (1966) discuss data clearly indicating that
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the CNS plays an essential role in the control of the pituitary-adrenal
axis, both in basal conditions and during stress-induced activation.
They discussed the fact that it is not yet clear whether the same nervous
pathways which control ACTH secretion through the steroid feedback mechanism are also involved in the activation of the pituitary during stress.
They cited evidence to indicate a certain degree of independence between
these two systems and supported the hypothesis that two seperate mechanisms are involved in the control of the pituitary-adrenal axis .

This

does not mean, however, that the two mechanisms are operating independently.

There is ample evidence to prove the contrary, that is, that the

final adjustment. of the secretory activity of the pituitary results from
a close interplay between the activating impulses (stress) which reach
the pituitary and the feedback effect of the steroids .
5.

Cathecholamines and Stress
E is discharged from the adrenal medulla during various types of

systemic stress.

A discharge of NE from adrenergic nerve-endings also

accompanies systemic stress.

The presence o f some NE-like entity is

thought to participate in the adrenergic response to stress .

This dis-

charge of its adrenergic hormones by the adrenal medulla during the GAS
appears to be mainly, if not entirely, a result of splanchnic stimulation
(Selye, 1950) .
Stressing factors involving the CA-producing systems may either induce a reaction from the adrenal medulla , chiefly provoking an increased
release of E, or activating the NE-producing nerves, or both.

The E-

release is the most common response t o a variety of stressing factors,
particularly those which invo lve a certain degree of emotional discomfort.
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From this point of view, the E-secretory response is in a sense unspecific .

Activation of the NE system appears to result from more specific

stimuli, which bring blood pressure and temperature homeostasis into
action (von Euler, 1964).
When NE is considered, the concern is not with the adrenal medulla
but rather with the ANS and, more spec ifically, with its sympathetic
branch .

NE is a chemical transmitter of the postganglionic sympathetic

nerves (von Euler, 1951) .

Very little NE comes from the adrenals in man,

as revealed by the slight effect of total adrenalectomy (von Euler , 1955).
The stimulus for adrenomedullary discharge travels via preganglionic
sympathetic pathways from the hypothalamic nuclei which are in close
anatomical relation t o the autonomic "centers" (Folkow and von Euler,
1954) .

Ordinarily, sympathetic activation accompanies adrenomedullary

discharge .
Leduc (1961) reported a constant and considerable increase in the
NE excretion in rats exposed to cold .
secretion .

There was also an increase in E

However, if the NE release in these rats was prevented by

pharmacologic agents, the animals died :

an indication of the importance

of this react i on as a homeostatic mechanism in the metabolic sector .
Other investigators have reported the import ance of NE in cold adaptation (LeBlanc and Pouliot, 1964; LeBlanc et al . , 1967).
Gutman and Weil -Malherbe (1967) studied the subcel.lular distribution
of NE in the heart and spleen in rats after exposure to cold.

Exposure

to -15° for 90 minutes induced release of NE from the coarse, particulate, and soluble fraction of heart mus c le .

Chang and Su (1967) exposed

rats to cold for two hours to study the effect of increased sympathetic
activities on the subcellular distribution of NE in the heart.

Cold
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exposure caused a 30% decrease of total NE content in both auricles and
ventricles of normal or adrenalectomized rats.

They suggested that the

NE in the particulate fraction is the functional part of the amine available for release by nerve impulses .

Ingenito (1968) reported an increase

in brain NE following 30 days of cold exposure .

He suggested that this

increase is derived from a source similar to that involved in the increases in

pe~ipheral

CA on prolonged exposure to cold.

Hsieh and Carlsson (1957 ) showed that in

cold ~ adapted

rats the

calorigenic effect of NE was potentiated and exceeded that of E.

This

calorigenic effect of NE in cold-adapted rats is considered to be dependent on an increased oxidation of lipids (Hanmon et al . , 1963).
~

Brodie

al. (1966) showed that the emergency mobilization of FFA from fat

depots is under the precise and direct control of NE rel.eased from the
sympathetic nerves and that E from the adrenal medulla is not needed for
this function.

They suggested that moderate exerci se may be fueled by

an increased release of FFA through the action of NE.
Ganong and Lorenzen (1967) reported that mo st stressful stimuli
and drugs which increase ACTH secretion also decrease brain NE .

Con-

versely, the monoamine oxi dase inhibitors (MAOI) increase NE content,
and some of these drugs decrease ACTH secretion .

Levi and Maynert

(1964), however, claimed that the stress-induced decrease in brain NE
is the result of a decline in NE that is outside the nerve endings,
pointing out that changes in NE content do not always accompany changes
in ACTH secretion.

They also reported that stressful stimuli cause in-

creased ACTH secretion, and that adrenal.ectomy has the same effect on
ACTH secretion .

One might expect that brain NE would be decreased by

adrenalectomy; however, adrenalectomy had no effect on brain NE.
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In conclusion, stress and exposure to cold are mainly associated
with an increase in the NE excretion, ·indicat i ng the importance of this
hormone in circulato ry and temperature controlling homeostatic mechanisms.
Mental stress involving exhilaratory or aggressive reactions is also
associated with an increase in the NE excretion.

The types of emotional

stress characterized by apprehension, anxiety, pain, or general dis comfort are regularly acc.ompanied by an increase in the E excretion
(von Euler, 1964).
B)
1.

CATECHOLAMINES

Catecholamine Metabolism
Research on the physiology and pharmacol ogy of the CA during the

past few years has introduced into the literature many excellent reports
concerning the syntheses and metabolism of the CA in the brain and heart
and also the role of these amines as neur ochemic al transducers.

Review

articles (Axelrod, 1963; 1965; Kopin, 1964; Glowinski and Baldessarini,
1966); two excellent symposia (Kr ayer, 1959; Achenson, 1966); and t wo
texts (von Euler, 1956; Wurtman, 1966) are available f or information on
·;

;.·
\\.
1
'

other aspects of CA functi on .
The CA have been rec ognized as hormones , and it is now known that
NE plays a dual

role :

it is the immediate precursor of E; and it is

also considered by many investigators to be the neurotransmitter substance at adrenergic nerve endings.

The steps in the formation of the

CA; E, and NE from phenylalanine were first pr oposed by Blaschko in
1939.

This pathway was estab lished by Gurin and Delluva (1947) who

administered radioactive phenyl alanine to rats and isolated radioactive
E fr om the adrenal gland .

Udenfriend and Wyngaarden (1956) demonstrated
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that, in addit ion to radioactive phenylalanine, radioactive tyrosine
and dopa also form radioactive E in the adrenal medulla.

It is now

accepted that this pathway represents the actual biosynthetic transformations.

Sympathetic nerve preparations are also capable of con-

verting radioactive tyrosine or dopa to radioactive E (Goodall and
Kirshner, 1958).
Some CA are synthesized in the brain (Udenfriend and Zal.tzmanNinenberg, 1963) and in chromaffin tissue such as the adrenal medulla,
but most of it is synthesized in the sympathetic nervous system
(von Euler, 1956).

The starting material. is the amino acid L-phenyl-

alanine, which is converted by a hydrolase enzyme to L-tyrosine (Gurin
and Delluva, 1947).

L-tyrosine can also be taken up by the blood and

is converted by L-tyrosine hydroxylase to L-dopa.

This hydroxylation

is the rate-limiting step (Levett et al., 1.964; Udenfriend et al.,
1966; Neff and Costa, 1.966; Spector et

~·,

196 7) .

Another step is

the conversion of L-dopa .to L-dopamine via the enzyme dopa decarboxylase (Holtz, 1.939; Lovenberg, 1962) .

Dopamine is then converted to

L-NE by the enzyme dopamine-beta-oxidase (Levin

et~.,

1960).

The

properties of this enzyme were reviewed by Schoot and Creveling (1965).
NE is then converted to E by the enzyme, phenylethanolamine-N-methyl
transferase (Axelrod, 1962).
adrenal medulla.

This enzyme is highly localized in the

The biosynthesis of E in the adrenal medulla appears

to be regulated by the pituitary-adrenocortical system (Wurtman and
Axelrod, 1965).
Blaschko and Welch ( 1953) showed that E is stored in chromaffin
tissue and that NE is stored in both chromaf fin tissue and in certain
neurons, including the sympathetic nerves.

The st orage complex contains
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adenosine triphosphate (ATP) and a protein in vesicles or granules
(Hillarp and Nelson, 1954 ) .

The neural storage mechanisms can store

not only locally synthesized by also circulat i ng CA (Axelrod et al.,
1959c), as well as structurally related substances (Crout and Shore,
1964); these mechanisms can also restore a portion of the CA released
from their granules (Mendlowitz

~al . ,

1964).

The uptake of circulating E and NE by various tissues was studied
in animals after the int. ravenous administrat ion of physio l ogical
amounts

of tr itium-labeled compounds (Axelrod e t al., 1959c; Whitby

et al. , 1961).

Within two minutes , heart, spleen, lung , and adrenal

gland took up the largest amounts of the c i rculating amines, while
muscle and brain took up the least .

The large amount of circulating

CA taken up by the heart suggests that these amines discharged from
the adrenal medulla int o the blood stream could serve to stock the
myocardial stores.

Kopin and Gordon ( 1963b) observed that 20% of the

CA stores in the heart are derived from t he circulating NE.

Only

neg ligible qµantities of the circulating CA were taken up by the brain
(Weil-Malherbe et al., 1959; 196la) , a resul t o f the presence of a
blood-brain barrier toward these amines.

The hypothalamus took up

small _ amounts of CA, whi le the pi tu i tary gland and the pineal gland
contained larger concentrat ions of radioactive CA, probably because
the blood-brain barrier is not in the immed i at e area of these structures.

The large amounts of CA that are present endogenously in the

brain are presumably synthesized from pr ecursors that are capable of
crossing the bl ood-brain barr i er .

Glowinski and Iversen (1966) show

that t.here are also differences i n NE turnover rates in specific areas
of the brain .

The rapid uptake and binding of CA occurs mainly in the
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sympathetic nervous system (Hertting and Axelrod, 1961) and is a major
means of CA inactivation (Kopin et

~·,

1962).

The amount of labeled

CA taken up into a tissue is related to the fracti on of the cardiac
output which perfuses the organ and the density of sympathetic nervous
tissue in the organ.

The heart, which has a rich sympathetic nerve

supply and which receives a relatively large proportion of the cardiac
output, takes up a large proportion of the administered CA.

Other

organs which have a rich sympathet ic nerve supply also bind NE (Kopin,
1966).

NE is not only taken up by tissues fr om the circulation but it

is also retained for long periods of time (Whitby et al., 1961).

Evi-

dence that bound NE is present in more than one pool has been derived
both from pharmacol ogic and from biochemical sources .

After the admin-

istration of labeled NE, there is a multiphasic decrease in the radioactive NE remaining in the

heart ~

both in vivo

(Axelrod et al., 196la)

and in vitro (Kopin et al ., 1962), indicating tha t there is more than
one compartment for storage of the amine.

Trendelenburg (196lb) sug-

gested a division of tissue NE stores into a " bound" and an "available"
store.

The binding protects NE from enzymatic attack (Whitby et al.,

1961).
As the CA are released for alpha or beta stimulation (Ahlquist,
1948), they are quickly degraded by enzymes, chiefly monoamine oxidase
(MAO) (Blaschko et al. , 193 '7; Zeller et al. , 1955) and catechol-0methyl transferase (COMI') (Axelrod, 1957).

The physiological activity

of the deaminated or the 0- methylated metabolites is only a fraction
of that of the parent compound , indicating that both types of transformation are inactivating.

After the administration of NE or E, the

main urinary metabolites are vanillyl-mandelic acid (VMA) (Armstrong
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et al., 1957), normetanephrine (NM), metanephrine (M) (Axelrod, 1957)
and 3-methoxy-4-hydroxyphenylglycol (MHPG) (Axelrod et al ., 1959a).
The following minor metabolit es have also been identified:

3,4-dihydro-

xymandelic acid (Kershaw et al ., 1958); 3,4-dihydroxyphenylglycol
(Kopin and Axelrod, 1960); N- acetylnormetanephrine (Smith and Wortis,
1962); N-methyladrenaline and N-methylmetanephrine (Axelrod, 1960) .
Some of these metabolites are conjugated in the liver to form
sulfates and glucuronides; and most of th em, as well as E and NE, can
be detec t ed in the urine and blood under c ertain circumstances (Manger
et al . , 1959; Armstrong and McMillan, 1957; Sjoerdsma et al . , 1959) .
MAO is a nonspecific enzyme; it deaminates alkyl and aromatic
amines that have an amine group attached to the terminal carbon atoms
(Blaschko

et al . , 1937).

This enzyme has been found in all mammalian

tissues, highly localized in the mitochondria (Bl aschko et al ., 1957).
MAO is inhibited by hydrazine derivatives in vitro and in vivo (Zeller
and Barsky , 1952).

Relatively large quant iti es of MAO are present in

sympathetic nerves (Snyder et al . , 1965).

Tyramine, dopamine and sero-

tonin are much better substrates for MAO than NE and E (Kopin, 1964).
When MAO activity is markedly inhibited in the intact animal, there is
a rise in the tissue levels of several mono amines, i ncluding NE and
serotonin (Shore et al ., 1957).

MAO inhibition also depresses the

spontaneous release of stored radioactive NE from sympathetic nerve
endings (Axelrod et al ., 196la) as well as the release of amine following the administrat ion of reserpine ( Shore et al ., 1957) .
COMT has been partially purif i ed and its properties studied
(Axelrod and Tomchick, 1958) .

It catalyzes the transfer of the methyl

group of S-adenosylmethionine to the 3-hydroxy group of catechols.

The
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enzyme is relatively nonspecific and 0-methylates a wide variety of
endogenous catechols such as E, NE, dopamine, dopa, 3,4-dihydroxyphenylacetic acid and 3,4-dihydroxymandelic acid as well as many
foreign catechols.

It does not 0-methylate monophenols.

COMT is

widely distributed in all organ tissues including sympathetic and
parasympathetic nerves, glands, blood vessels and all areas of the
brain; but it is concentrated chiefly in the liver and kidney
(Axelrod and Tomchick , 1958) 0

The enzyme is localized in the cyto-

plasm, in contrast to MAO which is found in the mitochondria.

COMT

is inhibited by pyrogallol (Axel.rod and Laroche , 1959b), catechols
(Carlsson et al., 1962) and tropolones (Belleau and Burba , 1961).
When given to intact animals, COMT inhibitors prolong the action of
administered CA or CA discharged from nerves.
In conclusion then , a hypothetical picture of the metabolism and
storage of CA, as shown by Bertler (1961) is as f oll ows :
1..

tyrosine is the precurs or of dopa;

2.

dopa is decarboxylated in the cytoplasm by dopa decarboxylase;

3.

the dopamine formed is immediately transferred to granules,

which probably are of the same type as the E and NE containing particles.
In these granules dopamine can be stored unchanged as in the caudate
nucleus;
4.

dopamine can also be transformed t o NE;

5.

the amines are liberated from their storage sites by nerve

impulses and then reach their receptors in relatively high concentrations;
6.

outside the granules a continuous inactivation of the CA is

going on by means of MAO and COMT;
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7.

most of the circulating NE is metabolized by 0-methylation;

the remainder is taken up and bound in dense core vesicle in sympathetic nerves;
8.

when NE is released, it is metabolized by MAO within the

nerve or by COMT outside the nerve;
9.

a large amount of the CA is inactivated by being bound again

or by diffusing into the circulation.
2.

Norepinephrine and the Concept of Neurochemi.cal Transducer
Background information on the role of NE as a neurotransmitter is

included in papers by Brodie and Bevane (1963) and Maynert and Kuriyama
(1964).

The sympathet i c or adrenergic nervous system is recognized as

one of the fine regulatory mechanisms in animals.

It is involved in

regulation of blood pressure , carbohydrate and fat metabolism, temperature, eye movement, and many other functions both central and peripheral.
The concept that the sympathetic nerves secrete a physiologically active
compound was first proposed by Elliott ( 1905).

He described the action

of E on smooth muscle organs and on the heart muscle and suggested that
sympathetic nerves release a pressor substance which could then act on
an effector organ.

Many years later, the cl assic experiments of Loewi

(1921) and of Cannon and Uridil (1921) revealed that a chemical substance secreted by the sympathetic nerves is the actual regulatory
agent.

Loewi provided experimental evidence that stimulation of sym-

pathetic nerves resul t ed in the release of an adrenalin-like substance.
These workers established the concept of neurotransmission.

The identi-

fication of the sympathetic neurotransmitter as NE was established by
von Euler in 1949.

Once the neurotransmitter was identified, it became
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obvious that its formation involved several intermediates and tissue
enzymes.

The demonstration by Goodall and Kirshner (1958) of the

formation of NE from tyrosine in homogenates of sympathetic nerve
tissue provided final evidence that the nerve trunk and terminals
can manufacture their own neurotransmitter from the dietary precursor,
tyramine.
Brodie and Beaven (1963) described a theoretic al model of the
biophysical units at nerve endings that are resp onsible for the formation, storage, inactivation and physiological release of NE and other
biogenic amines.

These units have been termed "neurochemical trans-

ducers", since they translate elctrical impulses into a quantity of
free hormone; the free amine, in turn, acts on a target organ to produce mechanical or chemical energy or on an adjacent neuron to produce
more electrical impulses.

The theoretical model of the neurochemical

3
transducer is based on kinetic data which describe the movement of H -NE
within compartments in sympathetic nerve endings after the amine is
taken up in tracer amounts.

Mathematical analysis of the kinetic data

has shown that endogenous NE is localized in an open two-compartment
system and that the content of stored amine is in a dynamic balance
between rates of synthesis and disappearance (Montanari

et~.,

1963).

One compartment is a mobile or readily available pool from which NE is
released by nerve impulses.

The amine f ormed in this pool is main-

tained at a high concentration by a transport mechanism or pump which
resists its free outward diffusion.

This mob ile NE pool is in chemical

equilibrium with a larger pool of NE in the second compartment, held
in granules, presumably as a complex .
to act as a reserve poo l o f amine .

The NE in granules is considered

Hence, if NE is released by a
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primary action on the mobile pool, some of the amine in the reserve
pool will also be mobilized in order to maintain chemical equilibrium.
According to the neurochemical transducer model, MAO controls the
amount of NE in the nerve endings so that at the s t eady-state level
the amine does not freely diffuse onto receptor sites.

In the absence

of sympathetic tone, NE can leave the storage compartments by simple
diffusion through the lipoid membrane onto MAO.

After nerve stimulation

the amine is r eleased directly onto the receptor sites and reaches the
blood stream as the free base.
The possib ility that the sympathetic nerves may be involved in the
selective uptake and retention of CA has been previously discussed.
Circulating NE and E are selec tively taken up and retained by sympathetic nerves.

This uptake and binding serves as an important mech-

anism for the rapid inactivation of these hormones .

The action of the

transmitter released at the adrenergic terminals may also be terminated
by localized enzymat ic destruction and by escape into the circulation.
A number of inves tig a tor s have reported that dur i ng sympathetic
nerve stimulation endogenous NE is released int o the circulation
(von Euler, 1956; Rosell et al., 1963; Boull.i.n , 1966b).

The fate of

thi s transmitter substanc e depends upon the fract i on of the cardiac
output to the tis sue and the density o f the sympathetic innervation
(Kopin et al., 1965).

Leduc (1 961) postulated the expectation that

steady state levels of the transmitter within adrenergic nerves could
be maintained by a mechani sm of local synthesis , c upled in some way
to the state of nervous act ivity and hence t. o the rate of secretion of
NE.
There is acceleration of CA biosyntheses due to increased nervous
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activity in the adrenal medulla (Bygdeman and von Euler, 1958;
Bygdeman et al., 1960).

The rate-limiting step f or the biosynthesis

of NE in heart tissue (Levitt et al., 1965) and in salivary glands
(Musacchio and Weise, 1965) has been shown to be the conversion of
tyrosine to dopa.

Roth et al. (1966) using an isolated hypogastric

nerve-vas deferens preparation, also reported a 3-fold increase in
the amount of NE synthesized from exogenous tyrosine.

They concluded

that the isolated vas def erens preparation is capable of synthesizing
NE from exogenous tyrosine and that local NE synthesis is in some way
regulated by nervous activity and is not a steady state phenomenon
independent of impulse traffic.

Austin et al. (196'7) confirmed these

re$ults, showing that on electrical stimulation of the nerve an increased synthesis and release of NE and dopamine was observed.

They

postulated that nerve stimulation increased production of some step
in the pathway subsequent to tyrosine hydroxylase.

Sedvall and Kopin

(1967), using the rat submaxillary gland preparation, suggested an
impulse-induced acceleration of NE synthesis in the adrenergic neurons
and an apparently stimulated synthesis at or before the tyrosine hydroxylation step.

They concluded that the rate of NE synthesis might be

controlled by tyrosine transport, product inhibition, endogenous inhibitors or cofactors of tyrosine hydroxylase.
Kopin (1967) stated that the events that occur following the
arrival of the sympathetic nerve impulse at the nerve terminals and
that lead to release of NE are essentially unknown.

Acetylcholine

can induce the release of NE from sympathetic nerves; however, the
importance of acetylchol.ine as an obligatory intermediary in release
of the adrenergic transmitter is not established.

There is evidence
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that , at least at some sites in some species, acetylcholine may play
a facilitory role in the release of NE from sympathetic nerve endings.
C)
1.

GUANETHIDINE

History and Pharmacology
Guanethidine, (2-(octahydro-1-azocinyl)-ethyl)-guanidlne -sulfate is

a potent

antihype+t~nsi've

agent which is purely a synthet:ic •c1:>mpou_nl1_.·.

Its synthesis was first described in 1959 by Maxwell, Mull and Plummer.
Maxwell et al. (1959; 1960a; 1960b) have comprehensively investigated
the pharmacology of guanethidine.
response :

Guanethidine elicits a biphasic

an initial sympathomimetic effect (hypertension and con-

traction of the nictitating membrane in the cat), followed by the
failure of postganglionic nerve stimulation.

Guanethidine also po-

tentiates the response of effector systems to NE , and after a single
dose the potentiation may be observed for up to five days.
et

~·

Maxwell

suggested that the initial sympathomimetic responses were due

to direct adrenergic effects and that the later sympatholytic actions
were due to a reserpine - like depletion of CA stores.
Page and Dustan (1959) gave five to 15 mg/kg i.v., of guanethidine
to normotensive dogs and cats.

They found an initial transient fall

in the arterial pressure, followed by a prominent rise and tachycardia
that persisted from 30 minutes t o two hours.

The increase in pressure

was associated with vaso - constriction and increase in cardiac output;
its degree and duration were directly related to the dose.

The pressor

response was accompanied by some sympathomimetic effects, such as piloerection-and contraction of the nictitating membrane, probably the
result either of the release of the endogenous stores of NE or of a

27

more direct syrnpathomimetic action of the compound.

The initial

syrnpathomimetic action was followed by a pr o longed period of sympathetic paralysis, accompanied by a decrease of arterial pressure (which
was more prominent in experimentally produced hypertensive animals than
in normal), bradycardia, decrease of pulse pressure and relaxation of
the nictitating membrane.

These effects persisted to some degree for

four to ten days .

~l·

Page et

(1961) tentatively concluded that guan-

ethidine caused a decrease in blood pressure by initially interfering
with the release of NE at the myoneural junction.

The pressor response

was associated with the initial depletion of endogenous amine stores,
especially in the heart and blood vessels.

The chronic hypotensive

effect was due to the depletion of peripheral stores of NE.
Mccubbin et al. (1961)
dogs.

reported similar effects in anesthetised

They showed that during the sustained pressor response, i.v. NE

responses were augmented in dogs with the vagus nerve severed.

No

signs of augmentation were observed in dogs with the nerve intact.
They concluded that the increase in pressure suggests the release of
bound endogenous CA stores .
Cass and Spriggs (1 961) suggested that guanethidine has a dual
mechanism in exerting its syrnpatholytic actions.

They proposed that

the syrnpatholytic action is secondary to its primary bretylium-like
action.

(Bretylium is a unique compound among the syrnpatholytic drugs,

since it is a quaternary ammonium compound that acts at nerve terminals
to prevent the physiol ogical release of the adrenergic transmitter and
neither releases apprec i able amounts of NE in vivo nor antagonizes the
effects of administered CA (Boura and Green, 1959)).

Their conclusion

was based on the finding that guanethidi ne blocks the effects of
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sympathetic stimulation in rats long before it produces an appreciable
decline in the anount of NE in sympathetic nerve endings.

This mech-

anism of action of guanethidine was reinforced by the findings ·
et~·

(1962).

~f

_Hertting

Bein (1960), however, has expressed doubt that guan-

ethidine action includes a mechanism similar to that

suggested . ~or

bretylium.
2.

Effects on Catecholamines
Sheppard and Zirmnerman (1959; 1960b) showed in rats that guanethi-

dine reduced the CA concentration of the spleen and heart, and in dogs
it lowered the CA concentration of the heart and arteries.

Cass et al.

(1960) reported that guanethidine depleted the NE in the heart of
rabbits and cats .

They suggested that the compound produced its chem-

ical sympathectomy through depletion of NE at the peripheral nerve
endings .

Cass and Spriggs (1961) observed that a single dose of guan-

ethidine in rats produced a considerable and longlasting depletion of
the CA.

Other workers have reported depletion of CA in peripheral

tissue with guanethidine (Butterfield and Richardson, 1961; Stone and
Beyer, 1962; Sanan and Vogt, 1962; Kuntzman

et~·,

1962) .

Hertting et al. (196lb) showed in male cats that guanethidine
markedly decreased the uptake of H3-NE in the heart and spleen, but
not in the adrenals, and only moderately decreased it in the liver.
These workers suggested that guanethidine appeared to act by preventing entry and/or binding of H3 -NE in the tissues.

Dengler et ~·

(1961) demonstrated that guanethidine inhibited the uptake of isotopic NE by cat tissue and depleted the peripheral tissues of NE but
not of serotonin .

They suggested that the depletion of the NE stores

in cells may depend on inhibition of the uptake mechanism.

Bisson and

Muschell (1962) suggested that guanethidine abolishes the ability of
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the tissue to bind CA.
Lindmar and Muschell (1961) used isolated rabbit hearts perfused
with Tyrode's solution to study the effect on the NE output.

Tyramine

and 1,1-dimethyl-4-phenylpiperazinium iodide (DPP) increased the output of NE.

Guanethidine decreased the NE release by tyramine and the

NE release induced by DPP was also blocked.

Similar results were also

reported by Kroneberg and Schumann (1962).

They showed that inhibition

of the tyramine response was due to a direct action of guanethidine and
not to a depletion of CA stores.
shown to

ppt~ntiate

However, guanethidine has also been

the response to NE and to inhibit the pressor

response to tyramine (Bhagat and Shideman, 1963a).

Bhagat (1963a)

showed that guanethidine had no effect on the depleting action of
tyramine in the rat heart.
Kuntzman et al. (1962) reported that guanethidine produces a
longlasting depletion of heart NE; however, it does not lower the
amine in the brain, presumably owing to the low rate of penetration
across the blood-brain barrier.

The investigators concluded that guan-

ethidine releases NE from sympathetic nerve endings by an action which
seems to differ from that of reserpine.

Evidence is also given for

the view that guanethidine acts oppositely to bretylium and activates
the process involved in the normal release of NE by nerve impulses.
Day and Rand (1963) showed that guanethidine acts on stores of NE
at sympathetic nerve endings.

Abercrombie and Davies (1963) discussed

the nature of the action of guanethidine and concluded that it blocks
the effect of postganglionic sympathetic nerve stimulation by interfering with the syntheses of transmitter and that it also has a direct
sympathetic effect.

Davanzo et al. (1964) showed that guanethidine
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decreased the effectiveness of sympathetic nerve stimulation by
causing a depletion of CA stores in peripheral nerves.

They concluded

that this depletion occurs by a mechanism different from that of the
ganglionic and adrenergic blocking agents.
Chang

~

al . (1964) reported that guanethidine does not release

NE by a simple one-to - one displacement .

Guanethidine must first be

taken up before appreciable amounts of CA are released .

Initially,

the drug shares occupancy of the nerve endings with the endogenous
amine, then, after entering the sympathetic neurons, it releases NE,
perhaps by enhancing the permeability of the terminal membranes .

At

first, guanethidine releases at a rapid rate the more available pool
of NE; in fact, large doses of guanethidine can elicit a pronounced
sympathomimetic effect .

Guanethidine also remains localized in adre-

nergic neurons for a considerable time and causes a steady loss of CA
after the period of rapid release .
The action of guanethidine in blocking adrenergic function is not
a direct result of NE loss; in fact, the amine levels are not yet
reduced when sympathetic blockade is complete and are still low when
it is terminated .

However, the intensity of the adrenergic blockade

ultimately produced by single doses of the drug is directly proportional
to the initial rate of NE depletion and is closely related to the amount
of guanethidine taken up by NE storage depots.

These results suggest

that the drug increases the porosity of the nerve membrane, thereby
releasing NE and making nerve terminals unresponsive to incoming stimuli (Brodie et al., 1965).
Shore and Giachetti (1966) presented evidence that guanethidine
at l0- 4M inhibited both a membrane amine pump and an intracellular
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amine-concentrating mechanism.

At a low concentration of guanethidine

(5 X 10 -6 M) the intracellular mechanism is preferentially inhibited.
The action of guanethidine on the membrane pump is readily removed by
washing .

They concluded, that at clinical doses, guanethidine acts

only on the intracellular mechanism, thus leading to depletion of NE.
Lundborg and Stitzel (1967) showed that guanethidine inhibits
both the transport of amines through the nerve cell membrane and an
uptake mechanism present in amine-storage granules.

They suggested

that the membrane pump-inhibiting ability possessed by guanethidine
may account for the sympathomimetic activity and exogenous amine potentiation which often accompanies guanethidine administration .
Fielden and Green (1967) did a study on the NE-depleting and
sympathetic-blocking action of guanethidine.

They concluded that

the sympathetic-blocking action of guanethidine is distinct from its
NE-depleting action.

The early action of guanethidine may be due,

then, to adrenergic neuronal blockade, and in light of the Burns and
Rand (1962) hypothesis, the drug may act by preventing the release of
acetylcholine and its ability to release, in turn , NE.
Guanethidine, like alpha-methyl NE, metaraminal, and octopamine,
is taken up and retained by adrenergic neurons; it causes the release
of NE and is itself released by reserpine
Brodie

et~ · ,

1965).

(Chang~

al., 1964; 1965;

Boullin et al . (1966) reported that the term

"false transmitter" has been applied to substances that replace NE in
sympathetic nerve endings and that on nerve stimulation are themselves
released onto adrenergic receptors to evoke sympathetic responses.
Guanethidine is also taken up by adrenergic neurons, displaces the
transmitter, and is discharged by nerve stimulation; but it fails to
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exert a sympathomimetic action of its own.
Boullin (1966a; 1966c) showed that calcium is also involved in the
storage and release of guanethidine, but not in guanethidine uptake.
Boullin (1968) showed that the removal of calcium ions causes release
of guanethidine primarily from nonspecific cellular binding sites and
not from the intra-neuronal stores.

He suggested that the action of

guanethidine is to destroy the intra-neuronal store, and that its action
may be particularly evident under calcium-free conditions.
Dixit et al. (1961) showed that guanethidine can also produce
neuromuscular blockade, possibly by preventing acetylcholine release.
Costa et al. (1962a) suggested that guanethidine might actually mimic
the action of acetylcholine in adrenergic fibers, thus leading to a
prolonged release of NE.

Agarwal et

~·

(1965) found that chronic

administration of guanethidine increased the acetylcholine content of
brain, intestines and heart of albino rats.

Rand and Wilson (1967)

proposed receptors for adrenergic neuron-blocking activity allied to
the acetylcholine receptors at other sites, and that interaction by
guanethidine with these receptors interferes with cholinergic transmission at the neuromuscular junction and the ganglionic synapse.
However, Chang et al. (1967b) in studies on the neuromuscular-blocking
action of guanethidine, reported that its main effect appeared to be
on muscle fibers.

Contractile responses to direct muscle stimulation

were reduced, and the form of muscle action potentials were changed.
There is also conflicting evidence for the effect of guanethidine
on brain CA.

Pfeifer et al. (1962; 1967) reported that guanethidine

produced some effect on the CNS and decreased the NE in the brain.
Dagirmanjian (1963) showed that single injections of guanethidine did
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not lower the hypothalamic NE in the cat, but daily injections over
a period of seven days consistently produced a decrease in the hypothalamic NE.

Attempts to lower the hypothalamic NE in rats after

single injections or daily injections of guanethidine were unsuccessful.

Sanan and Vogt (1962) observed a fall in NE of the hypothalamus

in cats after guanethidine and suggested that the effect was due to a
reflex stimulation of the sympathetic centers, rather than to a direct
effect on the hypothalamus.

Studies on the disposition of guanethidine

in the body show that the drug does not readily cross the blood-brain
barrier .

This seems to explain the lack of effect on brain amines,

since intracisternal injections of the drug can lead to depletion of
brain NE (Kuntzman
Cass et

~·

et~.,

1962).

(1960) reported that guanethidine did not affect the

CA in brain and adrenal glands.
lar results.

Stone and Beyer (1962) reported simi-

Kuntzman et al. (1962) reported the resistance of the CA

in the rat adrenal medulla to depletion by guanethidine.

(See page 48.)

Athos et al. (1962) demonstrated that direct perfusion of the isolated
denervated adrenal gland in situ in the dog with guanethidine had no
effect on the CA secretion.

Intravenous dose in intact dogs caused no

adrenal medullary stimulation; in fact, the adrenal secretion rate was
markedly lowered.

Garrett et al. (1965) did studies on isolated bovine

adrenal glands but reported that both E and NE were released in varying
proportions.
Superstine and Sulman (1966) found that guanethidine also influenced
the output of pituitary hormones.

Guanethidine suppressed the secretion

of follicle-stimulating hormone, luteinizing hormone and somatotropin,
while it stimulated the secretion of the luteotropic, adrenocortico-
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tropic and antidiuretic hormones.

Although the altered hormone

secretion did not bear directly on the mode of action of guanethidine,
the suggestion was made that the hypothalamus might be intermediary in
the drug's useful physiological effects.
3.

Miscellaneous
Kuntzman et al. (1962) reported that after the administration of

guanethidine, 35 mg/kg, i . v . , to

~ats,

from the animal in the first hour.

about half of the drug disappears

After two hours, the rate of dis -

appearance is sharply reduced and the level in the body declines
exponentially with a half-life of about seven hours.

At this time the

drug is highly localized in various tissues; however, brain and plasma
levels were barely measurable .
According to Chang et al. (1964), guanethidine is localized in rat
tissues by two kinds of binding sites : nonspecific sites, present in
all tissues and analogous to those which reversibly bind most drugs
with tissue components; and specific sites; present mainly in tissues
containing NE in high concentration .

They found guanethidine taken up

into heart slices by two processes, only one of which is readily saturated and which is inhibited by anaerobic conditions and by amphetamine.
In accord with this view are the results of Schanker and Morrison
(1965), who administered guanethidine to rats (3 . 5 - 28 mg/kg, i.v . )
and found that it became localized in a number of tissues.

After two

hours, the tissue/plasma concentration ratios were about 20 for heart,
10-12 for lung and intestines, 5-6 for skeletal muscle, spleen and kidney and 2 for liver .
time.

The general pattern of distribution changed with

Localization was greatest in liver and kidneys in the beginning,
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but later became greatest in heart and skeletal muscle.
Furst (1968) reported that after the injection of guanethidine
sulfate (20 mg/kg, i.p.) the drug was rapidly and extensively metabolized.

Approximately 70% of the drug was eliminated in the urine with-

in 24 hours, mainly as a polar metabolite.

Schanker and Morrison (1965)

reported similar results, citing rapid metabolism and excretion in
urine during the first hour after administration.

4.

Sumnary
Kopin (1968) briefly summarized the effect of guanethidine in the

following manner :

Guanethidine depletes NE stores in tissues (Sheppard

and Zimmerman, 1959; Cass et al . , 1960), is bound to some extent in the
same particulate fraction as NE (Chang et al., 1965), and can be released by sympathetic nerve stimulation (Boullin et al., 1966). Although
this guanidine derivative may displace NE and have a role as a false
transmitter (Boullin et al . , 1966), it interferes with sympathetic
neuronal function prior to any decrease in CA stores (Cass and Spriggs,
1961) .

Guanethidine may, therefore, diminish release of NE by inter-

fering with the process of transmitter release rather than by replacing
the transmitter .
D)
1.

RESERPINE

History and Pharmacology
Rauwolfia preparations employed clinically are obtained primarily

from the root of Rauwolfia serpentina (Benth), a climbing shrub of the
Apocynaceae family.

Although preparations of the Rauwolfia alkaloids

have been used for centuries i n India, their widespread use in Western
medicine began only after the isolation of reserpine in 1952 (Mueller
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et~.).

The principal pharmacological actions of reserpine are:

1.

mild CNS depression and blockade of conditioned avoidance behavior,

2.

hypotension, 3. hypothermia, and 4. marked peripheral ANS effects

consisting of an increase in parasympathetic and a decrease in sympathetic activity (DiPalma, 1965; Goodman and Gilman, 1965).
Plummer

~

al. (1954) reported that reserpine inhibited the hypo-

thalamus, initiating sympatholytic or parasympathomimetic responses.
Weiskrantz (1957), in studying the

behav~oral

pattern of reserpine,

observed that it appeared to inhibit sensory input to the brain.
Jacobson (1959), studied reserpine under psychic stress and found that
it produced nonspecific effects.

Domino (1962) concluded that reserp-

ine either stimulates or depresses most areas of the brain, except
the limbic system.
Holzhauer and Vogt (1956) found that reserpine depleted NE from
its normal brain stores and concluded that reserpine acts as a sympatholytic agent.

Brodie and Shore (1957) theorized that reserpine

produces its tranquilization effect by releasing serotonin from its
normally bound form .
Carlsson et al . (1957) demonstrated that dopa, a precursor of NE,
restored the normal activity of reserpinized animals .

Carlsson et al .

(1958) demonstrated that reserpine also depleted dopamine, a precursor
to NE and it is now believed that this latter compound has an action
of its own.

Carlsson theorized that reserpine produced its effects by

depriving central synapses of accessible NE and dopamine.
Brodie et al. (1961) and Burns and Shore (1961) presented evidence
that reserpine produces its effect through serotonin depletion.

They

showed that reserpine causes equal depletion of NE and serotonin from
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their normal bound states in the brain.

They observed that serotonin

produced sedative effects similar to those of reserpine; that alphamethyl-m-tyrosine (alpha MMT), which depletes the brain of its NE, had
no sedative effect; and that cold stress four hours prior to the administration of reserpine prevented its sedative effects and also inhibited
the depletion of serotonin induced by reserpine, but not that of NE.
Revizin

~

al. (1961) demonstrated a correlation between CNS depression

and lowered serotonin; however, they could demonstrate no relationship
between NE depletion and evoked potentials.
Giarman and Schanberg (1959), working with serotonin, and WeilMalherbe et al . (196lb), working with NE, found that in brain fractions
from reserpinized animals there was an increase in the free/bound ratio
of the concentration of both amines, an indication that reserpine has
the ability to increase the "free" form of NE and serotonin.

It is

assumed that it is this "free" form of the amine that is accessible
to central synaptic sites.
2.

Effect on Catecholamines
In spite of the numerous attempts to explain the sometimes dramatic

effect of reserpine, its mode of action is still largely unknown.

The

ability of reserpine to deplete tissue stores of their CA is well establised and has been reviewed by Shore (1963) and Costa et al. (1966).
Reserpine has been found to cause a depletion of the CA of various tissues and the extent of this depletion is found to be both species
(Collengham and Mann, 1958) and tissue dependent (Carlsson et al., 1958).
Very small, single doses of reserpine deplete the heart 0£ NE (Brodie
et al . , 1957), while somewhat higher doses are necessary to affect brain
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NE (Brodie et al., 1957; Holzhauer and Vogt, 1956) and dopamine
(Carlsson et al., 1958).

The depletion of CA from the adrenal medulla

is relatively resistant to reserpine and still higher doses are required (Carlsson et al., 1957); this depletion in the adrenal medulla
appears to be dependent, in part, on an intact nerve supply to the
gland (Holzhauer and Vogt, 1956; Mirkin, 1961).

Other investigators

confirmed the ability of reserpine to deplete the CA in peripheral
tissues other than the heart and adrenal medulla, these include:
arterial tissue (Burn and Rand, 1957); sympathetic ganglia (Muscholl
and Vogt, 1958); and fat (Paasonen and Pletscher, 1960).
Carlsson et al. (1957), Paasonen and Krayer (1958), and Bhagat
and Shideman (1964) all reported that a minimum of two weeks time was
required for the complete dissipation of the effects of reserpine upon
cardiac CA depletion.

In arriving at an explanation for this delayed

reversibility of the effect of reserpine on CA stores, different workers have ruled out such possibilities as:

1.

prolonged retention of

reserpine at the site of action (Shore and Olin, 1958); 2.
of CA biosynthesis (Paulson and Hess, 1963); or 3.
amines in the heart (Bhagat, 1963b).

inhibition

slower turnover of

However, there is now some accept-

ance of a possible reason for this long-lasting effect on CA stores as
being related to an effect on a storage mechanism.

Pretreatment of

animals with reserpine impairs the uptake of adrenalmedullary granules
of newly formed CA after dopa administration, or of administered NE
and Eby various tissues (Schaepdryver, 1959).
Axelrod

~

al. (196lb) and Hertting et al. (196la) showed that in

reserpinized tissues exogenous NE and E do not accumulate when the
tissues are exposed to NE and E.

Dengler et al. (1961) found that the
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presence of reserpine in the incubation medium prevented
of NE in tissue slices.

t~e

accumulation

This ability of reserpine to inhibit the tissue

uptake of CA has been widely accepted and theories have been elaborated
in an attempt to explain the action of reserpine on amine storage on
this basis (Brodie and Beaven, 1963).

However, studies by Kopin et al.

(1962) and Lindmar and Muschall (1964) present evidence that casts
doubt upon this interpretation .

Lindmar and Muschall measured the up-

take of NE in the perfused rat heart.

An analysis of the NE content

of the heart at the end of the perfusion revealed that in normal animals
the NE taken up from the medium could be accounted for almost entirely
as unchanged NE which accumulated in the tissue.

In reserpinized hearts

the amount of NE taken up from the perfusing medium was the same as in
normal hearts, but in this case the accumulated material did not appear
as unchanged NE in the heart .

These results suggest that the uptake

of NE is normal in reserpinized hearts but that the accumulated NE cannot be retained within the tissue and is rapidly lost by metabolism .
It follows then, that in reserpinized animals the tissues are able to
accumulate exogenous CA, but they are no longer able to retain the CA
thus accumulated.

Kopin et al . showed that in the reserpinized rat

heart the initial rate of accumulation of H3 -NE did not differ from
that in normal hearts.

They also reported that the kinetics of release

of NE from the isolated reserpinized heart suggest that this drug effects
the firmly bound reserve pool, but not the readily available pool.
Kopin and Gordon (1962; 1963a) showed that the NE released from rat
tissues by reserpine left the tissues largely in the form of MAO metabolites.

Kopin et al. (1962) and Axelrod

~ ~·

(1962) showed that

3
reserpinized rat hearts were unable to retain accumulated H -NE.

These

40
results also indicate that the NE accumulated in reserpinized hearts
did not leave the tissue as unchanged NE but was rapidly degraded by
MAO to acid and alcohol metabolites which then left the tissue .
Bhagat (1964b) also suggested that the main action of reserpine might
be its interference with the storage mechanism and not with the uptake
of CA.

There appeared to be little change in the initial :rate of up-

take of CA after reserpine; but the tissue was unable to store it, so
that which was taken up was rapidly lost through destruction by MAO .
This suggestion could explain the CA-depleting effect of reserpine .
Tissue whose ability to respond to nerve stimulation or to tyramine
has been reduced by reserpine, can have that responsiveness temporarily
restored by an infusion of NE (Burn and Rand, 1958; 1960; Rosell and
Sedvall, 1961), further evidence in support of the view that CA uptake is normal in reserpinized tissues .
~\

The conclusion that reserpine does not affect CA uptake thus :'
appears to be a reasonable one .

How reserpine affects the intracell-

ular storage of CA remains obscure, though reports that reserpine
affects the uptake and storage of NE in isolated NE storage particles
(von Euler and Lishajko, 1963; von Euler

~

this may be the site of action of res.erpine.

al., 1964) suggest that
Dahlstrom et al. (1965)

concluded that the primary action of reserpine in producing a longlasting block of storage function is not to block the mechanism for
amine uptake (reabsorption) localized in the cell membrane of the
entire adrenergic neuron, but to block the storage mechanism in the
amine granules.

They also concluded that the cell membrane is not the

primary site of action of reserpine .
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3.

Effects on the Pituitary-Adrenal Axis
A survey of the literature concerning the action of reserpine on

the pituitary-adrehocol:_d.cal system reveals a conflicting picture.
Several workers have shown . that reserpine reduces the reactivity of
the pituitary7.adrenocortical system, probably by depressing the response of the hypothalamic regions that control the secretion of ACTH.
This view was based on experiments which demonstrated that reserpine
pretreatrrent of rats and monkeys prevented the decline in AAA or the
rise in plasma corticosteroids ordinarily evoked by ether, histamine,
surgical trauma, cold exposure, or emotional stress (Wells
1956; Mahfouz and Ezz, 1958).
anism

et~ . ,

Investigation of this possible mech-

was complicated by the fact that reserpine stimulates ACTH

secretion. This has been shown in the rat (Khanzan et
Maickel et al., 1961; Saffran and Vogt, •

1960'~

"'Wells

~·,

~

1961;

al., 1956),

in the dog (Egdahl et al . , 1956) and in the monkey (Harwood and
Mason, 1957).

The dose levels found to stimulate ACTH secretion in

the rat were 1 mg / kg, i.v . or 2.5 mg/kg, i . p.; changes in AAA, blood
corticosterone or both were used as indicators of an increase in ACTH
secretion .
The endocrine aspects of reserpine were first noted by Gaunt
et al. (1954) in normal animals; changes in organ weight data indicated that reserpine caused mild stimulation of the adrenal cortex .
Egdahl et al . (1956) showed that single injections of large doses of
reserpine in dogs caused maximal ACTH release as judged by corticoid
secretion rates.

Work done in the monkey by Haward and Mason (1957)

was in agreement with these findings .

However, Mason and Brady (1956)

found that reserpine, given for one week in monkeys, completely
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suppressed the expected rise in plasma corticosteroids usually
associated with anxiety states.
Wells

~ ~·

(1956) resorted to repeated daily injections of

reserpine, counting on
stimulating

''adaptatio~'

to the drug, to eliminate the

effect on ACTH secretion.

In contrast to the marked

decrease in AAA seen four hours after the first injection, the values
were at the control level 24 hours after the last injection.
observations were confirmed by Kitay et al . (1959) and Maickel
(1961).

Wells~~·

These
~ ~·

(1956) concluded that reserpine in a single

initial injection caused marked ACTH release; however, after continued
injections the pituitary became refractory to subsequent ACTH-releasing
stimuli, and the workers concluded that reserpine in some way inhibited
the secretion of the hypothalamic secretory factor for ACTH.
Guillemin (1957) attempted to determine whether any of the proposed neuro-humoral agents (5-HT, NE, etc.) were identical to CRF.
He did not agree with previous findings regarding the ability of tranquilizers to inhibit acute stressors .

Guillemin used a psychological

stressor (forced restraint) in his study.

He observed that, while

reserpinized rats did not resist being restrained, the animals still
displayed adrenocortical hyperfunction as indicated by the depletion
of AAA.

He also found that reserpine itself is a potent stressor,

even though the animals were preinjected with the drug seven days prior
to the restraint.
Mahfouz and Ezz (1958) used very small doses of reserpine, 8 ug/kg,
i . m., before imposition of stress .

They reported that the decrease in

AAA seen in controls after exposure to heat, exposure to cold, or bloodletting under ether anesthetic did not occur in rats injected with
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reserpine.

Furthermore, reserpine was not able to inhibit the usual

depletion of AAA by various doses of ACTH, but did inhibit the stressors
mentioned above.

Therefore, these workers concluded that reserpine

inhibited the pituitary-adrenal axis by inhibiting some central regulatory mechanism, possibly the hypothalamus.
Kitay et al. (1959), in confirming the experimental data of previous
investigators in this field, added a new dimension which led to different interpretation.

They observed that when reserpine was given for

a three-day period, the adrenal hypertrophy implied a continuous, high
rate of ACTH secretion rather than a refractoriness after an initial
stimulation.

The essential new fact was that during this period, pitu-

itary ACTH remained low, about one-third of normal.

A presumably"non-

specific'' stressor, E, had similar effects; after either reserpine or
E had been administered over a period of three days, the stress of
ether anesthesia failed to cause

~

depletion of AAA.

They suggested

that the refractoriness of the ACTH response to stressful stimuli
after previous administration of a depressant drug might be due to
the reduction of pituitary ACTH provoked by the drug.

The fact that

E had no effects similar to reserpine provided additional support for
this hypothesis.

These observations were confirmed by Brodie et al.

(1961) and Maickel et al. (1961).

They further showed that exposure

of rats to cold also reduced pituitary ACTH content and that this was
followed by a period during which imposition of a second stressful
experience (reserpine or additional cold) failed to stimulate increased
ACTH secretion
In a series of papers, Maickel

et~·

(1961), Westerman

et~·

(1962) and Westerman (1965), by using the decrease in AAA, elevation
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of plasma corticosterone and FFA, increase in the activity of TP and
tyrosine transaminase in the liver, and increase in adrenal weight as
indices, studied the action of reserpine and cold exposure (4°) on the
anterior pituitary-adrenocortical system in rats.

Their results indi-

cated that reserpine depleted brain serotonin and NE, produced sedation,
and induced a sustained stimulation of the anterior pituitary-adrenocortical system.

Cold exposure had similar effects on the pituitary;

however, no data on brain amines were given .

Demonstration that these

effects of reserpine were not seen in hypophysectomized or adrenalectomized rats while the drug still depleted brain amines indicated
that the increased activity of the adrenal cortex was induced by a
hypersecretion of ACTH.

These investigators contended that the long

duration of the pituitary activation was not evoked by
~·

reserpine

which disappeared from the body within a few hours (Hess

1958), but by the amine-depleting action of the drug.

~

~ ~·

,

In these

studies, it was shown that reserpine (5.0 mg/kg, i.v.) or a prolonged
exposure to cold (4° for 20 hours) lowered the ACTH content of the
pituitary to such an extent that the animals were unable to respond to
an additional stressful stimulus or to another dose of reserpine by
increasing plasma corticosterone.
Eechaute et al. (i962) failed to confirm these observations.
~

~

They found that after pretreatment with a single dose of reserpine or
after a series of four daily injections, reserpine did not block the
adrenocortical response to stress of acute cold exposure.

Montonari

and Stockham (1962) presented similar results in different types of
experiments.

However, no pituitary ACTH or brain amine levels were

reported in either of these studies.
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Since CA injected in very low doses will stimulate ACTH secretion
(Harris, 1955), the possibility was considered that the reserpineinduced release of CA from the adrenal medulla and sympathetic nerve
endings might mediate ACTH hypersecretion.

However, Maickel

~ ~·

(1961) reported that administration of reserpine to adrenodemedullated
rats induced the same degree of pituitary activation as in the intact
rat.
Syrosingopine, a carbethoxy analogue of reserpine, in small doses ,
released only peripheral NE (Orlans

~al.,

1960),

~·£·•

from the

heart, but did not stimulate the pituitary adrenal system.

Only large

doses which also depleted brain amines and produced sedation caused a
sustained pituitary-adrenal stimulation .

Therefore, it was suggested

that the action of reserpine on the pituitary might be related to the
depletion of brain amines.
Costa et al.(1962b) showed that administration of R0-4-1284, a
benzoquinolizine derivative having reserpine-like action, produced
marked sedation, a depletion of brain amines, and an elevation of the
plasma corticosterone .
very short-acting .

This compound, in contrast to reserpine , was

After about eight hours the animals were no longer

sedated, and the brain amines returned to normal.

A corresponding

short-lasting elevation of plasma corticosterone indicated a correlation between brain amines and ACTH hypersecretion.

Whether the

reserpine-induced activation of the pituitary was more closely related
to changes in the brain CA or to the depletion of brain serotonin was
studied by using alpha-MMT, which in rats produced a long-lasting depletion of brain NE without signifi cant changes in brain serotonin (Hess
~

al., 1961).

There was no stimulation of the pituitary-adrenocortical
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system in these rats, as indicated by unchanged TP activity.

However,

administration of reserpine caused a marked sedation and increased
plasma corticosterone similar to those in the animals not pretreated
with alpha-MMT.

Westerman~ ~.(1962)

also concluded that discharge

of ACTH was related to serotonin depletion.
Giuliani et

~·

(1966) presented evidence to show that reserpine

is able to enhance synthesis and release of ACTH even after both of
these processes have been largely suppressed by the administration of
potent adrenocortical steroids .

They suggested that the main effect

of reserpine on the pituitary-adrenal axis was that of enhancing rather
than depressing ACTH secretion, and that this effect was achieved by
the suppression of the midbrain inhibitory action.

The reserpine-

induced block of stress reactions was thought to be a result of the
feedback effect of the enhanced blood levels of adrenal steroids.
4.

Miscellaneous
Reserpine has been shown to leave tissues rapidly after injection,

so that at the time of maximal NE depletion , little or no reserpine
can be detected in tissues (Hess et al., 1956).

However, experiments

with tritiated reserpine have revealed that the drug persists in
tissues in very low concentrations for at least 48 hours after injection
(Plummer et al . , 1957).
5.

Summary
Bloom and Giarman (1958) concluded that reserpine, which reduces

amine storage by acting on the storage particles, releases amines
earliest from unidentified structural elements present in the supernatant fraction, and does so with increased catabolism by MAO.

Recovery
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from reserpine-induced behavioral and autonomic symptoms correlates
with recovery of the accumulation process but not with the slower
recovery of endogenous amine levels.

Reserpine does not appear to

affect either the synthetic enzymes (Glowinski and Baldessarini,
1966; Glowinski et al., 1966) or uptake of amines into the neuronal
cytoplasm (Glowinski and Baldessarini, 1966; Dahlstrom et al., 1965;
Carlsson

et~.,

1965; 1966; Malmfors, 1965).

Overall synthesis could

be impaired by accelerated catabolism of unbound dopamine before the
latter is converted to NE.
E.

POINTS OF SIMILARITY AND DIFFERENCES REGARDING
GUANETHIDINE AND RESERPINE EFFECTS ON CATECHOLAMINES

Guanethidine and reserpine have several properties in conunon, but
there is much evidence to suggest that their mechanisms of action are
different.

In the first place, the chemical structures of the two

compounds are entirely different .

Guanethidine is a derivative of

guanidine and an extremely strong base with low lipid solubility; in
contrast, reserpine is a polycyclic, weakly basic structure having a
high lipid solubility .

It seems unlikely, therefore, that the two

compounds release NE by the same mechanism.
The biphasic response to guanethidine (Maxwell et al., 1959;
1960a; 1960b) and its potentiation of the response of effector systems
to NE (Boura and Green, 1962) are similar to those following reserpine
administration and this similarity is extended since the pressor action
of tyramine is reduced after guanethidine administration (Bhagat and
Shideman, 1963b).

Sheppard and Zinunerman (1960b) showed that guan-

ethidine partially depleted the CA of rat heart and spleen, an action
not entirely analogous to that exhibited by reserpine, because it did
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not deplete the CA of the brain or adrenal medulla

(Cass~

al., 1960).

The effects of guanethidine on biogenic amines differ from those
of reserpine in a number of respects:

guanethidine depletes heart NE

more slowly than does reserpine; guanethidine does not lower the serotonin content of platelets or intestines; and large doses of guanethidine produce a brief sympathomimetic effect which precedes the adrenergic
neuronal-blocking action and appears to depend on the availability of
stored NE (Bein, 1960; Burn, 1961) .
Kuntzman et al. (1962) showed that over a four-hour period guanethidine (35 mg/kg) lowered heart NE to about ten percent of normal.
The NE remained low for 24 hours and, during the next 24 hours, gradually started to rise.

Coincident with the rise in NE, the guanethidine

had virtually disappeared from the body.

These effects are in

contra~t

.

to those of reserpine which produces a depletion of heart NE that persists long after the drug is no longer detectable (Hess et al., 1956).
Kuntzman et al . also reported that in doses of 150 mg/kg (i.p . )
guanethidine did not reduce the content of CA in the adrenal medulla.
However, doses of 400 mg/kg, or 80 times those which reduce the content
of heart NE by 50%, did lower the content of medullary amines by about
50%.

Similarly, doses of reserpine necessary to reduce medullary

amines by one-half were about 80 times those which caused a 50% decline
in heart NE.

Kuntzman et al. further showed that heart NE was lowered

by 50% one hour after giving reserpine in doses large enough to deplete
heart NE completely.
was slower :

In contrast, the rate of release by guanethidine

about 50% in two hours .

As expected, guanethidine did

not lower the content of brain NE since it does not enter the brain in
appreciable amounts.
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Kuntzman et

~·

stated that although the action of guanethidine

in reducing heart NE is readily reversible, that of reserpine is
relatively nonreversible; however, they emphasized that this does not
necessarily mean that the two drugs affect NE storage by different
mechanisms.

The drugs could act on the same storage process, with

reserpine having a high affinity for the storage sites.

However,

guanethidine and reserpine appear to release NE by different mechanisms, since bretylium counteracts guanethidine but not reserpine in
releasing NE.

They concluded that guanethidine releases NE from sym-

pathetic nerve endings by an action which seems to differ from that
of reserpine; guanethidine may release NE by activating the normal
process of physiological release .
Harrison et al . (1963) showed that in three hours guanethidine
produced an initial loss of some 24% of the CA of the dog heart, while
reserpine produced a 65% loss in four hours .

These findings suggest

a different mechanism of NE depletion in the period innnediately after
administration of the drugs.

Also, the amine-depleting action of

guanethidine was accompanied by a sympathomimetic response which was
not seen with reserpine.

Apparently guanethidine releases CA on to

the receptor sites, but the CA released by reserpine do not gain access
to the receptor (Kuntzman et al., 1962; Bhagat, 1964a).
Reserpine releases NE onto MAO by inhibiting nonreversibly an
active transport mechanism or pump that maintains the amine in a
mobile pool at nerve endings (Spector et al., 1960).

In contrast,

guanethidine has been postulated to release NE onto receptor sites
(Kuntzman et al., 1962) .

Kopin and Gordon (1963a) claimed that CA

released by guanethidine are inactivated by MAO and COMT.

Nash et al.
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(1964) has shown that NE is released onto the receptor site and is
subsequently 0-methylated.

Their results showed that reserpine releases

NE almost entirely in the form of deaminated products whereas guanethidine releases the amine as the free base .
Gaffney et al. (1963) suggested that guanethidine's interference
with adrenergic transmission is independent of changes in the level of
stored adrenergic-transmitter .

The reserpine-induced blockade of adren-

ergic transmission may ultimately be dependent upon the depletion of
adrenergic transmitter, but almost complete depletion of stored adrenergic transmitter must occur before reserpine-induced adrenergic blockade occurs.
Chang et al. (1964) stated that guanethidine is localized in rat
tissue by two kinds of binding sites.

(See page 34).

Reserpine was

shown to release considerable amounts of guanethidine from tissues containing high levels of NE; however, reserpine released little or no
guanethidine from tissues having only small amounts of CA.

It was also

inferred that reserpine had completely blocked the uptake of guanethidine
into adrenergic neurons, since amphetamine produced no additional inhibition of guanethidine uptake .
Muskus (1964) presented evidence of different sites of action of
guanethidine and reserpine.

His results were discussed on the basis

of a two-compartment theory of the NE stores .

He indicated that guan-

ethidine differs from reserpine in its site of action, because guanethidine appears to act more strongly than reserpine on the small
compartment of tyramine-sensitive NE.

This was true for both the

depleting and the releasing action of guanethidine.
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Lundborg and Stitzel (196?) suggested ·that the membrane pumpinhibiting ability possessed by guanethidine, but not reserpine may
account for the sympathomimetic activity and exogenous amine potentiation which often accompanies guanethidine but not reserpine
administration.
Burns and Rand (1958; 1960) postulated that reserpine impairs
adrenergic function by its action in depleting the stores of the transmitter, NE.

Guanethidine was also found to deplete CA from peripheral

organs (Sheppard and Zirrnnerman, 1959), and it was suggested by Cass
et al. (1960) that the loss of adrenergic function might be attributed
to the loss of transmitter substance from the nerve endings .

However,

it was later shown that the ini tial blocking action of guanethidine
was not related to depletion of the NE stores (Cass and Spriggs, 1961;
Gaffney

et~.,

1963).

Chang et al. (1967a) concluded that the adren-

ergic neuron blocking effect of guanethidine is consequent on the rapid
depletion of the particulate NE which is available for release by
nerve impulse .

III.
A)

METHODS AND MATERIAL

ANIMALS AND ANIMAL HOUSING

Male, albino rats of the Sprague-Dawley strain , weighting between
75-lOOg, obtained from Charles River 1 , were used throughout the investigation.

All animals were kept at room temperature in uncrowded community

cages (51 x 56 x 38 cm) 2 for two to three weeks after arrival in the
laboratory .

Purina 3 rat chow and tap water were provided ad libitum.

At a period beginning two weeks prior to their use, the rats were transferred to suspended metabolism cages 2 , two per cage, where they were
kept throughout the study.

The metabolism cages were placed in an air-

conditioned animal room where the temperature was maintained at 21.1
0

+ 0. 5 .

Following the transfer, each animal was given 20g of Purina

rat chow daily at about 2 : 30 p . m. , and tap water was provided ad
libitum .
The animal room was illuminated artifically for a twelve hour
period beginning at 6 : 00 a . m.

In an effort to minimize any effect of

movement into and out of the animal room, only authorized personnel
were allowed admittance .

When not undergoing restraint , the experi-

mental animals were housed in the same room as the control animals.
Control rats were not restrained, but were kept in the suspended metabolism cages without food and water during the restraint period.

1.
2.
3.

Charles River Breeding Farms, North Wilmington, Massachusetts.
Wahmann Manufacturing Co . , Baltimore, Maryland.
Ralston Purina Co . , St . Louis, Missouri.
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B)

RESTRAINT STRESSOR PROCEDURE

Because innnobilization has been shown to produce considerable
stress due to the increased neuromuscular exertion involved (Selye,
1946), a restraint stressor procedure was used.

Rats were removed

from the animal room, about one hour after vehicle or drug injection,
and transferred to a second room where they were restrained.

The

illumination conditions and temperature in this room were identical
to those in the animal room.

The animals were placed on restraining

boards, similar to the ones used by Renaud (1959).
Each board was designed to restrain four rats simultaneously by
securing their paws to each of four vertical metal posts.

Strips of

adhesive tape, two cm wide to allow circulation, were wrapped cuffwise about the paws of the restrained animals, and size one safetypins were then pinned to the tape.

The tape and pins were left on

the animals throughout the entire period of the experimentation.

The

rats were restrained in a supine position simply by slipping the
closed safety-pins over the metal posts.
could be innnobilized in a few seconds.

With this method, a rat
The restrained animals were

held in this position for five hours.
The studies of Renaud (1959), reconnnended that the incisors of
rats restrained in such a position be cut to prevent them from biting
their paws.

This probiem was solved by innnobilizing the head by

placing it between two metal posts.
C)
1.

EXPERIMENTAL DESIGN

General Consideration and Daily Protocol
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Drugs. Aqueous solutions of guanethidine sulfate 1 (Ismelin™;
2
1
TM
2
A2448) and reserpine phosphate (Serpasil ; 65-293) were prepared
daily and administered intraperitoneally (i.p.).

The doses were cal-

culated in terms of the free base content of both drugs.
To permit the animals to adapt to the injection procedure, all
rats were weighed to the nearest gram and injected i.p. with the drug
vehicle, glass distilled water (1.0 ml/kg) every other day for 14 days
prior to the experiments.

The animals were kept undisturbed for 24

hours prior to their use.

Experiments were begun on the 15th day.

From 7:00 to 9:00 a.m. daily the animals were weighed and injected by
the same person with the vehicle or with the appropriate drug.

Ani-

mals weighed between 150-215g at the beginning of the experimental
period.

Water and food consumption were measured and the water jars

refilled during this period.
2.

Dose-Response Studies
The purpose of this study was to determine that dose of reserpine

effecting a 50% depletion of brain NE and that dose of guanethidine
effecting a 50% peripheral depletion of NE as measured in the heart.
One hundred and twenty rats were divided into twelve groups of
ten animals each.
scribed above.

Housing and daily preparatory protocol were as de-

Each day for six days all rats in each group were

injected i.p. with one of the following

1.
2.

d~ses

(mg/kg):

reserpine,

Both drugs graciously supplied by Mr. Jack Cooper, Ciba
Pharmaceutical Products, Inc., Summit, N.J.
Lot number.

'

··r.
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0 (vehicle), 0.05, 0.1, 0.25, 1.0, and 2.5; guanethidine, O (vehicle),
0.5, 1.0, 2.5, 5.0, and 10.0.

Approximately eight hours after the

last injection the animals were removed from the animal room and with1
in one minute were sacrificed by decapitation (manual guillotin) .

The

brain was removed from the skull, rinsed with saline at o0 and blotted;
the heart was removed from the body cavity, cut in half, rinsed with
cold saline and blotted.

These operations were accomplished in less

than a minute after decapitation .

Each organ was irrnnediately placed

into a separate aluminum mesh basket and irrnnersed into liquid nitrogen
contained in a wide-mouthed, vacuum-insulated jar.

When the nitrogen

stopped boiling, the tissue was removed, wrapped individually in
aluminum foil, coded and stored in a freezer at -40° until assay.
3.

Chronic Restraint Studies
The dose of reserpine and of guanethidine established in the

dose-response studies were used throughout this phase of experimentation.

The animal handling, the injection and the feeding were as

described above.

A total of 300 animals were used in this portion of

the study, according to the following procedure :

Individual experi-

ments of 1, 3, 6, 12, and 24 days duration were conducted on animals
that were randomly divided for each experiment into six experimental
groups of ten rats each.

The daily protocols for the various groups

were as follows:
1.

Vehicle control.

These animals received 1 ml/kg, i.p., of the drug

vehicle daily.

1.

Harvard Apparatus Co., Inc,, Dover, Massachusetts.
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2.

Guanethidine control.

These animals received 1.20 mg/kg, i.p., of

guanethidine daily.
3.

Reserpine control.

These animals received 0.2 mg/kg, i.p., of

reserpine daily.
4.

Vehicle restrained.

These animals received 1 ml/kg, i.p., of the

drug vehicle and were subjected to restraint daily.
5.

Guanethidine restrained.

These animals received 1.20 mg/kg, i.p.,

of guanethidine and were subjected to restraint daily.
6.

Reserpine restrained.

These animals received o.2 mg/kg., i.p., of

reserpine and were subjected to restraint daily.
Restrained animals were subjected daily to the immobilization procedure described above.

At the te:l!'lnination of the above experiments,

the restrained animals were sacrificed by decapitation within one minute
of their removal from the stressing room.

Control animals were decapi-

tated within one minute of their removal from the animal room.
After decapitation, blood was collected from the trunk of each animal into twelve ml centrifuge tubes and allowed to stand until a clot
formed.

The samples were then centrifuged 1 for ten minutes at 2000 rpm.

The serum was separated by decantation into four ml Kimax 2 test tubes
0

that were then stoppered, coded, and stored for assay at -40 .

The

adrenal glands were removed from the body cavity, freed of fatty tissue,
blotted and immediately frozen in liquid nitrogen; this procedure took
less than one minute.

The frozen adrenals were then placed in four ml

Kimax 2 test tubes, stoppered, coded and stored at -40° until assay.
Brain and heart were removed and stored as described above.

1.
2.

International Clinical Centrifuge, Model Cl 21890M, International
Equipment Co., Needham Heights, Massachusetts.
Owens-Illinois Glass Co., Toledo 1, Ohio.
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4.

Blood Pressure Studies
The object of this portion of the study was to determine whether

the dose of reserpine and of guanethidine used in the chronic restraint
studies had any effect on blood pressure.
into three groups of five animals each .
as follows:

Fifteen animals were divided
Daily drug doses (i.p.) were

group one, vehicle, 1 ml/kg; group two, reserpine,

0.2 mg/kg; group three, guanethidine, 1 . 20 mg/kg.

Daily protocols, in-

jecting and feeding procedures were as described above; however, there
was a slight variation in the housing :
individually housed.

in each group, one animal was

This modification proved to have no effect on the

blood pressure recording.

In order to permit the animals to adapt to

the handling, the container, the tail cuff and the recording apparatus,
blood pressures were determined on four separate days prior to drug
treatment.

During the actual determination, the animals were removed

from the animal room, and blood pressure was determined daily from
about 11:00 a.m . - 1 : 00 p.m. for twelve days and then every other day
until day 24 .
The tail cuff method for indirect systolic blood pressure
determination was used .
at 40

0

The animals were placed in an incubator box

for 15 - 20 minutes to cause peripheral vasodilation to f acili-

tate the determination of blood pressure.

After incubation each rat

was allowed to enter a clear plastic container (23 x 7 x 5 cm).

The

internal length of the container was regulated with a movable piston so
that the animal is snugly but not uncomfortably restrained .

The rear

door at the open end of the chamber was then placed in position, leaving only the rat's tail protruding .
after a few minutes in the container .

The rat generally becomes calm

58
1
An inflatable, blood pressure cuff , connected to a Physiograph

manometer system
possible.

2

.
was slipped on the rat's tail as far proximally as

The manometer system was connected to a hand bulb for manual

cuff inflation.

The end of the tail distal to the cuff was passed

through a small plastic holder , so designed that when a screw clamp
was tightened, the tail came into contact with a Beckman microphone
transducer . 3

The transducer lead was connected to a Beckman Infraton

signal divider set for maximum pulse .

3

The Infraton output lead was

connected to the di rect current input of an HP oscilloscope (Model 130B)

4

set at a sweep time of 20 msec/cm.
This system converts pressure pulses in the rat's tail to peaks
on the oscilio?cope screen.

Squeezing the rubber bulb of the manual

manometer system increases pressure in the system, causes the cuff to
be inflated with the consequence that the peaks on the oscilloscope
screen disappear as tail circulation distal to the cuff is cut off.
By allowing the air in the cuff to escape slowly, pressure in the monometer system is reduced and tail circulation is restored as indicated
by the reappearance of peaks on the screen.

Because it is assumed that

for distal circulation to be restored the pressure in the tail arteries
must be slightly greater than the pressure in the manometer system, the
pressure, as read on the manometer dial, at which pulsation first appears
on the screen is a measure of systolic blood pressure of the animal.
Diastolic pressures cannot be observed with this technique .

1.
2.
3.
4.

Harvard Instruments, Cambridge, Massachusetts .
E. and M. Instruments, Houston, Texas .
Beckman Co., Palo Alto, Cal i forn i a .
Hewlett-Packard Co . , Palo Alto, California .

The recorded
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blood pressure of a rat on a given day is reported as the average of at
least three successive determinations.

Once the animal was quiet,

successive determinations fell into a range not exceeding a few mm Hg.
D)
1.

ANALYTICAL METHODS

Estimation of Brain and Heart Norepinephrine
The extraction procedure here is a modification of the method

described by Shore and Olin (1958), and the quantities were reduced to
one-third.

This rapid and simple procedure for the chemical estimation

of NE in animal brain and heart tissue involves an extraction with
n-butanol from salt-saturated, acidified homogenate.
unstable at alkaline pH.

The amine is

Reduction of the polarity of the butanol by

the addition of n-heptane and extraction with dilute acid (O.OlN HCl)
returns the NE to the aqueous-acid phase.

An oxident is then added to

the aqueous-acid solution to form the aminochrome, which on the addition of alkaline ascorbic acid, yields the trihydroxyindole.

The oxi-

dation products of NE in alkaline solution shift the fluorescence
emission to the visible region (520 mu) .

The solutions were then

assayed for the development of fluorescence by a modification of the
method described by Maynert and Klingman (1962).
Solvents and Reagents :
Ascorbic acid (reagent grade, Matheson, Coleman and Bell)
Acetic acid, glacial (reagent grade, Baker and Adamson)
n-Butanol (reagent grade, Baker and Adamson)
Ethylenediamine (reagent grade, Eastman Organic Chemicals)
Hydrochloric acid (reagent grade, Baker and Adamson)
n-Heptane (reagent grade, Matheson, Coleman and Bell)
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Norepinephrine (Nutritional Biochemical Corp.)
Potassium ferricyanide (AR grade, Mallinckrodt)
Sodium acetate, anhydrous (AR grade, Mallinckrodt)
Sodium bisulfite (AR grade, Mallinckrodt)
Sodium chloride (reagent grade, Baker and Adamson)
Sodium hydroxide pellets (AR grade, Mallinckrodt)
Reagent grade n-butanol and n-heptane were purified by the method
of Shore and Olin (1958) .

Excess water was removed by decanting off

the butanol after about 24 hours .
Acetate Buffer, 2M, pH 6 . 0 :

One volume of 2M acetic acid is added

to 22 volumes of 2M sodium acetate.
meter, pH meter 28

The pH was checked with a Radio-

1

Alkaline Ascorbate Solution:

This solution was prepared fresh

daily prior to its use by mixing six ml of lON NaOH (Anton and Sayre,
1962) with one ml of one percent sodium bisulfite and 0 . 16 ml of ethylenediamine (von Euler and Lishajko , 1960), then adding one ml of a one
percent ascorbic acid solution .

All solutions used in the preparat ion

of this alkaline ascorbate solution were prepared fresh dai ly .
Norepinephrine standard :

NE . HCl was used for preparing the

standard solution, the concentration was calculated in terms of the
base.

Because it was observed that a solution of NE (100 ug/ml) in

O.OlN HCl deteriorated even when refrigerated, the solution was made
fresh daily and a working standard of suitable concentration (1 ug/ml
to 5 ug/ml) in 0.0lN HCl were prepared prior to the start of each assay.

1.

Landon Co . , Westlake, Ohio .
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Glass-distilled water was used in the preparation of all solutions.
All glassware and polyethylene tubes were washed three times with distilled water followed by two rinsings with glass-distilled water.
Method:

The method described here was used to determine NE from

whole rat brain and heart.

At the time of the assay, each brain or

heart was removed from the aluminum foil, weighed and immersed into
liquid nitrogen as described above .

The frozen tissue was then placed

into a steel tablet die of suitable size and crushed by striking the
upper punch with a hammer (Cullingham and Cass, 1963).
A steel tablet die and punch set with an internal diameter of
15 mm, was placed in a wooden block .

One punch (lower) served as the

base; the other punch (upper) was movable .

Prior to placing the tissue

into the die, the two punches and die were immersed into the liquid
nitrogen for 15 - 20 seconds to prevent local heating and destruction
of the NE.
Each brain was reduced to three pellets by carefully breaking the
frozen tissue into three approximately equal segments and compressing
each segment _into a pellet.

These pellets of still frozen tissue were

transferred to a 15 ml homogenizing tube
fied butanol .

1

containing five ml of acidi-

Each heart was reduced to two pellets by a similar pro-

cedure and transferred to another homogenizing tube containing acidified
butanol .

The butanol was chilled (Chang, 1964) to

o0

prior to its use.

The brain or heart was homogenized within two minutes in the
chilled butanol by a motor-driven Teflon homogenizer 2 .

1.
2.

The homogenizing

Catalogue number s35, TriR Instruments, Inc., Jamaica, New York.
Catalogue number s21, TriR Instruments, Inc., Jamaica, New York.
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tube was maintained in an ice bath during this procedure.

The homogenate

was transferred to a 50 ml, polyethylene test tube (29 x 105 mm) 1 containing four gm of NaCl.

Three successive washings of the homogenizing

tube with five ml portions of chilled butanol effected quantitative
transfer of the homogenate.
One-half or one ml of the NE working standard (1 ug/ml), with
volume adjusted to five ml with O.OlN HCl was simultaneously carried
through the assay procedure with the tissue homogenate.

Five ml of

O.OlN HCl was used for the blank.
The polyethylene tubes were capped and then shaken for 20 minutes
on a reciprocating shaker.

It was observed that the extraction of NE

was virtually complete after a 10 to 15 minute period and that shaking
carried on for periods up to one hour had no further effect on the amount
extracted.

Following centrifugation at 10,000 rpm for ten minutes, 13 ml

of the butanol phase was decanted into a 25 ml polyethylene cylindrical
graduate and poured into a second set of 50 ml, polyethylene tubes containing 23 ml of n-heptane and two ml of O. OlN HCl.

The tubes were

capped and then shaken for five minutes on a reciprocating shaker and
then centrifuged at 10 , 000 rpm for five minutes.

The organic phase

(upper) was removed by aspiration.
One-half ml of the aqueous-acid phase from each sample was then
carefully transferred to twelve ml polyethylene test tubes (16 x 100 mm) 1 .
The transfer of any trace of the organic phase was avoided by using 0.5 ml

1.
2.

Ivan Sorvall Inc., Norwalk, Conn .
Lourdes Model AB centrifuge, Lourdes Instruments Corp., Brooklyn, N.Y.

63

Kimax 1 volumetric pipettes.

Two-tenths ml of water and 0.1 ml of 2M

acetate buffer (pH 6) were added to each tube .
tube were mixed by manual inversion.

The contents of each

To this mixture was added 0.1 ml

of freshly prepared potassium ferricynide (40 mg%, w/v) and the contents
were mixed.

Two minutes later 0 . 2 ml of freshly prepared alkaline ascor-

bate solution was added and the contents were mixed.

The solutions were

then transferred to quartz cuvettes and their fluorescence intensities
were read by means of an -Animco-Bowman spectrophotofluorometer

2

at an

excitation wavelength of 400 mu, and fluorescence wavelength of 520 mu
(uncorrected) .

The source of emission was xenon arc lamp.

A standard curve for NE was prepared daily prior to the tissue
assay.

Blank, 0.5, 1, 2, 3 and 4 ml portions of the NE working standard

(1 ug/ml) were prepared and adjusted to five ml with O. OlN HCl.
ml of O.OlN HCl was used for the blank.

Fiv e

These samples were extracted

as were the tissue samples; however, these tissue-free solutions were
shaken for only a few minutes because prolonged shaking caused partial
loss of the NE (Shore and Olin, 1958) .

Standard curves were also pre-

pared by adding known amounts of NE to separate aliquots of tissue homogenate and by carrying these aliquots through the extraction procedure.
The slope of the line was approximately equal to that of the tissuefree NE samples.
Six samples of brain or heart tissue homogenate were extracted at
one time and assayed fluoreometrically along with an internal or external
(tissue-free) working standard plus the blank.

1.
2.

Periodically, tissue

Owens-Illinois Glass Co., To ledo, Ohio .
American Instrument Co., Silver Springs, Maryland.
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homogenates from control animals were extracted and assayed to check
the procedure.
The spectrophotofluorometer was turned on about 15 minutes before
the time of taking the readings to obtain a stable zero setting.

The

"zero-adjust" and "dark current" were balanced in the photo multiplier
as described in the manual .
all assays.

A seniitivity setting of 30 was used for

Eight cuvettes were calibrated while containing a known

amount of a NE (1 ug/ml) and were found to give approximately the same
relative fluorescence readings.

These cuvettes were used for all assays.

The fluorescence readings for the extracted samples were taken from five
to ten minutes after the addition of the alkaline ascorbate solution.
Two to three readings were taken of each sample or were continued until
the solution stabilized as indicated by consecutive readings which were
constant.

After about 30 - 45 minutes the fluorescence began to fade.

The samples were then allowed to sit for a period of about 24 hours,
and the fluorescence was read again .

This "tissue-blank" reading, which

was equal to or very close to the "reagent blank" fluorescence, was then
subtracted from the corresponding reading obtained for that sample the
day before, and the difference was taken as the actual fluorescence
contributed by NE.

In actual practice, however, it was not necessary

to take "tissue-blank" readings for each sanple .

Tissue-blank readings,

taken at random daily during the assays, were not substantially different
from "reagent-blank" readings.

Therefore, "reagent-blank" fluorescence

reading was subtracted from the fluorescence reading of each tissue sample, and this difference was considered to be the actual fluorescence
contributed by NE.
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All the conditions established in this assay were repeated precisely every time the assay was done, since there are many parameters
which can alter the ultimate fluorescent readings.

Duration of shak-

ing, centrifugation, type of test tubes , etc., were kept constant once
they were established.

Exposure of NE to different reagents for dif-

ferent times may cause a variable rate of destruction of the NE.

This

is particularly important when one is dealing with very dilute solutions.

It was also considered necessary to run a set of standards with

each set of unknowns.
Distribution of NE between the salt saturated aqueous phase and
n-butanol was such that, with the volumes used in this procedure, only
about 65% of the amine was extracted.

This partition ratio is inde-

pendent of the CA concentration (Shore and Olin , 1958) and is used
because lesser amounts o f interfer i ng substances are extracted.

When

n-heptane is added to the water-saturated n - butanol , water separates
out from the solvent and increases the volume of the aqueous-acid phase.
It was for these reasons that standards were prepared by carrying known
amounts of NE through the entire ex traction proc edure.
NE added to the tissue h omogenates (heart and brain) was extracted
to the extent of 97 to 103% compared with aqueous s o lutions not containing tissue homogenates.
The hydrochloric acid and sodium hydroxide solutions were standardized according t o the method in United States Pharmacopea XVII.
2.

Estimation of Serum Corticosterone
The predominant adrenal c ort i costeroid present in the rat plasma

is corticosterone ( Bush , 1953 ) .

The method described here utilizes
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0 . 5 ml of rat serum and is a modification of the method described by
Guillemin et al. (1959a).

Corticosterone was extracted with CHC1 3 and

the fluorescence was developed using 30N

H2 so .
4

Solutions and Reagents :
Absolute ethyl alcohol (reagent grade, U.S. Industrial
Chemical Co.)
Chloroform (spectrophotometric grade, Mallinckrodt)
Cort i costerone (alcohol free, Nutritional Biochem . Corp.)
Iso-octane (2,2,4-trimethylpentane, practical grade ,
Matheson, Coleman, and Bell)
Sodium hydroxide ( AR grade, Mallinckrodt)
Sulfuric acid (AR grade , Mallinckrodt)
Fluorescence reagent :

The 30N H2so

4

was prepared as described by

Guillemin et al . (1959) (420 ml concentrated H2 so4 up to 500 ml with
glass-distilled water).
stirring.
bath.

1~e

water was added slowly and with constant

The bottle containing the H2S04 was kept at o 0 in an ice

It was observed that this fluorescence reagent was stable for at

least four weeks under refr i geration .
Stock standard:

A solution containing 1 mg/ml of cor t icosterone

(free alcohol) was prepared in absolute ethanol .
stable for at least two months when refrigerated .

This solution was
Another solution

containing 10 ug/ml of corticosterone was made in ethyl alcohol and was
used for preparing the worki ng standard.
Working standard:

A working standard containing 0 . 4 ug/ml of

corticosterone was made by di lut i ng one ml of an ethanolic solution
containing 10 ug/ml of cort i cos t erone to 25 ml wi th glass-distilled
water .

The working standard was stored i n a refrigerator and was found

to be stable for at least a month .

However, a worki ng standard was
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prepared fresh daily.
Method :

At the time of assay, the serum samples were removed from

the freezer and thawed out,

One - half ml of each serum sample was placed

in an 18 ml glass-stoppered Kimax (Cat. #45100) test tubes.

Two-tenths

and 0.4 ml aliquots of the corticosterone working standard were placed
in similar tubes.

The volume in all tubes was adjusted to two ml with

glass-distilled water .
the reagent blank.

Two ml of glass-di stilled water was used for

Two blanks were used in each assay .

curve was prepared dai ly, prior to the serum assay.

A standard

Four ml of iso-

octane were added to all the tubes via a 50 ml buret, and the contents
were mixed for 15 seconds with a Vortex 1 mixer.

Following centrifugation 2

at 2500 rpm for three minutes, the iso-octane layer was removed by aspiration .

This step removed the neutral ster oids.

Two ml of glass-dis-

tilled water, followed by five ml of chloroform , were added to each
tube, and the contents were mixed v i gorously for 30 seconds on a Vortex
mixer and then centrifuged for f i ve mi nu t es at 3000 rpm .

In the case

of standards and "reagent blanks", the aqueous layer was aspirated off
by a capillary tube (connected t o a water vacuum pump) unt il the waterchloroform interface was broken .

The t i p of the cap i llary was then

moved around inside the tube above the liquid in order to remove all
the water in contac t with the sides of the tube.

In the serum samples,

water was removed to just withi n the prote i n layer, the film was broken,
and the rest of the water removed along with the protein precipitate.
One-half ml of O. lN NaOH was added, and the tubes were shaken

1.
2.

Vortex Model K-500 J, Sc i enti f i c Industries Inc., Queens Village, N.Y.
International Model RN , Internat i onal Equ i pment Co . , Needham Hts.,Mass.
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for 15 seconds and centrifuged for three minutes at 3000 rpm.

This step,

which removed phenolic estrogens, was carried out rapidly, since prolonged exposure to alkali destroys corticosteroids.
was removed by aspiration.

The aqueous layer

A four ml aliquot of the chloroform extract

was then transferred to another set of glass-stoppered test tubes containing 1.5 ml of the fluorescence reagent (30N H2so 4 ).

The time was

noted and the contents were mixed on a Vortex mixer for 30 seconds and
centrifuged for five minutes, at 3000 rpm.

The chloroform layer (upper)

was removed by aspiration, and one ml of the acid extract was transferred
to a fluorometer quartz cuvette.

Fluorescence was determined in about

35 - 45 minutes after the last mixing step (excitation 470 mu and fluorescence 520 mu - uncorrected) .

The values for the unknowns were ob-

tained from the standard curve.
The exact time for reading the fluorescence was determined to be
that time (about 40 minutes) at which the reading of the standards was
stable and at amaximum . Figure 7 shows that stability and maximum fluorescence were of relatively long duration; therefore, consistent timing was not absolutely necessary .

The intensity of fluorescence was a

linear function of the concentration of the corticosterone over a range
of 0.05 mg to 0.40 mg (Figure 8).

The recovery of corticosterone added

to the serum was about 100% over the range of 0 . 1 mg to 0.4 mg.
Chloroform (spectrophotometric grade) and iso octane (practical
grade) were found suitable for the assay .
necessary .

Further purification was not

Sulfuric acid obtained from Baker and Adamson gave the

highest "blank fluorescence" values .
the lowest "blank" values.
alcohol (analytical grade).

Mallinckrodt sulfuric acid gave

It was not necessary to redistill the ethyl
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The sensitivity of any fluorescence assay is usually limited by
the fluorescence contributed by the reagents used.

It is always nee-

essary to determine the fluorescence of each reagent at the wavelength
used in the particular assay.

Table 1 gives the fluorescence (fluor-

eometer readings) values of each reagent used for corticosterone and
norepinephrine assays .

The readings were taken under experimental

conditions of the respective assay procedures .

It can be easily seen

that analytical grade reagents made by different manufacturers show a
wide variation in their fluorescence .
3.

Estimation of Adrenal Ascorbic Acid
The Sullivan and Clark (1955) method for assaying ascorbic acid

in urine is based on the reduction of ferric to ferrous ion by ascorbic
acid and the colorimetric measurement of the ferrous ion through formation of a red-orange-colored complex with alpha - alpha - dipyridyl.
Other reducing material was inhibited by the addition of orthophosphoric
acid and by maintaining a low pH (pH 1. . 0) .

Maickel (1960), adapted this

reaction for the determination of ascorbic acid in the adrenal gland .
The procedure described here is a modification of this method .
Solutions and Reagents:
Trichloroacetic acid (reagent grade, Baker and Adamson)
Metaphosphoric acid (AR grade, Mallinckrodt, HP03 approximately 35%, the remainder being sodium metaphosphate)
Orthophosphoric acid (reagent grade, Baker and Adamson)
Alpha -Alpha-dipyridyl (Calbiochem.)
Ascorbic acid (reagent grade, Matheson, Coleman and Bell)
Ferric chloride (AR grade, Mallinckrodt)
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5% Trichloroacetic acid+ 2% metaphosphoric acid reagent:

Fifty

grams of trichloroacetic acid (TCA) was dissolved in about 500 ml of
glass-distilled water.

Twenty grams of metaphosphoric acid (MPA) dis-

solved in about 200 ml of glass-distilled water was added to the TCA
solution, and the resulting solution was diluted to one liter.
solution was stored in a refrigerator at o0

.

The

A fresh solution was

prepared each week .
1% Ferric chloride solution :

One gram of ferric chloride was

dissolved in glass-distilled water; about 0.1 ml of concentrated HCl
was added, and the solution was diluted to 100 ml .

A fresh solution

was prepared daily .
0.5% aqueous alpha -alpha- dipyridyl solution :

Five grams of

crystalline material was dissolved in about 500 ml of hot double-distilled water and diluted to one liter.

A fresh solution was made each

week.
Ascorbic acid standards :
Stock standard :

One hundred mg of ascorbic acid were dissolved in

5% TCA + 2% MPA reagent, and this was diluted to 100 ml with 5% TCA +
2% MPA.

A fresh solution was prepared daily .

Working standard :

A working standard containing 100 ug/ml of

ascorbic acid was made from the stock solution each day, just prior to
the assay, by diluting 2.5 ml of the stock standard to 25 ml with
5% TCA + 2% MPA.
Method:

At the time of assay, the adrenals were removed from the

test tube, weighed and transferred to a 15 ml homogenizer tube containing five ml of 5% TCA + 2% MPA reagent.

The homogenizing tube was

placed in an ice bath and the tissue was homogenized in less than a
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minute by a motor-driven Teflon homogenizer .

.

The contribution of the

adrenal tissue to the total volume of the homogenate was negligible.
The homogenate was transferred to a twelve ml polypropylene test tube. 1
The homogenate was centrifuged 2 for ten minutes at 2000 rpm and the
supernatant liquid was used for the assay.

One ml of the supernatant

(containing 10 - 15 mg of ascorbic acid) was then placed in a 1 . 25 cm
3
colorimeter test tube (cat . #33-29-27) .
Two-tenths, 0 . 3, 0 . 4, 0 . 5, and 0 . 6 ml aliquots of the ascorbic
acid working standard were placed into 1.25 cm colorimeter test tubes
and the volume was adjusted to one ml with the 5% TCA + 2% MPA reagent.
One ml of the 5% TCA + 2% MPA was used for the reagent blank .
Five ml of 0.5% (w/v) alpha -alpha-dipyridyl solution was added
to each tube, followed by the addition of 0.2 ml of 85% orthophosphoric
acid and one ml of one percent ferric chloride solution.
were thoroughly mixed after each addition .

The contents

Tubes were kept for 25 min-

utes at 37° - 38° and the absorbance of each sample was determined at
525 mu on a Bausch and Lomb, Spectronic 20 3 , colorimeter .

If the tubes

were kept at room temperature, readings were taken after 70 minutes.
The final readings were the same whether the reaction was run at room
temperature or at 37-38° .

The concentration of unknown was obtained

from a standard curve prepared daily prior to the assay.

Absorbance

readings of standards were reproducible from day to day.

The recovery

of the ascorbic acid added to the homogenate was about 95% .

1.
2.
3.

Ivan Sorvall Inc . , Norwalk , Conn .
International Model HN, International Equip. Co . , Needham Hts. ,Mass.
Bausch and Lomb, Rochester, N. Y.
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The color developed was stable for some time .

The colorimeter was

allowed to warm up for about 15 minutes and was adjusted to zero with
the reagent blank.
rang~

The optical density followed Beer's law over the

of 5.0 to 70.0 mg in a 7.2 ml final volume (Figure 10).
E)

STATISTICAL ANALYSIS

All values reported herein were analyzed statistically; the significant difference between means was calculated using the Student's "t"
test.

The level of significance is reported at the 0.05 level.

Stand-

ard error (SE) of the mean was calculated according to the following
formula:

SE

Analysis of variance was ·aone according to the Aardvark program
used by the University. o·f Rhode Island computer laboratory (Hemmer le,
1967, p. 177).
All statistical calculations were done by means of an IBM 360
computer.

IV.

RESULTS

Tables and figures are contained in this section .
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TABLE I
RELATIVE FLUORESCENCE OF THE REAGENTS USED IN FLUORESCENCE ASSAYS
OF SERUM CORTICOSTERONE AND BRAIN AND HEART NOREPINEPHRINE

Relative Fluorescence

Reagent

Norepinephrine Assay
A=400
F=520
Sensitivity=30
Tap water
Distilled water
Glass distilled water

0.000
0.000
0.000

Heptane (not washed)
Heptane (washed)

0.002
0.002

n-Butanol (not washed)
n-Butanol (washed)
n-Butanol (spec. grade)

0.010
0.009
0.002

O.OlN HCl (AR-Baker Adamson)
lON NaOH (AR-Mallinckrodt)
Potassium ferricyanide (AR grade)
Alkaline ascorbic acid solution

0.000
0.001
0.000
0.004

Corticosterone Assay
A=470
F=520
Sensitivity=30
0.000
0.000
0.000

Chloroform (AR grade)
Chloroform (spec. grade)

0.000
0.000

Iso octane (practical)
Iso octane (spec. grade)

0.001
0.000

Ethyl alcohol (AR)

0.000

Fluorescence reagent
(AR Baker Adamson)
Fluorescence reagent
(AR Mallinckrodt)

0.015

A = activation wavelength
F = fluorescence wavelength

0.009

_· TABLE II
THE EFFECT OF RESTRAINT ON MEAN CUMULATIVE DAILY WEIGHT GAINS
OF MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE.
Control Animals
Days of
Treatment

Vehicle

Guanethidine

Restrained Animals

11

Reserpine

Vehicle

Guanethidine

Reserpine

2

7 + 6a
(10) b

4 + 4
(10)

2 + 2
(10) Ac

-2 + 4
(10) A

5 + 6
(10) B

3

7 + 5
(10)

9 + 4
(10)

5 + 4
(10)

-2 + 5
(10) A

3 + 9
(10)

4

11 + 5
(10)

9 + 5
(10)

7 + 5
(10)

-3 + 5
(10) A

2 + 7
(10) AC

-2 + 5
(10) AD

5

18 + 9
(10)

14 + 6
(10)

10 + 6
(10) A

-3 + 6
(10) A

-1 + 10
(10) AC

-3 + 6
(10) AD

6

19 + 7
(10)

15 + 7
(10)

8 + 7
(10) A

-8 + 8
(10) A

7

20 + 8
(10)

17 + 8
(10)

9 + 9
(10) A

-7 + 7
(10) A

0.1 + 9
(10) AC

-10 + 8
(10) AD

8

23 + 8
(10)

21 + 6
(10)

7 + 10
(10) A

-8 + 8
(10) A

0.6 + 8
(10) AC

-14 + 9
(10) AD

9

27 + 7
(10)

23 + 8
(10)

8 + 11
(10) A

-5 + 8
(10) A

0.3 + 8
(10) AC

-11 + 12
(9) AD

10

27 + 7
(10)

24 + 10
(10)

10 + 12
(10) A

-5 + 8
(10) A

2 + 9
(10) AC

1 + 7
(10) ABC

4 + 3
(10) BD
0.4 + 4
(10) AD

-7 + 9
(10) AD

-14 + 10
(9) ABD

-....)

Vl

TABLE II - continued

Control Animals
Days of
Treatment

Vehicle

11

32 + 9
(10)

12

33 + 8
(10)

+ 8

Guanethidine

II

Restrained Animals

Reserpine

Vehicle

29 + 8
(10)

13 + 14
(10) A

-4 + 13
(10) A

29 + 8
(10)

7 + 13
(10) A

-4 + 10
(10) A

o. 7 + 9

+ 9

Guanethidine
3 + 12
(10) AC

(10) AC

Reserpine
-6 + 9
(9) AD
-13 + 9
(9) ABD

(lo)

(lo)

9 + 12
(10) A

-5 + 12
(10) A

0.2 + 10
(10) AC

-16 + 14
(9) AD

14

37 + 9
(9)

31 + 8
(10)

10 + 13
(10) A

-5 + 12
(10) A

0 + 13
(10) AC

-14 + 21
(9) AD

15

37 + 9
(9)

33 + 9
(10)

11 + 12
(10) A

-6 + 12
(10) A

-0.8 + 11
(10) AC

-16 + 25
(9) AD

16

41 + 10
(9)

33 + 8

(lo)

12 + 13
(10) A

-6 + 13
(10) A

o. 5 + 11
(10) AC

-10 + 21
(8) AD

17

39 + 9
(9)

35 + 10
(10)

11 + 12
(10) A

-7 + 14
(10) A

-3 + 10
(10) AC

-14 + 26
(8) AD

18

41 + 11
(9)

36 + 10
(10)

12 + 16
(10) A

-7 + 14
(10) A

-0.8 + 11
(10) AC

-14 + 29
(8) AD

19

43 + 10
(9)

35 + 10

12 + 20
(10) A

-7 + 15
(10) A

-5 + 11
(10) AC

-6 + 21
(7) A

13

33

28

(lo)

-....J

°'

TABLE II - continued
Control Animals
Days of
Treatment

Vehicle

Guanethidine

Reserpine

Vehicle

Guanethidine

Reserpine

20

43 + 11
(9)

36 + 10
(10)

12 + 16
(10) A

-8 + 14
(10) A

-7 + 14
(10) AC

-14 + 21
(7) AD

21

45 + 13
(9)

40 + 9
(10)

13 + 15
(10) A

-7 + 15
(10) A

-4 + 14
.(1-0) AC

(7)

22

47 + 12
(9)

38 + 7
(10)

14 + 23
(10) A

-4 + 15
(10) A

-2 + 14
(9) AC

-14 + 26
(7) AD

23

46 + 15
(9)

41 + 10
(10)

15 + 26
(10) A

-4 + 14
(10) A

-8 + 14
(9) AC

(7)

49 + 13
(9)

44 + 9
(10)

17 + 21
(10) A

-5 + 15
(10) A

-4 + 14
(9) AC

2 + 15
(6) A

24

-8 + 20

-9

A

+ 27
A

mean+ S.E., cumulative weight gains (grams) from day one.
number of rats.
statistical comparison at probability, P ( O. 05.

a:
b:
c:
A
B
C
D

Restrained Animals

II

-

significantly
significantly
significantly
significantly

different
different
different
different

from
from
from
from

vehicle- control group.
vehicle-restrained group.
guanethidine-control group.
reserpine-control group.

Drug doses, (i.p.) daily for 24 days: Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.

-..J
-..J
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Figure 1

THE EFFECT OF RESTRAINT ON MEAN CUMULATIVE DAILY WEIGHT GAINS
ON MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
50
()-()vehicle control
Q-0 guanethidine control
~reserpine control
0- -0 vehicle restrained
O--Oguanethidine restrained
[r-l:i.reserpine restrained

45
40

35

0

25
20

G
R
A

M

15

s
0

5

t
-5
-10

-15
0

I
2

DAYS OF TREATMENT
Solid symbols designate significant difference (P< 0. 05) from vehicletreated group. Drug doses, (i.p.) daily for 24 days. Guanethidine,
1.20 mg/kg. Reserpine, 0.2 mg/kg. Vehicle, glass-distilled water,
1 ml/kg.

TABLE III
THE EFFECT OF RESTRAINT ON MEAN DAILY WATER CONSUMPTION
OF MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Control Animals
Days of
Treatment

Vehicle
a

Restrained Animals

II

Guanethidine

Reserpine

Vehicle

Guanethidine

Reserpine

34 + 1. 23
(10)

36 + 1. 93
(lo)

31 + 0.95
(10)

30 + 3. 01
(10)

37 + 1. 52
(10)

1

32 + 1. 71
c1o)b

2

36 + 1. 65
(10)

32 + 1. 33
(10)

36 + 0.66
(lo)

35 + 1.42
(10)

41 + 5.35
(10)

42 + 1.23
(10) cc

3

33 + 1.27
(10)

32 + 1.17
(10)

32 + o. 73
(10)

36 + 1. 84
(10)

38 + 1. 08
(10) B

44 + o. 79
(10) c

4

34 + 1.17
(10)

31 + 1. 96
(10)

32 + 1. 84
(10)

37 + 1.61
(10)

36 + o. 95
(10) B

40 + o. 92
(10) c

5

33 + 0.76
(10)

31 + 0.85
(10)

32 + 0.98
(10)

36 + 1. 39
(10) A

42 + 3. 73
(lo) B

41 + 1. 99
(10) c

6

35 + 1.17
(10)

33 + 1.49
(10)

34 + 1. 36
(10)

39 + 1.68
(10) A

43 + 1. 99
(10) B

46 + 2.41
(10) c

7

35 + 0.85
(10)

35 + 1. 74
(10)

33 + 1. 17
(10)

36 + 1. 93
(10)

39 + 1.61
(10)

43 + 1.11
(10) c

8

31 + 2.15
(10)

36 + 2.25
(10)

32+1.27
(10)

37 + 1.42
(10) A

40 + o. 76
(10)

42 + 1.17
(9)
c

9

37 + 1. 39
(10)

35 + 1. 80
(10)

31 + 1.61
(10)

39 + 1. 84
(10)

38 + 1. 01
(10)

41 + 1.00
(9)
c

-...J
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TABLE III - continued

II

Control Animals
Days of
Treatment

Restrained Animals

Vehicle

Guanethidine

Reserpine

31 + 1. 20
(10)

30 + 1.63
(10)

31 + 1. 04
(10)

35+1.61
(10)

38 +
(10)

11

36 + 1.52
(10)

36 + 2.22
(10)

32 + 1. 93
(10)

38 + 1. 36
(10)

37+1.14
(10)

39+0.83
(9) c

12

34 +
(10)

o. 66

33 + 1. 90
(10)

25 + 1. 52
(10)

38 + 2.18
(10)

36 + 1.23
(10)

36 + 1. 53
(9) c

13

36 + 1. 93
(10)

34 + 2.47
(10)

28 + 1.14
(10)

33 + 1. 30
(10)

34 + 1.42
(10)

31 + 0.90
(9) c

14

36 + 1. 80
(10)

33+2.97
(10)

26 + 1. 65

(lo)

35 + 1. 39
(10)

35 + 1.49
(10)

29 + 1.47
(9)

15

35+0.60
(9)

32 + 1. 33
(10)

21 + 1.49
(10)

34 + 1. 61
(10)

36 + 1.08
(10) B

37 + 3.70
(9) c

16

32 + 1. 00
(9)

31 + 1. 65
(10)

26 + 2.12
(10)

33 + 1. 58
(10)

35 + 1.42
(10) B

32 + 2. 08
(8)

17

46 + 1. 87
(9)

35 + 2. 06
(10)

24 + 1. 90
(10)

37 + 2.22
(10) A

39 + 1. 80
(10)

30 + 4. 95
(8)

18

43+ 1.87
(9)

34 + 1. 96
(10)

33 + 2.97
(10)

37 + 1. 80
(10) A

40 +
(10)

o. 89

33 + 4.42
(8)

38 + 0.97
( 9)

32 + 1. 42
( 10)

28 + 1. 23
( 10)

38 + 2.69
(10)

36 + 1. 39
(10)

10

19

II

Vehicle

Guanethidine

o. 54
B

B

Reserpine
40 + 0.70
(9) c

33 + 2.98
(7)

00

0

TABLE III - continued
Control Animals
Days of
Treatment
20
21
22
23
24

a:
b:
c:

Restrained Animals

u

Vehicle

Guanethidine

Reserpine

Vehicle

Guanethidine

Reserpine

37 + 0.47
(9)

31 + 1.23
(10)

27+1.14

33 + 1. 68
(10)

37+1.17
(10) B

37 + 7.77

37 + 0.80
(9)

34 + 1. 01
(10)

29 + 1.49

39 + 1. 55
(10)

38 +
(10)

o. 60

35 + 2.83

40 + 1. 47
(9)

33 + 2. 34
(10)

27+1.87
(10)

36 + 2.18

38 + 1.47
(9)

32 + 1.51

(10)

38+1.57
(9)

34 + 1. 87
(10)

25 + 2 .12
(10)

38 + 1. 84
(10)

41 + 1. 37
(9)
B

29 + 1. 96

37 + 1. 70
(9)

34 + 1. 71

28 +
(10)

o. 79

32 + 1. 55
(10)

39 + 1.37
(9)
B

25 + 0.87

(10)

(lo)
(10)

(7)

(7)

(7)

(7)

(7)

c

mean+ S.E., ml of water consumed/rat/day.
number of rats.
statistical comparison at probability, P( 0.05.

A - significantly different from vehicle-control group.
B - significantly different from guanethidine-control group.
C - significantly different from reserpine-control group.
Drug doses, (i.p.) daily for 24 days: Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.
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Figure 2

THE EFFECT OF RESTRAINT ON MEAN DAILY WATER CONSUMPTION OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
50

0 control
o restrained

VEHICLE

40
ml
30
20
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2

12

24

22

18

GUANETHIDINE
50
40
ml
.--0----0

30
20

2

4

20

22

RESERPINE
50

ml

DAYS OF TREATMENT
Solid symbols designate significant difference (P( 0.05) from vehicletreated animals. Drug doses (i.p.) daily for 24 days: Guanethidine,
1.20 mg/kg. Reserpine, 0.2 mg/kg. Vehicle, glass-distilled water,
l ml/kg.
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TABLE IV
THE EFFECT OF CHRONIC GUANETHIDINE OR RESERPINE TREATMENT
ON THE MEAN SYSTOLIC BLOOD PRESSURE OF MALE ALBINO RATS
Days of
Treatment

Vehicle

1

114±3.1~

115 + 2. 2

100 + 1. 7 ABC

2

117+1.7

118+0.8

91 + 3.5 AB

3

119 +

o. 8

115 + 1. 7

95 + 3.1 AB

4

117 + 3.5

119 + 4.4

108 + 1. 3 AB

5

114 + 3.1

113 + 1. 7

98 + 4.4 AB

6

118 + 1. 7

120 + 2.6

97 + 2. 6 AB

7

114 + 4.0

116 + 2. 6

100 + 2.6 AB

8

117 + 3.1

121 + 0.8

104 + 4. 9 AB

9

115 + 1. 3

112 + 1. 7

96+2.2 AB

10

119 + 2.6

122 + 2.6

96 + 2.2 AB

11

118 + 3.1

117 + 2.2

100 + 4.9 AB

12

116 + 2.6

114 + 2. 2

99 + 4.0 AB

14

113 + 2.2

123 + 2. 6 Ac

97 + 4.4 AB

16

112+3.5

119 + 3.1

18

114 + 2. 2

116 + 2.6

96 + 4.9 AB

20

111 + 4.4

112 + 4. 9

94 + 3.5 AB

22

126 + 3.1

124 + 4.0

93 + 5.3 AB

24

124 + 3.5

125 + 2. 6

88 + 4. 0 AB

a:
b:
c:

Control Animals
Guanethidine

Reserpine

101 + 3.5

mean systolic blood pressure (mm Hg) ± S.E.
N = 5 animals/group
statistical comparison at probability; P ( 0.05.

A - significantly different from vehicle-control group
B - significantly different from guanethidine-control group
Drug doses, (i.p.) daily for 24 days: Guanethidine, 1.20 mg/kg.
Reserpine, 0.2 mg/kg. Vehicle, glass-distilled water, 1 ml/kg.
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Figure 3

THE EFFECT OF CHRONIC GUANETHIDINE OR RESERPINE TREATMENT
ON THE MEAN SYSTOLIC BLOOD PRESSURE IN MALE ALBINO RATS
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DAYS OF TREATMENT
Solid symbols designate significant difference (P < O. 05) from vehicletreated group. Drug doses, (i.p.) daily for 24 days: Guanethidine,
1.20 mg/kg. Reserpine, 0.2 mg/kg. Vehicle, glass-distilled water,
1 ml/kg.
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TABLE V
THE EFFECT OF RESTRAINT ON ABSOLUTE ADRENAL WEIGHT OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE

I

Control Animals
Days of
Treatment

a

Guanethidine

Reserpine

Vehicle

Guanethidine

Reserpine

0.020 + .001
(10)

0.022 + .001
(10)

0.021 + .002
(9)

0.022 + .002
(10)

0.021 + .001
(10)

1

0.022 + .002
(lO)b -

3

0.023 + .002
(10)

0.024 + .001
(10)

0.025 + .002
(10)

0.025 + .002
(10)

0.024 + .002
(10)

0.030 + .002
ABDC
(9)

6

0.017 + . 001
(10)

0.015 + .002
(10)

0.016 + .002
(10)

0.020 + .002
(10)

0.024 + .001
(10)

0.022 + .001
(10) AD

12

0.025 + ,001
(10)

0.025 + .001
(10)

0.026 + .002
(10)

0.030 + .002
(10)

o. 033 + . 003

0.027 + .002
(9)

0.028 + .002
(10)

0.024 + . 002
(10)

0.024 + .002
(10)

0.031 + .002
(10)

0.031 + .003
(9)

24

a:
b:
c:
A
B
C
D

Vehicle

Restrained Animals

(9)

AC

0.035 + .004
(6)
D

mean± S.E. (mg).
number of rats
statistical comparison at probability, P<0.05.
-

significantly
significantly
significantly
significantly

different
different
different
different

from
from
from
from

vehicle-control group.
vehicle-restrained group.
guanethidine-control group.
reserpine-control group.

Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Note: Twenty animals selected at random, no treatment, had adrenal weights of 0.029 + 0.002 mg.
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Figure 4
THE EFFECT OF RESTRAINT ON ABSOLUTE ADRENAL WEIGHT OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
CONTROL ANIMALS
0 vehd.cle

.035

0 guanethidine
6. reserpine
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1
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24

RESTRAINED ANIMALS
.035
.030

~

.025
.020
.015

1

3

6

2

DAYS OF TREATMENT
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg . Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Solid symbols designate a significant difference (P(0.05).
See Table V for statistical comparison.

TABLE VI
THE EFFECT OF RESTRAINT ON ABSOLUTE HEART WEIGHT OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
imals

Restrained Animals

II

Days of
Treatment

Vehicle

Guanethidine

Reserpine

Vehicle

Guanethidine

Reserpine

1

0.62 + .02a
c1o)b-

0.65 + .01
(10)

0.62 + .02
(10)

0.63+ .01
(9) -

0.59 + .02
(10) -Bee

0.61 + .02
(10)

3

0.68 + .02
(10)

0.66 + .02
(10)

0.64 + . 02
(10)

o. 75 + .02
(10) A

0.70 + .02
(lo)

0.69 + .02
(9) B

6

0.69 + .02
(10)

o. 71 + .02
(10)

0.71 + .01
(10)

0.68 + .02
(10)

0.68 + .03
(10)

0.67 + .01
(10)

12

o. 78 + . 03
(10)

o. 72 + .02
(10)

0.76+ .02
(10)

0.69 + .02
(10) A

0.71 + .02
(9)

0.61 + .02
(9) ABD

24

0 . 80 + .03
(10)

o. 72 + .02
(10) A

0.76 + . 03
(10)

0.66 + .02
(10) A

0.67 + .02
(9)
A

0.69 + .03
(6) A

a:
b:
c:
A
B
C
D

mean + S. E. (grams).
number of rats.
statistical comparison at probability, P ( 0. 05.
-

significantly
significantly
significantly
significantly

different
different
different
different

from
from
from
from

vehicle-control group.
vehicle-restrained group.
guanethidine-control group.
reserpine-control group.

Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Note: Ten animals selected at random, no treatment, had heart weight of D.84 + - 0.03 grams.
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Figure 5
THE EFFECT OF RESTRAINT ON ABSOLUTE HEART WEIGHT OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
CONTROL ANIMALS

o vehicle
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DAYS OF TREATMENT
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Solid symbols designate a significant difference (P( 0.05).
See Table VI for statistical comparison.

TABLE VII
THE EFFECT OF RESTRAINT ON ABSOLUTE BRAIN WEIGHT· OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE

Days of
Treatment

Control Animals

II

Restrained Animals

Vehicle

Guanethidine

Reserpine

Vehicle

Guanethidine

Reserpine

1

1. 62 + . 02a
(lO)b-

1. 69 + . 02
(10)

1.67 + .02
(10)

1. 60 + . 02
(9) -

1.61 + .02
(10) -

1. 66 + . 02
(10) -

3

1. 70 + . 04
(10)

1. 66 + . 02
(10)

1.65 + .03
(10)

1. 64 + . 03
(10)

1. 64 + . 04
(10)

1.62 + .03

1. 59 + . 03
(10)

1.63 + .03
(10)

1. 64 + . 02
(10)

1. 56 + . 03
(10)

1.55 + .02
(10) c

1. 59 + .03
(10)

12

1. 58 +
- .05
(10)

1. 66 +
- . 03
(10)

1. 70 + . 02
(10) -Ac

1. 57 + . 04
(10) -

1. 52 + . 02
(9)
c

1.53 + .02
(9)
D

24

1. 68 + .04
(10)

1.66 + .03

1. 62 + . 04
(10)

1.59 + .03
(10)

1. 65 + . 04
(9)

r. 58 +

6

a:
b:
c:

(10)

(~)

. 06

(6)

mean + S. E. (grams).
number of rats
statistical comparison at probability, P(0.05.

A - significantly different from vehicle-control group.
B - significantly different from guanethidine-control group.
D - significantly different from reserpine-control group.
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg.
Vehicle, glass-dis~illed water, 1 ml/kg.

Reserpine, 0.2 mg/kg.
·
00

Note:

Ten animals selected at random, no treatment, had brain weights of 1.64

± 0.03

\0

grams.
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Figure 6
THE EFFECT OF RESTRAINT ON ABSOLUTE BRAIN WEIGHT OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
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DAYS OF TREATMENT
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Solid symbols designate a significant difference (P( 0.05).
See Table VII for statistical comparison.
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Figure 7

TIME COURSE FOR THE DEVELOPMENT OF CORTICOSTERONE
FLUORESCENCE IN 30 N H2S04
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Figure 8
TYPICAL STANDARD CURVE FOR CORTICOSTERONE
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Fluorescence intensity at varying concentrations of corticosterone.
Fluorescence is given in arbitary units,
(meter multiplier x % transmission x 100)
Activating wave length, 470 mu.
Fluorescence wave length, 510 mu.

TABLE VIII
THE EFFECT OF RESTRAINT ON SERUM CORTICOSTERONE OF MALE
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Control Animals
Days of
Treatment

Vehicle

Guanethidine

Reserpine

Vehicle

Guanethidine

Reserpine

1

22+3.2a
c1o)b

23 + 2. 5
(10)

19 + 2.8
(10)

30 + 1. 7
(9) Ac

33 + 1. 9
(10) AC

31 + 1. 3
(10) AD

3

19 + 2.2
(10)

19 + 2.2
(lo)

16 + 1. 3
(10)

24 + 2. 2
(10)

25 + 1. 9

25 + 2.0
(9)
D

19 + 3. 5
(10)

25 + 1. 6
(10)

29 + 3.2
(10) A

24 + 2.2
(lo)

26 + 2.2
(10)

25 + 1. 6

21 + 2.2

20 + 2. 8
(10)

15 + 1. 6
(10) A

20 + o. 9
(10)

23 + 1. 7
(9)

28 + 2.5
(9)
ABD

25 + 2.8
(10)

25 + 2.2
(lo)

21 + 3. 2
(10)

27 + 2.3
(9)

33 + 3. 7
(6) B

6
12

(10)

24

23 + 2. 2
(10)

(10)

(10)

mean+ S.E. (mg/100 ml)
number of rats
statistical comparison at probability, P< 0. 05.

a:
b:
c:
A
B
C
D

Restrained Animals

-

significantly
significantly
significantly
significantly

different
different
different
different

from
from
from
from

vehicle-control group.
vehicle-restrained group.
guanethidine-control group.
reserpine-control group.

Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Note: Ten animals selected at random, no treatment, had serum corticosterone levels
of 16 ± 3.0 mg/100 ml.
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Figure 9
THE EFFECT OF RESTRAINT ON SERUM CORTICOSTERONE OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
CONTROL ANIMALS
35

O vehicle
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DAYS OF TREATMENT

Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, l ml/kg.
Solid symbols designate a significant difference (P ( O. 05).
See Table VIII for statistical comparison,
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Figure 10

TYPICAL STANDARD CURVE FOR ASCORBIC ACID
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TABLE IX
THE EFFECT OF RESTRAINT ON ADRENAL ASCORBIC ACID OF MALE
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE

a:
b:
c:

Restrained Animals

II

Control Animals
Days of
Treatment

Vehicle

Guanethidine

Reserpine

Vehicle

Guanethidine

Reserpine

1

570 + 3oa
(lO)D

492 + 23
(10)

503 + 29
(10)

371 + 41
(9) -Ac

359 + 23
(10) AC

367 +
29
(10) - AD

3

551 + 32
(10)

462 + 47
(10)

468 + 42
(10)

519 + 31
(10)

490 + 27
(10)

464 + 35
(9)

6

750 + 59
(10)

743 + 77
(10)

651 + 50
(10)

646 + 48
(10)

555 + 57
(10) A

690 + 47
(10)

12

585 + 39
(10)

518 + 27
(10)

593 + 44
(10)

521 + 39
(10)

580 + 39
(9)

551 + 27
(9)

24

560 + 28
(10)

572 + 40
(10)

623 + 50
(10)

581 + 53
(10)

596 + 34
(9)

595 + 58
(6)

mean + S.E. (mg{lOOg)
number of rats
statistical comparison at probability, P<0.05.

A - significantly different from vehicle-control group.
B - significantly different from guanethidine-control group.
D - significantly different from reserpine-control group.
Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Note: Twenty animals selected at random, no treatment, had adrenal ascorbic acid levels of
579 + 35 ug/lOOg.
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Figure 11
THE EFFECT OF RESTRAINT ON ADRENAL ASCORBIC ACID OF
MALE ALBINO RATS TREATED ' WITH GUANETHIDINE OR RESERPINE
CONTROL ANIMALS
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DAYS OF TREATMENT
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Solid symbols designate a significant difference (P <0. 05).
See Table IX for statistical comparison
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Figure 12
A TYPICAL GRAPH OF THE EFFECTS OF 10 N NaOH AND 5 N NaOH
ON THE RELATIVE FLUORESCENCE OF NOREPINEPHRINE
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138: 360, 1962.
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Figure 13
A TYPICAL GRAPH OF THE EFFECT OF ETHYLENEDIAMINE (EDA)
ON THE RELATIVE FLUORESCENCE OF NOREPINEPHRINE
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Figure 14
TYPICAL STANDARD CURVES OF NOREPINEPHRINE (NE) AND EPINEPHRINE (E)
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Figure 15
TYPICAL STANDARD CURVE FOR NOREPINEPHRINE
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Fluorescence intensity at varying concentrations of norepinephrine.
Fluorescence is given in arbitrary units,
(meter multiplier x % transmission x 100)
Activating wavelength, 400 mu.
Fluorescence wavelength, 520 mu.
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TABLE X
COMPARISON OF THE CONTROL TISSUE NOREPINEPHRINE (~) ASSAY WITH
PREVIOUSLY REPORTED VALUES USING THE SHORE AND .OLIN (1958) METHOD

Tissue
Rat brain

NE Cone. (ug/g)
0.237 + 0.008
0.236 + 0.010

Rat heart

This report

b

This report

0.238 + 0.023 (SD)

Porter et al. (1961)

0.243 + 0.011

Green et al. (1962)

0.255 + 0.026 (SD)

Green and Sawyer (1960)

a

1.032 + 0.049

b

This report

1. 022 +

o. 041

1. 060 +

o. 030

Bhagat (196 7)

1. 020 +

o. 040

Bhagat and Gillman (1960)

0.990 + 0.060

a:
b:

a

Source of Data

This report

Kuntzman and Jacobson (1964)

10 rats selected at random, no treatment
70 rats, vehicle-control, glass-distilled water, 1 ml/kg, i.p.

All values are expressed as the mean± S.E., except where indicated.
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TABLE XI
DOSE-RESPONSE EFFECT OF RESERPINE OR GUANETHIDINE ON BRAIN AND HEART
NOREPINEPHRINE (NE) OF MALE ALBINO RATS INJECTED (IP) DAILY FOR SIX DAYS

Treatment

ug/gm
Vehicle
Reserpine

Vehicle
Guanethidine

a:
b:

....

ml/kg
1.00
mg/kg
0.05

HEART NEa

BRAIN NEa

Dose

percent
deeletion

percent
depletion

ug/gm

0.224 + 0.005

00.0

1. 017 + 0. 044

00.0

0. 171 + 0. 008

23.7b

0.036 + 0.005

96.Sb

0.10

0.140 + 0.008

37. Sb

0.018 + 0.004

98.2b

0.25

0.092 + 0.003

58.9b

0. 009 +

o. 003

99.lb

1. 00

0.013 + 0.003

94.2b

0.005 + 0.003

99.sb

2.50

0.004 + 0.001

98.2b

0.002 + 0.002

99.8b

0.236 + 0.014

00.0

1. 016 +

0.274 + 0.007

00.0

0.714 + 0.046

29.7b

1. 0

0.238 + 0.016

oo.o

0.358 + 0.037

64.8b

2.5

0.242 + 0.014

00.0

0.198 + 0.016

80.Sb

5.0

0.247 + 0.016

00.0

0.096 + 0.008

90.6b

10.0

0.226 + 0.016

00.0

0.063 + 0.006

93.8b

ml/kg
1. 0
mg/kg
0.5

o. 028

00.0

Concentration of NE expressed as mean± S.E. for 10 animals in
each group.
significant difference from controls (P<0.01) .
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Figure 16
CALCULATION OF THE DD 1 50 FOR CENTRAL NOREPINEPHRINE
DEPLETING ACTION OF RESERPINE
100
90
80
70

~
H

H
rz:l
,..:i
p..
rz:l

60

~

~ 5

rz:l

u

i:.::
rz:l
p..

4
3

2

1

.10

.15

.20

• 25

• 30

DOSE (mg/kg)
A plot of the six day dose-response curve for norepinephrine
depleting effect of reserpine in the brain tissues of male albino
rats. (o) are the original points. Line was fitted by the method
of least squares (Snedecor, 1956).
1.

DD - depleting dose.
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Figure 17
CALCULATION OF THE DD 1 50 FOR PERIPHERAL NOREPINEPHRINE
DEPLETING ACTION OF GUANETHIDINE
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A plot of the six day dose-response curve for epinephrine
depleting effect of guanethidine in the heart tissues of
male albino rats. (o) are the original points. Line was
fitted by the method of least squares (Snedecor, 1956).
1.

DD - depleting dose,

TABLE XII
THE EFFECT OF RESTRAINT ON BRAIN NOREPINEPHRINE OF MALE
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Control Animals

Restrained Animals

II

Days of
Treatment

Vehicle

Guanethidine

Reserpine

1

0.257+ .007a
(lO)b -

0.228 + .009
(10) Ac

0.252 + .022
(10)

0.229 + .010
(9)
A

0. 243 + .009
(10)

0.188 + .008
(10) ABD

3

0.227 + .014
(10)

0.221 + .007
(10)

0.169+ .017
(10) A

0.209 + .007
(10)

0.231 + .004
(10) B

0.150 + .017
(9)
AB

6

o. 220

o. 214

12
24
a:
b:
c:
A
B
C
D

II

Vehicle

Guanethidine

Reserpine

+ . 006

(10)

(10)

0.110+ .012
(10) A

0.220 + .009
(10)

0.249 + .013
(10) c

0.064 + .008
(10) ABD

0.226 + .008
(10)

0.221 + .015
(10)

0.060+ .007
(10) A

o. 246

o. 300

(10)

(9)

+ .013
ABC

0.061 + .006
(9)
AB

0.259 + .014
(10)

0.238 + .019
(10)

0.025 + .006
(10) A

0.275 + .010
(10)

0.254 + .015
(9)
c

0.028 + . 005
(6)
AB

+ . 009

+ .014

mean+ S.E. (ug/g)
number of rats
statistical comparison at probability, P <.0.05.
- significantly different from vehicle-control group.
- significantly different from vehicle-restrained group.
- sign~ficantly different from guanethidine-control group.
- significantly different from reserpine-control group.

Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Note: Ten animals selected at random, no treatment, had brain norepinephrine levels of
0.237 ±. .008 ug/g,
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Figure 18
THE EFFECT OF RESTRAINT ON BRAIN NOREPINEPHRINE OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
CONTROL ANIMA;LS

o vehicle

.30

D guanethidine

'··

6. reserpine

.20
00

~.15
:J

.10

.05

RESTRAINED ANIMALS
.30

.25
.20

00
00

:J

.15

.10

.05

1

3

6

12

24

DAYS OF TREATMENT
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Solid symbols designate a significant difference (P(0.05).
See Table XII for statistical comparison.

TABLE XIII
THE EFFECT OF RESTRAINT ON HEART NOREPINEPHRINE OF MALE
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Control Animals
Days of
Treatment

Vehicle
a

Restrained Animals

II

Guanethidine

Reserpine

Vehicle

Guanethidine

Reserpine

o. 759 + .040
(10) -Ac

0.071+ .013
(10)
A

0.942 + .034
(9)

0.844 + .038
(10)
A

0.075 + .018
(10) - AB

1

1.003 + .033
c1o)b -

3

1.035 + .051
(10)

0.756 + .089
(10)
A

0.011+ .005
(10)
A

o. 702 + .034
(10)
A

0.545 + .047
(10)
AB

0.007 + .004
(9)
AB

6

0.967 + .032
(10)

0.528 + .025
(10)
A

0.014 + .004
(10)
A

0.635+ .022
(10)
A

0.698+ .045
(10)
AC

0.012 + .004
(10)
AB

12

1.091 + .037
(10)

0.638 + .041
(10)
A

0.020 + .005
(10)
A

1. 034 + . 046
(10)

0.864 + .029
(9)
ABC

0.018 + .009
(9)
AB

24

1. 023 + . 055
(10)

0.453 + .042
(10)
A

0.022 + .009
(10)
A

1.128 + . 046
(10)

0.845 + .055
(9)
ABC

0.047 + .017
(6)
AB

a:
b:
c:

mean± S.E. (ug/g)
number of rats
statistical comparison at probability, P < 0. 05.

A - significantly different from vehicle-control group.
B - significantly different from guanethidine-control group.
C - significantly different from reserpine-control group.
Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Note: Ten animals selected at random, no treatment, had heart norepinephrine levels of
1.032 + .049 ug/g.
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Figure 19
THE EFFECT OF RESTRAINT ON HEART NOREPINEPHRINE OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
CONTROL ANIMALS
O vehicle
D guanethidine
A reserpine
1.0

0.8
~0.6
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;:l
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0.2
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24

RESTRAINED ANIMALS

1. 0

0.8

bl)

o. 6

b l)

;:l

0.4
0.2

3

6

12
DAYS OF TREATMENT

Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
Solid symbols designate a significant difference (P ( O. 05).
See Table XIII for statistical comparison.

TABLE XIV
THE EFFECTS OF RESTRAINT ON THE FOOD INTAKEa, WATER INTAKE, MEAN WEIGHT
GAIN AND MORTALITY RATE OF RATS TREATED WITH GUANETHIDINE OR RESERPINE

Groups

Mean Water Intake
(ml/rat/day)

Mean Weight
Gain/Day (g)

Mortality
(percent)

Vehicle Control

36 +

o. 71

2.0 + 0.2

lOb

Guanethidine Control

33 + 0.35

1.8 + 0.1

0

Reserpine Control

30 + 0.76

0.7+0.3

0

Vehicle Restraint

36 + 0.49

0.2 + 0.2

0

Guanethidine Restraint

38 + 0.57

0.0+0.2

10

Reserpine Restraint

37 + 1. 06

0. 1 +

o. 3

40

All values are expressed as the mean + S.E. for the 24 day study.
a: food intake; 20 g/day.
b: accidental death.
N = 10 animals/group.
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.

,.....
,.....
0

TABLE XV
THE EFFECT OF RESTRAINT ON ADRENAL WEIGHT OF MALE
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE

I

Control Animals
Days of
Treatment
1

Vehicle
100 + 9a
(10) 0

Guanethidine
100 + 5
(10)

Reserpine
100 + 5
(10)

3

100 + 9
(10)

104 + 4
(10)

109 + 8
(10)

6

100 + 6
(10)

88 + 13
(10)

12

100 + 4
(10)

24

100 + 7
(10)

a:
b:
c:
A
B
C
D

Restrained Animals
Vehicle
95 + 10
(9)

Guanethidine
100 + 9
(10)

Reser ine
95 + 5
(10)

109 + 8
(10)

104 + 8
(10) -

130 + 7
(9 )-ABDc

94 + 13
(10)

118 + 10
(10)

141 + 4
(10)-AC

129 + 5

100 + 4
(10)

104 + 8
(10)

120 + 7
(10)

132 + 9
(9) AC

108 + 7
(9)

86 + 8
(10)

86 + 8
(10)

111 + 6
(10)

111 + 10
(9)

125 + 11
(6)-D

(10) AD

values are expressed as the percent of vehicle-control group. (mean+ S.E.)
number of rats
statistical comparison at probability, P<0.05.
-

significantly
significantly
significantly
significantly

different
different
different
different

from
from
from
from

vehicle-control group.
vehicle-restrained group.
guanethidine-control group.
reserpine-control group.

Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.
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TABLE XVI
THE EFFECT OF RESTRAINT ON HEART WEIGHT OF MALE
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Control Animals
Days of
Treatment

Restrained Animals

Vehicle

Guanethidine

Reser ine

1

100 + 3a
(lO)o

105 + 2
(10)-

100 + 3
(10)-

3

100 + 3
(10)

97 + 3
(10)

6

100 + 3
(10)

12
24
a:
b:
c:
A
B
C
D

Vehicle

Guanethidine

Reser ine

2
102 +
(9) -

95 + 3
(10)-BC

98 + 3
(10)

94 + 3
(10)

110 + 3
(10)-A

103 + 3
(10)

101 + 3
(9) B

103 + 3
(10)

103 + 1
(10)

99 + 3
(10)

99 + 4
(10)

97 + 1

100 +
- 4
(10)

92 + 3
(10)

97 + 3
(10)

88 + 3
(10)-A

91 + 3
(9)

78 + 3
(9) ABD

100 + 4
(10)

90 + 3
(10)-AC

95 + 4
(10)

83 + 3
(10)-A

84 + 3
(9) A

86 + 4
(6) A

(lo)

values are expressed as the percent of vehicle-control group (mean± S.E.).
number of rats
statistical comparison at probability, P<:0.05.
-

significantly
significantly
significantly
significantly

different
different
different
different

from
from
from
from

vehicle-control group.
vehicle-restrained group.
guanethidine-control group.
reserpine-control group.

Drug doses (i.p.) daily: Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.
I-'
I-'
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TABLE XVII
THE EFFECT OF RESTRAINT ON BRAIN WEIGHT OF MALE
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Control Animals
Days of
Treatment

Restrained Animals

Vehicle

Guanethidine

Reser ine

Vehicle

100 + 1 a
(10) 0

104 + 1
(10)

103 + 1
(10)

99 + 1
(9) -

99

100 + 2
(10)

98 + 1
(10)

97 + 2
(10)

6

100 + 2
(10)

103 + 2
(10)

12

100 + 3
(10)
100 + 2
(10)

1

3

24

a:
b:
c:

II

Guanethidine

Reser ine

+ 1

102 + 1
(10)

96 + 2

96 + 2

(10)

(10)

95 + 2
(9)

103 + 1
(10)

98 + 2
(10)

97 + 1
(10) c

100 + 2
(10)

105 + 2
(10)

108 + 1
(10)-AC

99 + 3
(10)

96 + 1

97 + 1
(9) D

99 + 2
(10)

96 + 2
(10)

95 + 2
(10)

98 + 2
(9)

(lo)

(9)

- c

94
(6)

+ 4

values are expressed as percent of vehicle-control group (mean+ S.E.)
number of rats
statistical comparison at probability, P< 0. OS.

A - significantly different from vehicle-control group.
B - significantly different from guanethidine-control group.
C - significantly different from reserpine-control group.
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.
I-'
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Figure 20

A COMPARISON OF THE EFFECTS OF RESTRAINT ON VARIOUS ORGAN WEIGHTS OF NORMAL AND GUANETHIDINIZED
MALE ALBINO RATS
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Solid symbols designate significant difference (P<0.05) from vehicle-treated group.
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Vehicle, glass-distilled water, 1 ml/kg.
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Figure 21

A COMPARISON OF THE EFFECTS OF RESTRAINT. ON VARIOUS ORGAN WEIGHTS OF NORMAL AND RESERPINIZED
MALE ALBINO RATS
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Solid symbols designate significant difference (P(0.05) from vehicle-treated group.
Drug doses, (i.p.) daily: Reserpine, 0.2 mg/kg. Vehicle, glass-distilled water, 1 ml/kg.

,......

,......
V1

TABLE XVIII
THE EFFECT OF RESTRAINT ON ADRENAL ASCORBIC ACID OF MALE
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Control Animals

Restrained Animals

II

Days of
Treatment

Vehicle

Guanethidine

Reser ine

Vehicle

1

100 + 5a
(lO)b

86 + 5
(10)

88 + 6
(lo)

65 + 11
(9) Ac

63 + 6
(10) AC

64 + 8
(10) AD

3

100 + 6
(10)

84 + 10
(10)

85 + 9
(10)

94 + 6
(10)

89 + 6
(10)

84 + 8
(9)

6

100 + 8
(10)

99 + 10
(10)

87 + 8
(10)

86 + 7
(10)

74 + 10
(lo) A

92 + 7
(lo)

12

100 + 7
(10)

89 + 5
(10)

101 + 7
(10)

89 + 7
(10)

99 + 7
(9)

94 + 5
(9)

24

100 + 5

102 + 7

111 + 8

104 + 9

106 + 6

106 + 10

a:
b:
c:

Guanethidine

Reser ine

values are expressed as the percent of vehicle-control group. (Mean + S. E.)
number of rats
statistical comparison at probability, P< O. 05.

A - significantly different from vehicle-control group.
C - significantly different from guanethidine-control group.
D - significantly different from reserpine-control group.
Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.
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TABLE XIX
THE EFFECT OF RESTRAINT ON SERUM CORTICOSTERONE OF MALE
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Control Animals
Days of
Treatment
1

Vehicle
100 + 14a
(lo)'D

Guanethidine
105 + 11
(10)

Reserpine
86 + 15
(lo)

136 + 6
(9) -AC

150 + 6
(10) AC

Reser ine
141 + 4
(10)-AD

Vehicle

Guanethidine

3

100 + 12
(10)

100 + 12
(10)

84 + 8
(10)

126 + 9
(10)

132 + 8
(10)

132 + 8
(9) D

6

100 + 18
(10)

132 + 6
(10)

153 + 11
(10) A

129 + 9
(10)

137 + 8
(10)

132 + 6
(10)

12

100 + 10
(10)

95 + 14
(10)

71 + 10
(10) A

95 + 5
(10)

110 + 7
(9)

133 + 9
(9) ABD

24

100 + 10
(10)

109 + 11
(10)

91 + 15
(10)

117 + 9
(9)

144 + 11
(6) B

109 + 9
(10)

values are expressed as the percent of vehicle-control group (mean+ S.E.).
number of rats.
statistical comparison at probability, P< O. 05.

a:
b:
c:
A
B
C
D

Restrained Animals

II

-

significantly
significantly
significantly
significantly

different from vehicle-control group.
different from vehicle-restrained group.
different from guanethidine-control group.
different ~ro~ reserpine-control group.

Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.
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TABLE XX
THE EFFECT OF RESTRAINT ON HEART NOREPINEPHRINE OF MALE
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE

ii

Control Animals
Days of
Treatment
1

a:
b:
c:

Vehicle
100 + 3a
(10)0

Restrained Animals
Guanethidine

Reser ine

94 + 4
(9) -

84 + 5
(10) A

7 + 28
(10) AB

Reser ine

Vehicle

76 + 5
(10) AC

7 + 18
(10) A

Guanethidine

3

100 + 5
(10)

73 + 12
(10) A

1 + 45
(10) A

68 + 5
(10) A

53 + 9
(10) AB

o. 5 + 57
(9) AB

6

100 + 3
(10)

55 + 5
(10) A

1 + 29
(10) A

66 + 3
(10) A

72 + 6
(10) AC

1 + 33
(10) AB

12

100 + 3
(10)

6 + 6
(10) A

2 + 25
(10) A

95 + 4
(10)

79 + 3
(9) ABC

2 + 50
(9) AB

26

100 + 5
(10)

44 + 9
(10) A

2 + 41
(10) A

110 + 6
(lo)

83 + 7
(9) ABC

5 + 36
(6) AB

values are expressed as the percent of vehicle-control group. (mean± S.E.)
number of rats.
statistical comparison at probability, P<0.05.

A - significantly different from vehicle-control group.
B - significantly different from vehicle-restrained group.
C - significantly different from guanethidine-control group.
Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.
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TABLE XX!

THE EFFECT OF RESTRAINT ON BRAIN NOREPINEPHRINE OF MALE
ALBINO RATS TREATED WITH GUANE'IHIDINE OR RESERPINE
Control Animals
Days of
Treatment

Guanethidine

Reser ine

Vehicle

Guanethidine

Reser ine

1

100 + 3a
(10)0

89 + 4
(10) Ac

98 + 9
(10)

89 + 4
(9) A

95 + 4
(10)

3

100 + 6
(10)

97 + 3
(10)

74 + 10
(10) A

92 + 3
(10)

102 + 2
(10) B

66 + 11
(9) AB

6

100 + 4
(10)

97 + 3
(10)

50 + 11
(10) A

100 + 4
(10)

113 + 5

29 + 13
(10) ABD

100 + 4
(10)

98 + 7
(10)

27 + 12
(10) A

109 + 6
(10)

133 + 4
(9) ABC

27 + 10
(9) AB

100 + 5
(10)

92 + 8
(10)

10 + 24
(10) A

106 + 4
(10)

98 + 6
(9) c

11 + 18
(6) AB

12
24

(10)

c

73 + 4
(10) ABD

values are expressed as the percent of vehicle-control group (mean± S.E.)
number of rats
statistical comparison at probability, P< O. 05.

a:
b:
c:
A
B
C
D

Vehicle

Restrained Animals

II

-

significantly
significantly
significantly
significantly

different
different
different
different

from
from
from
from

vehicle-control group.
vehicle-restrained group.
guanethidine-control group.
reserpine-control group.

Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.
I-'
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Figure 22
PITUITARY-ADRENAL RESPONSES AND CHANGES IN BRAIN AND HEART NOREPINEPHRINE AFTER DAILY ADMINISTRATION
OF SMALL DOSES (1.20 mg/kg, i.p. ) OF GUANETHIDINE. A COMPARISON OF THE EFFECTS OF RESTRAINT ON
ADRENAL ASCORBIC ACID , SERUM CORTICOSTERONE , BRAIN AND HEART NOREPINEPHRINE LEVELS

GUANETHIDINE CONTROL

RESTRAINT

GUANETHIDINE RESTRAINED

50
40
30

20

~ 10
~N

l§ 10
P:::
~

20

~

~ 30
::c: 40
u
~

50

~

~
~

P-<

60
70

O adrenal ascorbic acid
serum corticosterone
!:::.. brain norepinephrine
O heart norepinephrine

<>

80

90

1 3

6

12

24

1 3

6

12

24

1

3

6

12

24

DAYS OF TREATMENT
Solid symbols represent values differing significantly from normal (P(0,05). Each point represents
the mean of 6 - 10 animals except normal values which represent the mean of 60 animals.
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Figure 23
PITUITARY-ADRENAL RESPONSES AND CHANGES IN BRAIN AND HEART NOREPINEPHRINE AFTER DAILY ADMINISTRATION
OF SMALL DOSES 0.2 mg/kg, i.p.) OF RESERPINE. A COMPARISON OF THE EFFECTS OF RESTRAINT ON
ADRENAL ASCORBIC ACID, SERUM CORTICOSTERONE, BRAIN AND HEART NOREPINEPHRINE LEVELS
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TABLE XXII
ANALYSIS OF VARIANCE ("F" VALUES)

Source of
variation
Days
Drug
Restraint
Day vs Drug
Day vs Restraint
Drug vs Restraint
Interaction
(Day vs Drug vs Restraint)
a
b
c
d

-

Adrenal
Ascorbic Acid
7.8la
(4.26)d
0.00
(2.26)
10.89a
(1. 26)
10.3la
(8.26)
1.26
(4.26)
0.68
(2.26)
2.74a
(8.26)

Serum
Corticosterone
1.44
(4.26)
0.60
(2.26)
33. 23a
(1. 26)
4.44a
(8.26)
1.25
(4.26)
2.90c
(2.26)
2.98a
(8.26)

Brain
Nore~ine~hrine

Heart
NoreRineJi!hrin~

261. 70a
(4.26)
14.17a
(2.26)

686.90a
(4.26)
65.30a
(2.26)

(1. 26)
9.92a
(8.26)
7.80a
(4.26)
2.84c
(2.26)
2.84a
(8.26)

(1. 26)
37.79a
(8.26)
20.57a
(4.26)
0.21
(2.26)
11. 69a
(8.26)

o.oo

o.oo

Weight
Gains
13.65a
(4.26)
0.91
(2.26)
316.54a
(1. 26)
14.17a
(8.26)
5.6la
(4.26)
4.4lb
(2.26)
19.50a
(8.26)

significant at P<0.01.
significant at P<0.05.
significant at P <0.10.
degrees freedom

Note:

took into account unequal number of animals/group due to deaths.

Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.
,.....
N

N

V.
A.

DISCUSSION

Circadian Rhythms and Lighting Schedule
Wurtman (1967) stated that there are two major cycles governing the

amount of time for which a particular geographic locus is exposed to sunlight:

an on-off, 24-hour cycle of day and night, whose components are

usually of unequal length but average twelve hours per day in the course
of a year; and a continuous, annual cycle of change in the length of the
daily light period.

These cycles are accompanied by parallel cycles in

the intensity of the sunlight.
Isomorphic with, and frequently dependent upon, these two physical
cycles are two major endocrine phenomena:

diurnal and annual rhythms.

Many endocrine functions in animals demonstrate a 24-hour periodicity.
In all cases where these diurnal endocrine rhythms have been studied,
they have been found to be naturally synchronized with the ambient lighting schedule.

The adrenal-dependent rhythms tend to respond to experi-

mental lighting regimens, where they rapidly resynchronize to new
lighting schedules (Wurtman, 1967).
The studies of Hemmingsen and Krarup (1937) demonstrated that rats
were able to adapt ,to a complete reversal of the light-dark cycle in
eight to ten days.

Pittendrigh (1960) reported that in some animals a

repeated light-dark phase shift of a few hours may synchronize the
physiological rhythms after several days.

Pauly and Scheving (1967)

showed that circadian rhythms are synchronized by the light-dark cycle
to which the animals are subjected.
To minimize the annual variations also known to occur in an animal
(Leduc, 1961), the chronic restraint phase of the study was completed
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in approximately two months, from October 16th to December 19th.
B.

Stress.ing Procedure
The safety-pin method, described in the "methods and material"

section, was used to secure the animals during the stressing period, as
an alternate to the more usual method (Renaud, 1959) of taking the rats'
four paws directly to the metal posts of the restraining board.
safety-pin modification was employed for two reasons.

This

First, direct

taping of the rats' four paws to the metal posts each day required excessive handling of the animals; this extra handling affects behavior
(Weltman et al., 1961) and also introduced delays into the stress procedure.

Second, the daily removal of the tape from the chronically

restrained animais caused inflanunation, local edema, and general irritation to the paws.

All of these reactions were eliminated by leaving

the tape intact on the paws throughout the 24 days.

Preliminary studies

showed that most of the animals adapted to the tape and pins in two to
three days as was evidenced by the fact that they no longer tried to
remove them.
C.

Weight Gain Studies
This phase of the investigation was initiated to provide informa-

tion on the effects of restraint on the individual body weight of rats
treated with guanethidine or reserpine.

All animals used in this study

were routinely weighed to the nearest gram, daily, using an Ohaus 1 smallanimal balance.

Individual records were kept of the daily weights.

rats were housed, fed and watered as previously described.

1.

Ohaus Seale Corp . , Union, New Jersey.

The
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Steinberg and Watson (1959, 1960) showed that a variety of stressful procedures brought about a decrease in growth rate and a reduction
in the animals' intake of food and water.

Scott (1955) and Imms (1965)

ruled out a connection between the growth rate decrease in rats caused
by stress, and the reduction of either food or water intake.

Imms (1965),

however, did report some changes in water excretion which varied with
the types of stress.

He concluded that the data could be explained by

an increase in the rate of oxidative metabolism, since food consumption
was unchanged during stress while the rate of growth decreased.

Similar

results were noted in this study.
Jackson (1962) reported that comparing gross weights of the treated
animals to the gross weights of the untreated, control animals is valid
only when starting weights of both groups do not . differ.

Weight can be

quantified either in terms of animal weight on the first day of drug
treatment compared percentage-wise with animal weight at the end of the
study, (first day weight/final day weight X 100), or by subtracting beginning weight from final weight at the end of the study .

Two methods

of analysis of the body weight data were employed in this study :
a)

Daily weights .

For each day of the study, the individual

daily weights of all animals in each group were compared to the individual daily weights of the control groups .
b)

Cumulative daily weight gains .

These were determined by sub-

tracting the weight of each animal on day one from its weight on each
of the remaining days of the study.
Daily comparisons were made between the control groups and each
treatment group .

Mendillo (1965 ) and Guarino (1966) observed that the

second method is the most sensit i ve in a study such as this .
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The total weights of the control (vehicle-treated) group were
compared to the total weights of each experimental group on each day of
the study (Table XXIII, appendix).

There were no significant differ-

ences on days 1, 2 or 3; however, a significant difference between the
control group and the stressed (vehicle-treated) group occured on day 4
and continued until the end of the experiment.

This same observation

was noted with the reserpine-treated, stressed animals.

However, the

guanethidine-treated, stressed animals showed no significant change in
total weight from the total weight of the control animals until day 5.
The drug-treated, non-stressed animals showed no difference from the
control animals on any day of the study.
When the weights of drug-treated, stressed animals were compared
to those of the stressed, vehicle-treated animals, there was no significant difference .

However, when the weights of the control, guanethi-

dine-treated animals were compared to those of the stressed, guanethidine-treated animals, a significant decrease occured on day 5 and continued throughout the remainder of the study .

Further, when the weights

of the control reserpine-treated group were compared to those of the
reserpine-treated stressed group, a significant decrease occured on day
1 and continued throughout the study.
The cumulative weight gains from day 2 were calculated for each
animal.

The mean+ SE of these values was determined.

The cumulative

weight gains of the control group were compared to the gains of each
of the experimental groups for each day of the study.

This method of

presenting the data is very sensitive both to small changes in food
consumption and to altered metabolic rates (Mendillo, 1965) .
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Data presented in this manner are found in Table II and Figure 1,
which demonstrate that the reserpine-treated, control animals showed a
significant decrease in weight gains from day 2 to the end of the study,
except for days 3 and 4.

These values are negligible; however, in view

of the overall pattern.

The weight loss in these animals was completely

obscured when total weights were considered.

Guanethidine-treated, con-

trol animals had weight gains that were as stable as those of the vehicletreated control animals.
All stressed animals showed a decrease in weight gains.

Beginning

on day 2 and continuing throughout the study, weight changes in the
vehicle-treated, stressed animals were significantly lower than values
for the control group .

These animals exhibited negative weight changes;

that is, they lost weight.

At the end of the treatment these rats were

-5 + 15 grams lighter than their individual starting weights, while the
control rats were 49 + 13 grams heavier than their individual starting
weight.
Reserpine-stressed rats showed significant weight loss on day 3,
whereas the guanethidine-stressed rats showed a significant weight loss
on day 4.

These significant changes continued throughout the study.

When the cumulative daily weight gains of the stressed drug-treated
animals were compared to the stressed, vehicle-treated animals, a different daily pattern was seen; however, there was no significant difference
in the majority of the daily comparisons .
When comparing the cumulative daily weight gains of the control,
guanethidine-treated animals to the stressed, guanethidine-treated animals, there was a significant difference from day 4 on to the end of the
study.

A similar comparison between the two reserpinized groups revealed
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a significant difference on day 3 and on to the end of the study.
D.

Food and Water Intake Studies
This phase of the study involved the observation of daily food and

water intake of normal and of stressed rats treated with guanethidine
or reserpine.

A similar study done in this laboratory (Rosecrans, 1963)

showed a 50% mortality in reserpine-treated, restrained rats.

He stated

that reserpinized animals subjected to restraint appeared to die from
starvation which seemed to stem from their inability to adapt to the
stress, since normal reserpinized animals had a mortality rate one-fifth
that of the stressed animals.

The decreased water and food balance

caused by reserpine would attest to this nonadaptation.
Animals were housed, fed and watered as previously described.
During the 5-hour period that test animals were being restrained, the
control animals were kept without food and water.

At the end of the

study the rats were sacrificed as previously described.
Analysis of the food intake data during the 24-day study showed
that the rats ate all the food offered to them.

Analysis of the water

intake data during this 24-day period showed that the mean total ml
intake per control animal per day was 36 + 0.71 .

In comparison to the

vehicle-treated, control animals, the control, guanethidine-treated
animals drank 8% less water per day and the control, reserpine-treated
animals drank 17% less water per day.
The water intake data for the stressed animals showed that there
were no significant differences in the mean total ml intake per animal
per day.

The vehicle-treated, stressed animals drank 36 + 0.49 ml/day;

the stressed, guanethidine-treated animals drank 38

± 0.57

ml/day; and
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the stressed, reserpine-treated animals drank 37

±

1.06 ml/day.

However,

when data for the control, guanethidine-treated animals were compared to
those for the stressed, guanethidine-treated animals, and when the data
for the control, reserpine-treated animals were compared to those for
the stressed, reserpine-treated animals, there appeared to be a significant difference.

A summary of the mean daily intake per rat per day

for water and for food is found in Table XIV.

The daily variations in

water intake are shown in Table III and Figure 2.

The restrained, drug-

treated animals drank more water per day than did the control, drugtreated animals.
E.

Blood Pressure Studies
Since both guanethidine and reserpine have the ability to lower

blood pressure in rats, it was thought that a reduction in blood pressure might affect the ability of the rats to adapt to the chronic (24-day)
restraint procedure.

Therefore, the object of this study was to

determine whether the dose of guanet hidine or of reserpine used in the
chronic restraint studies had any effect on the blood pressure of the
test animals.

Guanethidine (l . 20 mg/kg) and reserpine (0 . 2 mg/kg) were

administered i.p., daily for 24 days .

Drug vehicle, glass-distilled

water (1 ml/kg), was administered daily to the control animals.

There

were five animals per group .

Housing, handling and daily protocol were

all as previously described .

Blood pressures were recorded daily for

the first 12 days and then every other day until day 24 .

The pressure

was measured by means of the tail cuff (indirect) method .

Blood pres-

sure was not recorded in the rats that were restrained for the 5-hour
period, because the blood-pressure method requires incubation of the
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rat at about 40° for 15 to 20 minutes .

This incubation would add to

the daily protocol, another stressor procedure that might obscure the
results (Mendillo, 1965) .
The results from this series of experiments showed that the systolic blood pressure of the guanethidine-treated rats did not signif icantly differ from that of the control rats during the 24 days of
treatment.

The mean systolic pressure in the guanethidine-treated ani-

mals ranged from 112 + 1.7 to 125 + 2 . 6 mm Hg and the mean systolic
pressures in the control animals ranged from 111 + 4.4 to 126 + 3 . 1 mm
Hg.

However, in rats receiving reserpine, the systolic blood pressure

was decreased by some 17%, a significant difference from both the control rats and the guanethidine-treated rats .
range was 88

±

4.0 to 108

±

The systolic pressure

1 . 3 mm Hg in the reserpine-treated rats.

The results are summarized in Table IV and Figure 3 .
F.

General Observation Studies
Throughout the chronic phase of the study, all the control animals

appeared to be sedated.

The onset of maximal sedation was not observed

in these animals because of the daily protocol; however, the onset of
sedation appeared about one to two hours following the administration
of reserpine and about one hour following guanethidine administration.
Recovery from sedation was evident after 24 hours in all animals.
The sedation observed in the vehicle-treated animals was not as
pronounced as in the drug-treated animals .

Reserpine-treated animals

were less responsive to noise and mild probing than were guanethidinetreated and vehicle-treated animals .
most responsive .
progressive:

The vehicle-treated animals were

The degree of sedation with reserpine seemed to be

less response to noise was observed by the twelfth day,
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and it decreased even more by day 17.
All drug-treated animals exhibited some degree of ptosis.

Mild

ptosis was observed daily in the guanethidine-treated animals, but it
was more pronounced from the fifth:aay t~ the completio~ of the study.
The daily onset of ptosis in the guanethidine-treated animals was
earlier than in the reserpine-treated animals; however, ptosis was
more pronounced in the reserpine-treated animals.
All control animals were defensive; also, the reserpine- or the
guanethidine-treated animals were more irritable than the vehicletreated animals.

Vehicle-treated animals subjected to daily restraint

demonstrated an extreme degree of excitability during the first six
days:

a behavioral effect that progressively decreased with the dura-

tion of the experiment, indicating some degree of adaptation .

Rosecrans

and DeFeo (1965) reported similar findings .
The excitability of the vehicle-treated, stressed animals was
greatest at the onset of the restraining procedure :

they struggled

excessively when being tied down, concentrating their efforts on release
from the restraining boards .
easy to handle.

When released, they were exhausted and

The guanethidine-treated, stressed animals were moder-

ately active when being tied down and during restraint .

On release

from the restraining boards these animals, although they were more
active than their vehicle-treated counterparts, could nevertheless be
handled without difficulty .

The reserpinized-stressed

animals were

less excitable at the onset of the exper iment; however, they became
more excitable and difficult to handle as the experiment progressed.
More specifically, throughout the experiment, the reserpine-treated
animals

were very eas ily tied down and lay still on the boards; but,
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as the experiment progressed, they became increasingly vicious upon release from restraint.

These animals appeared to exhibit a type of "sham

rage", attacking, biting and clawing anything that came within their
reach.

They frequently fought amongst themselves after being placed in

their cages.

These symptoms would indicate a type of non-adaptation.

Generally, by day 5 all the stressed animals were noisy, but not
aggressive.

The next day all the animals struggled harder on the boards

and were more difficult to handle when released; particularly, the reserpine-treated animals were very aggressive when released.
the animals became more restless when tied down.

Day 7, all

By day 10 the animals

were hard to handle when released from stress; in addition they took on
the appearance of exhaustion, a condition that increased slowly to day 12.
On that day the reserpine-treated animals showed decreased activity when
restrained.

Day 13, the vehicle-treated, stressed animals were gasping

during the restraint procedure and looked lethargic .

On day 18 the

reserpine-treated animals appeared semiconscious and by day 24 there was
40% mortality in the reserpine-treated, stressed animals .
All the stressed animals showed increased activity, compared to the
control animals.

All stressed animals defecated and urinated when being

tied down and also when they were tied down.

Diarrhea was noted in the

stressed animals but not in the control animals .

Priapism was noted in

all stressed animals; however, it did not occur daily in every animal.
There was 10% mortality in the guanethidine-treated stressed animals.
When the animals were sacrificed, the hyperreflexia associated with
decapitation was absent only in the reserpine-treated animals.
Chromodacryorrhea was noted in all stressed animals at some time
during the restraining procedure .

This varied from 10 to 40% in vehicle-
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treated animals, 30 to 50% in the guanethidine-treated animals and 30
to 80% in reserpine-treated animals.

This response was occasionally

observed in · some of the drug-treated control animals.
In summary, the vehicle-treated, stressed animals were excessively
active and struggled when being tied down but were easy to handle when
released.

The guanethidine-treated stressed animals were moderately

active and somewhat harder to handle when released from the stress.
The reserpine-treated stressed animals became progressively excited
when released from restraint, although the tie-down was initiated with
greater ease then with the control animals.
G,

Effects of Restraint on the Pituitary-Adrenal Axis and Various
Organ Weights of Normal, Guanethidine or Reserpine Treated Rats

1.

Organ Weight Studies
Organ weight relationships, expressed as absolute weights, are

shown in Tables V, VI, VII and in Figures 4, 5, 6; the relationships,
expressed as the relative weight (g/lOOg of the body weight), are shown
in Tables XXIV, XXV, XXVI in the appendix.

These values are given in

both forms to demonstrate the relationship of the organ weights, both
when compared to each other and when compared to body weight .
Although the most direct index of ACTH hypersecretion would be the
elevation of the plasma level of the hormone, a routine method for its
estimation is not available .

Therefore, indirect indices that reflect

the action of ACTH on the adrenal cortex were sought .

However, no

single test adequately defines the time-course of ACTH release (Maickel
et~ · ,

1961).

The classical biochemical response evoked by cold stress

is a decrease in AAA, a rise in plasma corticosterone , an increase in
liver TP activity, an increase in the weight of adrenal glands, and an
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excessive metabolization of FFA from body fat depots, (Westermann et al.,
1962).

These various responses are also indices of pituitary-adrenal

stimulation in the rat (Maickel et al., 1961).

In the present report,

three of the preceding responses were used to indicate pituitary-adrenal
activation: increase in adrenal weight; decrease in AAA; and increase in
plasma corticosterone.
The adrenal hypertrophy is a measure of the cumulative effect of
ACTH, since maximal increases are attained only after several hours of
pituitary stimulation .

This index is particularly useful in describing

a prolonged pituitary stimulation, because adrenal hypertrophy can persist long after corticosterone have returned to almost normal (Maickel
et al., 1961).

The AAA test indicates the approximate intensity of an

acute discharge of ACTH; but it is of little value in determining the
time-course, since ascorbic acid does not return to normal for some hours
after the pituitary stimulus has stopped (Long, 1947).

The plasma corti-

costerone in the rat is an accurate barometer of the intensity of the
ACTH discharge, and it is also a good indicator of its duration, since
the adrenal glucocorticoid secretion returns to normal shortly after the
stimulus is discontinued ( Schonbaum et al . , 1959) .
The application of these tests in this study indi cate that restraint,
guanethidine and reserpine elicit similar signs of pituitary-adrenal
activation:

adrenal hypertrophy; decreased AAA; and elevated plasma

corticosterone.

Maickel et al.(1961) reported that similar responses

in hypophysectomized rats, exposed to cold (4°) and given reserpine, do
not occur and inferred that they are caused by hypersecretion of ACTH.
According to Selye's theories regarding chronic stress, animals
respond differently to individual stressors only in a guantitative way,
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the responses all being qualitatively the same.

Therefore, one of the

objectives of this experiment was to characterize the effect of CRS in
normal animals in terms of GAS.

Since the brain, heart, and adrenals

had to be weighed for the analysis of NE and AAA, respectively, it became of interest to see if the stress procedure or drug treatment had
any effect on the weight of these organs.

Selye (1950) stated that, in

the case of GAS, the AR might be subdivided into two, more or less distinct phases:

1.

the phase of shock, which might vary from a few min-

utes to about 24 hours, depending upon the intensity of the damage
inflicted; and 2 .

the phase of counter-shock.

Here, Selye observed

an increase in the adrenal weight, indicating adrenal hyperfunction.
In general, he tnaintained that the reversal of most of the changes seen
during the shock phase occurred in ·the phase of counter-shock.
Gray and Munson (1951) reported that the responses of the hypothalamic-pituitary-adrenocortical system to stress are extremely
rapid.

Virnikos-Danelles, (1964) and Stockham, (1964), demonstrated

an increase in plasma and adrenal corticosteroid in the rat as early
as 100 seconds after application of a stimulus.

Jones and Stockham

(1966) showed that a second stress maintained the high levels of adrenocortical synthesis induced by the first stress for a longer period of
time, rather than inunediately causing an increase in the plasma levels.
Because of experimental design and since the pituitary-adrenal
axis response to stress is rapid, it was not within the scope of these
studies to characterize the AR completely, or to characterize it in
terms of different shock-phases .

Nevertheless, appearance of the

shock-phase might be suggested to some degree by the slight decrease
in the absolute adrenal weight in stressed animals treated with vehicle
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or with reserpine on day 1 as compared to the non-stressed animals
(Table V and Figure 4).
slight increase.

Guanethidine-treated, stressed rats showed a

Also, appearance of the counter-shock phase might be

suggested by the enlargement observed in the adrenals in all groups of
animals on day 3.

The maximal increase in relative adrenal weight was

noted on day 24 for stressed rats treated with vehicle or with reserpine
and on day 12 for the guanethidine-treated, stressed rats.

Control rats

treated with the vehicle or with the drugs showed similar responses.
In general, there was an increase in the absolute adrenal weight
in all the groups studied, but the stressed animals showed a greater
variation in the adrenal weight than did the control animals.

Vehicle-

treated control animals showed an increase of 0,006 mg from day 1 to
day 24, whereas the vehicle-treated, stressed animals showed an increase
of 0 . 010 mg over the same period of time.
from the drug-treated animals.

Similar results were

obt~ined

The reserpine-treated stressed animals

showed the largest variation in weight, 0.014 mg .

Significant differ-

ences, however, appeared only on days 6 and 12 with the guanethidinetreated animals and on days 3 and 6 with the reserpine-treated group.
(See Table V for a statistical comparison.)

The data in Table V shows

an increase in the absolute adrenal weight, in the vehicle-treated control animals suggesting that the injection of water also induced a form
of stress; however, the data in Table XXIV (appendix) shows that there
was no change in the relative adrenal weight in these animals over the
24-day study, except for day 6 .

These data also show that, in the

vehicle-treated, stressed animals, there was an increase in the relative adrenal weight, reaching a maximum on day 12.

In fact, all of the

stressed animals showed the maximum increase on day 12.

Table V,
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representing the absolute adrenal weight, failed to demonstrate this
point.

The control animals did not show a significant change when the

adrenal weight was represented in this manner.

Comparison of the rela-

tive adrenal weight, Table XXIV, makes clear that the control animals
treated with vehicle or with drug showed no significant increase in the
adrenal weight; however, there was an increase in adrenal weight in the
stressed animals.
With the possible exception of biological variation, the low
figures observed on day 6 are impossible of a valid explanation.

In

nearly all parameters tested, day 6 gave an unusual response.
It is difficult to analyze glandular activity from a weight change
only, but on the basis of the severity of restraint, the increase in
weight of the adrenals could be due to ACTH stimulation and associated
chemical depletion during extreme activation.
Selye (1950) reported that congestion, edema, and hemorrhage in
the brain are often particularly conspicuous in men who die from heatstroke.

Acute swelling, shrinkage, or pyknosis of cells have also been

reported, but some investigators regard these as postmortem artifacts .
All these changes are so similar to those produced by other types of
intense acute stress that they may well be nonspecific manifestations
of the GAS.

Also, experimental evidence has shown that stress and over-

dosage with various hormones which are produced during stress can cause
characteristic morphologic changes in the heart.

Mineralocorticoids can

elicit a type of myocarditis very similar to that seen in acute rheumatic
fever.

Irritation of animals with an electric current is also effective

in causing cardiac lesions.

Shapiro and Melkado, in 1957, reported an

increase in heart size in stressed animals.

However, these same

138
investigators, in 1958, reported that there was no significant change
in heart weight due to stress.
In this study, analysis of heart weights varied according to the
method of data treatment.

The absolute heart weights of the stressed

animals treated with vehicle or with drug varied from day to day, perhaps an indication of the effect of stress.
in the control animals

The absolute heart weights

treated with vehicle or with drug (Table VI and

Figure 5) showed an overall increase from day 1 to day 24, perhaps an
indication of growth.

However, when the relative heart weights (Table

XXV; appendix) were compared, an inverse relationship for these data
appeared in the control animals (vehicle and drug treated); whereas
the data for the stressed animals all showed an increase.

All groups

reached I maximum relative heart weight on day 12, and again, there was
an unusual response on day 6.

Because the relative heart weights were

higher for the stressed animals than for the control animals (See
Tables VI and XXV for a statistical comparison), there is some indication that stress had an effect on the total heart weight.
Absolute brain weights likewise varied from day to day to the
extent that no correlation could be made in all the groups studied.
(Table VII and Figure 6).

However, when the brain weights were ex-

pressed as the relative weights, Table XXVI (appendix), an inverse
rel~tionship

was noted as with the heart weights.

There w.as also a

change in t:he brain weight on day 12 of all the stres·sed ani'mals,
except the guanethidine-treated animals, that corresponded to the
changes seen with adrenal and heart weight, when expressed in this
manner.

(See Tables VII and XXVI for a statistical comparison.)

summary, the most significant statement that can be drawn from the

In
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brain weight data is that expressing brain weights as percentage of body
weight seems to be the most sensitive method for analysis.
The effects of daily restraint on the organ weights of normal rats
make evident to a degree their ability to adapt.

Following the initial

AR, the tendency of the adrenal weight to return to the original values
is a good example of animal adaptation to external environment, as is
perhaps the stabilization of the heart and brain weights on day 12.
2.

Serum Corticosterone Studies
To establish a reliable method of assay for corticosterone, the

method described by Guillemin et al., 1959a was used.

Two modifica-

tions of the fluorescence reagent were tried and checked for their
stability and fluorescence ability.

A mixture of sulfuric acid and

50% aqueous ethanol in a ratio of 2.4:1 (Zenker and Bernstein, 1958)
was tested, as was a mixture of sulfuric acid and absolute ethanol in
a 65:35 ratio (Peterson, 1957).

However, it was found that Guillemin's

original fluorescence reagent (30N H so4 ) gave maximal fluorescence,
2
sufficient to be measured in a final volume of four ml in an AmincoBowman spectrophotofluorometer.

A comparison of the control tissue

corticosterone values with previously reported values (Maickel et al.,
1967) using the Guillemin et al (1959a) method was also carried out.
A statistical comparison of the effects of restraint on serum
corticosterone in the rat treated with guanethidine or reserpine is
given in Table VIII and Figure 9 .

There was an increase on day 1 from

day 0 in the vehicle-treated, control animals, but it was not as great
as in the vehicle-treated, stressed animals .

There were similar in-

creases in all the other groups, but the stressed group values on day 1
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were approximately double those on day 0.

There was a return to lower

levels on day 3 in the drug-treated, control animals, followed by an
even greater increase on day 6.

By day 12 and day 24, the cycle appeared

to repeat itself.
3.

Adrenal Ascorbic Acid Studies
The reliability of the method for the assay of AAA (Maickel, 1960)

was determined.

It was observed by Dixit (1965) and in this laboratory

that, when a stock solution of ascorbic acid (10 mg/ml) in 5% TCA was
prepared in double-glass-distilled water, it oxidized very rapidly, even
when refrigerated .

The rate of oxidation was found to be related to the

concentration of TCA (Dixit, 1965).

Dixit also observed that the addi-

tion of 2% MPA protected the ascorbic acid from oxidation, and that the
solution was stable for at least five dµys in the refrigerator.

However,

the addition of 2% MPA increased the time required for the development
of maximal color intensity at room temperature (24-25°), and consequently
increased the time required to complete the assay .

This difficulty was

0

overcome by completing the reaction at 27-38 ; under these conditions,
maximal color intensity was obtained within 20 minutes .
Musulin and King (1936) showed that the oxidation of MPA serves to
protect ascorbic acid in solution against oxidation in the presence of
TCA.

They suggested that the high aci_dity could protect the ascorbic

acid from oxidation; and in this respect, MPA (5.0 to 8.0%) was rated
highest.

In the present study, it was found that the pH of 5% TCA and

of 5% TCA + 2% MPA were practically the same, pH 1.0 and 0.95 respectively, an indication that high acidity, as such, is of little importance in preventing the oxidation of ascorbic acid.

A comparison of

the control AAA values with previously reported values (Dixit, 1965),
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both using the Maickel (1960) method, was carried out.
The AAA values are presented in Table IX and Figure 11.

Values

for vehicle-treated, control rats were fairly stable throughout the
study, except for day 6, which showed an unusual response.

Control ani-

mals treated with guanethidine or reserpine showed similar responses
throughout the study; however, on day 6, the response with the reserpinetreated animals was less than that with the guanethidine-treated animals.
Both these groups showed higher values on day 24 than those for the
vehicle-treated, control animals.
The restrained animals, vehicle and drug treated, showed initially
the same response; a decrease on day 1, followed by increases on days
3 and 6.

Guanethidine-treated animals showed less of a gain on day 6

than did either the vehicle- or reserpine-treated animals .

The values

from day 12 to day 24 were not significantly different from controls.
These tables and figures show that there was a fall in AAA and a
rise in serum corticosterone on day 1 in the vehicle-treated, stressed
animals:

an indication of an AR and an activation of the pituitary-

adrenal system.

These responses were reversed by day 3 :

of physiological adaptation.

an indication

By day 6 the responses were fairly constant,

a confirmation of the animals' adaptation to the external environmental
changes.
Control animals, treated with guanethidine or reserpine, exhibited
variations in AAA and serum corticosterone that were similar to the stress
reaction seen with the vehicle-treated, stressed animals; reserpinetreated rats were less reactive to the stress than were the other animals.

The response varied somewhat in each group of animals, but the

guanethidine-treated, control animals appeared to adapt by day 12,
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whereas the reserpine-treated, control animals never seemed to adapt.
This was not unexpected; Maickel

~

al. (1961) had shown that reserpine

produces a biochemical picture similar to that produced by cold stress.
Nor was the response seen with the guanethidine-treated, control animals unexpected; however, it has not been reported in the literature.
The vehicle-treated, control rats also exhibited a slight AR .
ag~in

Day 6

showed the unusual response in the control animals.
In general, the drug-treated, stressed animals exhibited a

greater AR as compared with the vehicle-treated, stressed animals.
The

respons~s

reversed themselves by day 3 in both groups of animals;

however, the reserpinized animals did not

appea~

to adapt until about

day 12, another indication that reserpine tends to prevent adaptation.
The pituitary-adrenal system was apparently active throughout the
period of chronic stress even though serum corticosterone returned to
normal by day 12.

The fact that the adrenal weight did not return to

control values, but showed a general trend of returning toward normal,
may indicate an increase in adrenal efficiency or responsiveness.
lar observations were noted by Rosecrans and DeFeo (1965).

Simi-

This effect

may be the result of a progressive response of the adrenals to ACTH as
demonstrated by Stark et al . (1963).

AAA, however, returned to normal

by day 24 .
Although an apparent decrease in pituitary and adrenal function
prevailed during adaptation to stress, the serum corticosterone exhibited relative adaptation and appeared to be maintained at high levels
throughout the experiment, especially in the guanethidine- and reserpinetreated animals .

If the adrenal weights can be considered an indication

of corticosteroid synthesis and release, then the concurrent maintenance
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of both serum corticosterone and increased adrenal weight would indicate
an increased adrenal efficiency during adaptation to stress.

These

indices are also good indications of the duration of ACTH discharge and
prolonged pituitary stimulation respectively.
Reserpine appears to have produced a definite effect of its own on
the pituitary-adrenal axis.

At the beginning, the effects of reserpine

on organ weights of normal animals were almost identical to the effects
of restraint in the vehicle-treated animals.

However, on day 3, the

heart weights in the vehicle-treated, stressed animals showed an increase,
while the reserpine-treated, non-stressed animals showed a decrease in
weight.

Organ weight changes, Figures 20 and 21, were divergent, in con-

contrast to untreated animals under stress; however, there were some
signs of adaptation in the organ weight values.
The serum corticosterone values would indicate that reserpine does
not prevent animals from achieving adrenal adaptation, since these values
are approximately the same .as those of untreated stressed animals.
Reserpine evoked adrenocortical responses similar to those seen in the
restrained animals (Figure 23), but it apparently did not inhibit CRS
to any degree.

In fact, it seemed to act as an acute stimulator of the

pituitary-adrenal axis and prevented the animal from adapting to the
stress.

How reserpine prevented adaptation has not been determined.

Guanethidine also produced a definite effect on the pituitaryadrenal axis.

Guanethidine-treated, control animals showed responses

in organ weights almost identical to those for the reserpine-treated,
control animals.

Similar responses were also noted in the stressed

drug-treated animals with regard to organ weights.

Guanethidine also

appeared to prevent adaptation to stress, as indicated by its dissimilar
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effects on the various organ weight changes.

However, by day 24, the

adrenal weights were returning toward normal, an indication of a type
of adaptation.
Serum corticosterone and AAA in guanethidine-treated, nonstressed
rats were identical to those of the reserpine-treated, nonstressed rats.
Similar responses were also noted in the vehicle-treated, nonstressed
animals .

These responses lead to the suggestions, first, that the in-

jection per

~

had some effect on the pituitary-adr-enal axis, second,

that a drug having a systemic response stimulates the ~i.tuit. µ-y-adrenal
f ,'

I

axis to a greater degree, and, third, that the response observed may
be identical in most if not all drug studies .

While these suggestions

are admittedly based on mere speculation at this point, it is fact
with the two drugs used in this study and may not apply to other drugs.
It can also be seen in Figure 22 that the guanethidine-treated, stressed
rats appeared to adapt to the stress, as indicated by the tendency of
serum corticosterone and AAA to return to normal .

Reserpine-treated,

stressed rats showed quite a different picture, Figure 23.
H.

Effect of Restraint on the Brain and Heart Norepinephrine Levels
in Normal, Guanethidine or Reserpine Treated Male Rats

1.

Norepinephrine Assay Studies
The method used was designed to permit a rapid evaluation of the

ability of certain compounds to deplete both brain and heart of NE; it
is a modification of existing procedures, principally the Shore and
Olin (1958) organic extraction method.

According to Anton and Sayre

(1962), this method is probably the most convenient one to determine
CA in tissue; however, it can be used only for tissue, and it may be
further restricted to certain tissue, such as the brain and heart.
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They could not completely recover added CA from rat and guinea pig liver,
and occasionally recoveries from brain decreased from about 60% to about
25% for no apparent reason.

This variability was also noted by other

investigators (Green and Erickson 1960).
Shore and Olin (1958) reported that the partition coefficient of
NE between the butanol and the aqueous-acid phase (10:1) was 0.65.

In

this investigation about 65% of NE added to tissue homogenates was recovered.

These recoveries were not consistant; however, replicate

determinations carried out on homogenates without adding NE gave values
for the endogenous CA that were reproducible within 10% (±3 SEM).
Since the present investigation was concerned with the effect of
drugs on tissue levels of NE, the absolute amount of NE in the tissue
was of consequence, only if, under rigidly controlled analytical conditions, the replicate determinations of NE were constant.

Hence, all

the results reported are in terms of micrograms of endogenous NE per
gram of tissue, without correction for the partition coefficient of
added amine, between the organic phase and the aqueous-acid phase.
It was observed in this laboratory that the alkaline ascorbic
acid solution prepared by the method of Maynert and Klingman (1962)
tends to age rapidly, turning pink in less than an hour.

Anton and

Sayre (1962) observed that the use of lON NaOH made the ascorbate
solution more stable and less subject to discoloration.

They also

found that in their oxidation procedure, as the volumes of a standard
CA solution increased, an almost linear response was obtained with
alkaline ascorbate made with lON, but not with SN NaOH.

A similar

response was noted in the present investigation (Figure 12).

However,

it was observed that the mixture of ascorbic acid and the lON Na(ji was
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also somewhat unstable, discoloring after a few hours.

This change was

usually accompanied by increased relative fluorescence values in the
blank sample and sometimes by a decrease of the net fluorescence.

These

effects were minimized by the addition of 0.16 ml of ethylenediamine to
the alkaline ascorbate solution, which stabilized the solution by delaying the development of the pink color in the alkaline ascorbate solution
for 3 - 4 hours (von Euler and Lishajko, 1961).

These workers also

observed that the net fluorescence values for NE were markedly higher
if transformation of lutines was made with alkaline ascorbate solution
to which ethylenediamine had been added.
in this study (Figure 13) .

Similar results were obtained

The increased fluorescence action of this

reagent is attributed to condensation of the CA with ethylenediamine
(Weil-Malherbe and Bone, 1952).
Since other CA can be extracted and may therefore interfere with
this method, standards were prepared using E, NE and dopamine.

Dopamine

did not fluoresce at the particular wavelength used, but there was some
interference from E as is seen in Figure 14.

According to Udenfriend

(1962), however, there is little or no measurable E in the brain or
heart tissue of the rat.
The relative fluorescence at varying concentrations of NE is shown
in Figure 15.
The reliability of the modified Shore and Olin (1958) NE assay
method was established by performing numerous assays on untreated animals selected at random from those present in the laboratory.

The

results were then compared with accepted literature values and appear
in Table X.

The data for brain and heart NE fall within an accepted

range and are consistent throughout the study.
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Udenfriend (1962) reported an average of 0.44 ug/g of NE in wet
brain tissue of rats.

Other investigators, including Maynert and

Klingman, 1961; Merrills, 1962; Anton and Sayre, 1964 and Grabarits and
Harvey, 1966, reported similar values.

In this study, the modified

Shore and Olin (1958) NE assay method gave values that were approximately
half those reported by the other workers.

Nevertheless, other authors,

those listed in Table X, all using the Shore and Olin (1958) method or
a modification of it, reported values similar to those seen in this
report.

The heart NE values were similar to those reported by Udenfriend

(1962) and others.
2.

Dose-Response Studies
The purpose of this experiment was to determine what dose of re-

serpine would effect a 50% depletion of brain NE and what dose of guanethidine would effect a 50% depletion of heart NE.

These two doses, as

determined here, were then used in the chronic restraint studies.
The results obtained from these experiments show that reserpine
(Figure 16) exhibited a typical dose-response relation to the NE concentration in the rat brain, when given over a suitable range, and that
guanethidine (Figure 17) has a similar effect on the NE concentration
in rat heart.

The results are summarized in Table XI.

Reserpine had a gradual, depleting effect on brain NE and exerted
a maximal or near-maximal effect when given at a dose of 1.0 mg/kg.
However, the effect of reserpine on heart NE showed near-maximal depletion following the administration of 0.05 mg/kg and larger doses exhibited no significantly greater effect.
Since this phase of the study was done to determine which dose of
reserpine gave a 50% depletion of brain NE, and since 1.0 mg/kg showed
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a near-maximal effect, only the data from rats given the first three

doses of reserpine, and from rats given the
the dose-response curve.

vehici~

were used to plot

Figure 16 shows that the dose of reserpine

causing a 50% depletion of brain NE was calculated to be 0.19 mg/kg;
therefore, a reserpine dose of 0.2 mg/kg was used throughout the
chronic restraint phase of the study.
The results in Table XI show that increasing amounts of guanethidine,
up to 5 mg/kg, led to progressively greater decrease in heart NE.

How-

ever, when 10 mg/kg of guanethidine were administered, the decrease
obtained was about the same as that from only 5 mg/kg.
Guanethidine showed no depletion of brain NE at any dose tested.
At the 0.5 mg/kg dose level, however, guanethidine effected a slight
increase in brain NE and this value was significantly different from
the control values (P< 0.05), whereas none of the other doses altered
brain NE.

It is difficult to draw any significance from this finding

and it may well be an artifact.

Inasmuch as the action of guanethidine

on cardiac NE was the principal aim of the study, and since the increase
in brain NE was not related to the investigation, the finding was not
followed up at this time.
As with reserpine, the data from rats given the first three doses
of guanethidine, and from rats given the vehicle, were used to plot the
dose-response curve.

The dose of guanethidine effecting a 50% depletion

of cardiac NE was 1.20 mg/kg (Figure 17).

This dose was used throughout

the chronic restraint phase of the study.
The method of least squares was used to plot the dose-response
curve for both drugs (Snedecor, p. 124, 1956), with the aid of an IBM
360 computer.
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3.

Chronic Restraint Studies
Brain and heart NE was calculated and fluctuations were noted.

NE

is released from neurons at accelerated rates by stimuli (Glowinski and
Baldessarini, 1957) and its decline after pharmacological inhibition of
its biosynthesis is dependent on the presence of adequate stimuli
(Hillarp et al., 1966b).

In some instances its concentration

in brain

(Maynert and Levi, 1963) and in heart (Chang and Su, 1967) has been
reported to be lowered by stress.
Comparative determinations for brain NE are presented in Table XII
and Figure 18.

There does not appear to be a significant change in

brain NE in vehicle and guanethidine control rats.

Reserpine control

animals showed a progressive decline in brain NE from day 1 to day 24.
Vehicle-treated, stressed animals showed a decline in brain NE on day 3,
followed by a gradual increase.

The guanethidine-treated, stressed ani-

mals also showed an increase in brain NE on day 1 and then a significant
decrease on day 3, followed by a gradual increase on days 6 and 12 and
then a decline again on day 24 .

The reserpine-treated, stressed animals

showed a significant decrease in brain NE on day l; it decreased even
further on the consecutive days of study.
Usually brain NE is resistant to decline, even under conditions of
a highly intensified stimulus (Paulsen and Hess, 1963); in some circumstances, a stressor, which under certain circumstances or in different
degrees might have reduced NE, may actually raise it (Welch and Welch,
1968) .

This resistance to reduction of brain NE was noted in these

studies, especially in the vehicle- and guanethidine-treated, stressed
animals.
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The exact mechanism whereby stress causes the release of brain NE
is unknown (Maynert and Levi, 1964); however, Welch and Welch (1968)
postulated a mechanism to explain the rapid elevation of brain NE that
may be induced by stress.

They suggested that a mechanism is activated

which conserves NE by inhibiting its normal intraneuronal catabolism
concurrent with the increased requirement for it to maintain neurotransmission.
A statistical comparison of the heart NE values is
Table XIII and Figure 19.

presented in

Heart NE was lower on day 6, as compared to

the other animals in the vehicle-treated, control group.

Guanethidine-

treated, control animals showed a significant decrease on day 1, and a
further significant decline on the following days.

Reserp i ne-treated,

control animals showed almost no cardiac NE from day 1, and it fell
even lower as the experiment progressed.

Vehicle-treated, stressed

animals showed a low level of NE on day 1, compared either with the
vehicle-treated, control animals or to day 0.

This level fell even

further by day 6; however, the values on day 12 compared favorably to
those of vehicle-treated, control animals and to those of non-treated
animals on day O.
animals.

By day 24, the heart NE rose even higher in these

The guanethidine-treated, stressed animals showed a signifi-

cant decrease in heart NE on day l; it fell even lower by day 3, but
by day 12, it returned to values comparable to those on day 1 .

Reser-

pine-treated, stressed animals had values comparable to those of the
reserpine-treated, control animals.

Control brain and heart NE was

fairly stable throughout the experiment.
Chang and Su (1967) demonstrated that increased sympathetic activities in the rat heart, induced by exposure to cold, primarily release
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NE.

Others (Leduc, 1961; Feller and Hales, 1964) postulated that the

increased excretion of CA during exposure of animals to cold stress
might indicate a gre~t~f~ activity of the sympathoadrenal system.
4.

Adaptation Studies
Along with behavioral adaptation, there also appeared to be a

neurohumoral adaptation.

The problem in analyzing these results was

the fact that the brain NE of stressed rats was not significantly
different from control rats, except for day 1..

Some correlation can

be seen among the differences between these two groups of animals and
their heart NE.

The decrease in brain NE, shown in Figure 22 corre-

sponds fairly well to the general activity of the stressed animals
during the first week of the study. The significant decrease in heart
NE during this period is perhaps an indication of increased sympathetic
activity and non-adaptation at this stage of the study.

Graham (1966)

obtained increased E and NE excretion rates in restrained rats and
suggested that the stress of physical restraint caused marked increases
in both adrenomedullary and neurogenic sympathetic activity.
The importance of a possible correlation between behavioral
adaptation and brain and heart NE is not to be denied, although it is
difficult to quantify the behavioral parameters studied here.

The fact

that stress brought about a decrease in brain NE at first and then an
increase on day 12 appeared to associate this amine with the behavioral
activity associated with this group of animals.

Guanethidine-treated,

stressed animals demonstrated an intermediate behavioral effect as compared with vehicle-treated, stressed animals (exhausted) and reserpinetreated, stressed animals (hyperactive), upon their release from restraint.

In the guanethidine-treated, stressed animals, the heart NE
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was identical with the vehicle-treated, stressed animals but not to the
guanethidine-treated, control animals.

There appeared to be no deple-

tion of the heart NE due to the action of guanethidine.

This effect

may be due to the ability of the stress situation to stimulate the
drug's metabolism by mediating a rapid induction of the liver microsomal
enzymes responsible for its metabolism (Driever and Bousquet, 1965).
Reserpine treatment led to dissimilar response effects on heart NE.

The

deviation may be due to the fact that reserpine action is seen long
after there are no traces of the drug.

This evidence also suggests that

these two drugs do not deplete heart NE by the same mechanism.

J.

General Discussion
There were no deaths attributable to the experimental design in any

of the control groups (vehicle or drug-treated).

That no deaths were

noted in the vehicle-treated, stressed rats in the 24-day study indicated that the animals adapted to this procedure.

Similarly, the one

death in the guanethidine-treated, stressed group also indicated adaptation in this group of animals.

The mortality of the reserpine-treated,

stressed rats was very high; 40% in 24 days clearly indicated the inability of reserpinized animals to adapt to the chronic, forced restraint
stress (Table XIV).
Other investigators, using other forms of stress, reported a high
mortality in reserpinized animals.

Rosecrans and DeFeo (1965), using

restraint for three hours, reported 50% mortality in reserpinized rats.
They stated that the high mortality may have resulted in part from starvation (they noted a decreased food and water intake); but starvation
does not appear to be the answer, since in this study and in others
(See page 124) the animals ate all the food offered to them.

Buckley
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et al. (1964), using flashing lights, autogenic stimulation, and cage
oscillation stressors, showed that reserpine not only failed to protect
the rats from chronic stress but potentiated the lethal effect of the
stressors .

The mortality of reserpine-treated animals under stress was

over 200% at the end of 27 weeks .

They concluded that under prolonged

chronic stress the reserpine produced a potentiating or an additive
effect on the pituitary-adrenal response to stress, thus producing
adrenal insuff i ciency that l ed to t he death of t he animals .

Westermann

et al . (1962) stated that failure of rats to respond to stressful stimuli after large doses of reserpine m·i .ght be attributed partly to a
pituitary-adrenal system which is already under maximal stimulation and
partly due to exhaustion of the pi tuitary ACTH.

If the animals were

then exposed to cold, the plasma corticosterone did not rise further
(Maickel et al . , 1961) and the inability of the animal to respond to
cold-exposure was reflected in a higher death rate, resulting from the
stress .

Other investigators (Leduc, 1961; Johnson, 1963) suggested

that failing NE excretion in animals exposed to cold could be due to
the inhibition of NE synthesis by reserpine despite the report by
McDonald and Weise (1961), who demonstrated that reserpine does not
alter the biosynthesis of CA.

Johnson (1966) reported that survival

of cold-exposed animals appeared to be related to the liberation of
NE, with E release serving as an important secondary mechanism of
defense against cold .
Pouliot (1966) stated that a drug should be free of central effects
if the correlation between NE secretion from peripheral tissue stores
of CA and resistance to cold stress is to be considered.

He employed

guanethidine, whose act i on is largely peripheral and without effect on
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brain NE, in adrenodemedullated rats, all of which died when exposed to
cold stress. The failure of the guanethidine-treated rats to increase
their NE excretion led him to conclude that guanethidine prevents either
the increase in release or the biosynthesis of NE, or both, normally
induced by cold exposure.

He also concluded that the sympathetic block-

ade by guanethidine could be partly responsible for the lack of acceleration of CA liberation.

His results corroborated those of previous

investigators who showed that cold resistance is dependent upon the
liberation and action of NE.
Since non-adaptation may be associated with the inhibition of some
physiological mechanism, it would be interesting to speculate on the
relationship between apparent exhaustion of central and peripheral NE
with non-adaptation.

Many data are available in the literature to

suggest that NE plays an important role in enabling animals to respond
to pituitary-adrenal stimulation induced by environmental stress.

Ani-

mals without a functioning peripheral sympathetic nervous system would
not be able to adapt to a chronic stress, even though the pituitaryadrenal system might be functioning normally (Rosecrans and DeFeo,

1965).
It is not possible to correlate completely non-adaptation in
reserpinized, stressed animals and CA depletion.

In Figure 23, the

heart NE patterns are similar to those in the brain; hence, the depletion of peripheral NE alone does not explain the toxicity in the stressed,
reserpinized rats.

Further, the heart NE is virtually the same in the

stressed, reserpinized rats as in the nonstressed, reserpinized rats.
Guanethidine and its principal action on peripheral NE also offers no
clue to the cause of death in reserpinized, stressed rats because here

155
the heart picture and mortality are different and no correlation can be
seen.

However, when speculations on the increased toxicity in reserpin-

ized, stressed rats are set forth, it should be kept in mind that reserpine affects both peripheral and central CA and indolamines and that it
produces marked sedation, whereas, guanethidine affects only peripheral
CA and at the low dose used here it probably does not affect the CA in
the adrenal medulla.

Pouliot (1966) suggested the dependency of sur-

vival of cold-stressed adrenodemedullated animals upon a peripheral
secretion of NE, Bygdeman

~

al. (1960) reported an acceleration of CA

synthesis in the adrenal medulla following an increased nervous stimulation and Pouliot (1966) assumed that the same mechanism occurs in
noradrenergic fibers.

The work of Leduc (1961) also suggests increased

synthesis of NE occurs as a result of increased nervous activity.
The rats in the present study were not demedullated; hence, the
guanethidine-treated animals were able to respond to the stress and
adapt perhaps by increased NE synthesis .

The stress seemed to override

the NE-depleting action of guanethidine (Figure 22).

Since reserpine

affects total CA content in the rat, then, in a sense, they were chemically demedullated and could not adapt to the stress by increasing their
NE content.

However, it is not certain that the increased toxicity in

reserpinized, stressed rats was due solely to CA depletion per se, either
central or peripheral.

That CA play an important role in adaptation can

be seen from the work of Necinu and Kregei (1961), who observed that the
usual peptic ulcer produced by reserpine and cold stress could be completely inhibited by the administration of DOPA, a NE precursor, and that
the usual 50% mortality produced by cold stress was prevented by DOPA in
reserpinized rats .
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The decrease in central sympathetic outflow in reserpine-treated
animals (McCubbin and Page, 1958) may also be an important
\

non-adaptation with these animals.

fac~or

in

However, numerous other parameters

(mentioned both by other investigators and throughout this report) may
also come into play, and CA depletion is but one factor in the total
picture of adaptation and reserpine toxicity.
The work of Welch and Welch (1968) should also be kept in mind,
when attempts are made to correlate stress and CA depletion,

They state

that during stress, mice , which differ in behavioral reactivity because
of differences in their previous environmental conditions, metabolize
brain biogenic amines at different rates and also activate to different
degrees temporal mechanisms which control the availability of the amine
during stress ,
Neurochemical adaptation which appears to parallel behavioral
adaptation for the most part has been characterized in normal drugtreated rats ,

The increased behavioral activity associated with the

initiation of restraint followed the changes in brain NE and it tended
to return to normal when behavioral adaptation occurred ,

Serum corti-

costerone also appeared to be a good index of behavioral adaptation,
The results from previous investigations support the validity of these
observations.

Pfeifer and Galarnbos (1967) suggested that NE has a

more important role in the change of susceptibility to seiz4res than
serotonin or dopamine,

·smith (1963) showed that enhancement of the

activity-increasing effect of d-amphetamine after alpha-methyl dopa
followed changes in brain NE more closely than changes in either brain
serotonin or dopamine.

Mayner t and Klingman (1962) discussed the possi-

bility that brain NE functions as part of the sympathetic nervous system
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and that its release is accompanied by arousal or excitement,
Grundfest (1957), summarizing research from previous years, concluded that central nervous transmission is accomplished via neurochemicals.
He was unable to demonstrate electrically excitable central dendrites.
Rothboller (1959) and Brodie and Shore (1957) contended that changes in
brain NE represent fluctuations of excitatory activity initiated by an
adrenergic system.

Rosecrans (1963) and Guarino et al. (1967) also

showed that NE was associated with increased CNS excitation .
It should be pointed out again that reserpinized, stressed animals
demonstrated abnormal behavior after release from restraint, although
they were quiet while under restraint, an important observation because
it cannot be concluded that stress inhibited the reserpine-induced sedation.

At the same time, reserpine produces chemical sympathectomy

(Trendelenburg, 196la), a fact that may account for the decreased activity in these rats under restraint.

Reserpine may be stimulating the

excitatory brain mechanisms that are controlled by NE, since restraint
caused variations in NE and overt activity was noted when brain NE was
decreased .

Reserpine also, by producing its exhaustive depletion of

the central sites of NE, may have produced a central hypersensitivity
similar to nerve postsynaptic hypersensitivity following denervation.
Such an apparent hypersensitivity may be responsible for the behavioral
excitation observed in reserpinized, stressed rats (Rosecrans, 1963).
The ability of reserpine to prevent adaptation was again demonstrated
beyond doubt.

The means by which it was accomplished, however, are de-

batable, for it should be remembered that reserpine has important depleting effects on both brain CA and indolamines (Sheppard and Zimmerman,
1960a).

The guanethidine-treated, stressed animals appeared to adapt
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to the stress, and their behavioral pattern, similar to the vehicletreated, stressed animals, also indicates that perhaps NE plays a role
in behavior patterns.

VI.
A.

SUMMARY AND CONCLUSIONS

A modification of the Shore and Olin (1958) method for the extraction

of tissue NE has been described, which was applied to the routine estimation of brain and heart amines of rats subjected to restraint and
treated with guanethidine or reserpine.
B.

Serum corticosterone was estimated by the method of Guillemin et

~·

(1959a) and AAA was estimated by the method of Maickel (1960).
C.

Dose-response studies were carried out over a period of six days,

to establish what dose of reserpine would effect a 50% depletion of
central CA and what dose of guanethidine would effect a 50% depletion
of peripheral CA.
D.

The dose of reserpine (0.2 mg/kg, i.p.) and of guanethidine

(l.20 mg/kg, i.p.), established in the dose-response studies were used
throughout the chronic (24 day) phase of the study.
1.

Reserpinized, control animals gave adrenalcortical responses

similar to those of the stressed animals.

That reserpinized, stressed

rats failed to adapt to the stress was indicated by the high mortality,
40% in 24 days.

Starvation was eliminated as a causative factor in the

increased mortality, since all animals ate all of the food offered to
them.

The high mortality could not be attributed either to the peri-

pheral depletion or to the central depletion of CA per se, since
reserpine depletes both areas of their CA.

There was some evidence to

indicate that depletion of both central and petipheral CA may account
in some degree for the increased mortality.

A mechanism is postulated

to explain why reserpine prevented adaptation.
noted between the brain NE levels and behavior.
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Some correlation was
The abnormal behavior
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noted in the reserpinized, stressed rats may have been due to the
depletion of brain NE.
2.

Guanethidine also produced adrenalcortical responses similar

to those evoked by restraint; however, the responses were not as great.
All values tended to return to normal by day 6, except heart NE which
showed a continuous depletion until day 12 and then a gradual return
toward normal.

The guanethidine-treated, stressed rats showed the

characteristic adrenalcortical responses:

increased adrenal weight;

increased serum corticosterone; and decreased AAA.

The stress appeared

to overcome the peripheral NE depletion caused by guanethidine and
values started to return to normal by day 12.

This may have been the

result of increased syntheses of CA, particularly from the adrenal
medulla, since it has been reported that low doses of guanethidine do
not affect adrenal E and NE.

This may also account for the adaptation

of these animals to restraint, since there was only 10% mortality.
These animals displayed behavioral patterns similar to those of the
vehicle-treated, stressed animals; their brain NE patterns were also
similar.
E.

Evidence is presented indicating that reserpine and guanethidine

affect CA by different mechanisms.
F.

Adaptation to CRS was demonstrated by organ weight changes and by

the analyses of the interrelationship among serum corticosterone, AAA,
brain and heart NE.

After an initial AR, all of the parameters measured

tended to return to control levels:
adaptation.

an indication of physiological

The pituitary-adrenal system was apparently active through-

out the period of chronic stress.

Control animals, subjected to stress,

exhibited some degree of behavioral adaptation, passing from an extreme
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degree of excitability at the initiation of the stress to a moderate
degree of docility when released from it .

Brain NE showed an initial

decrease, followed by an increase on day 12.
to normal also by day 12.

Heart NE tended to return

The vehicle-treated, control animals showed

some indication of pituitary-adrenal stimulation which was due probably
to the handling and to the injection procedure .
Non-adaptation of rats subjected to chronic

' res~raint

may be due

at least in part to exhaustion of both central and peripheral NE since
the reserpine-treated, stressed animals showed an increased mortality
(40%) in 24 days and the guanethidine-treated, stressed animals had 10%
mortality over the same time period .

The results from this study sug-

gest the possible significance of the sympathetic division of the ANS
and adrenal CA in adaptation of the animals to chronic stress .

VIII.
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TABLE XXIII
THE EFFECT OF RESTRAINT ON MEAN DAILY BODY WEIGHT OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Control Animals
Days of
Treatment
1

Restrained Animals

11

Vehicle
215 + l 7a
(10)0

Guanethidine

Reser ine

Vehicle

Guanethidine

Reser ine

218 + 25
(10)

230 + 24
(10)

209 + 22
(10)

212 + 14
(10)

208 + 17
(10)-C

2

222 + 20
(10)

222 + 25
(10)

231 + 24
(10)

207 + 23
(10)

217 + 14
(10)

212 + 16
(10)-C

3

222 + 21
(10)

227 + 23
(10)

235 + 23
(10)

207 + 21
(10)

214 + 15
(10)

209 + 17
(10)-C

4

226 + 20
(10)

227 + 24
(10)

237 + 21
(10)

206 + 21
(10)-AC

214 + 14
(10)

207 + 17
(10)-AC

5

233 + 23
(10)

232 + 25
(10)

240 + 23
(10)

206 + 22
(10)-A

211 + 16
(10)-AB

206 + 17
(10)-AC

6

235 + 22
(10)

233 + 23
(10)

238 + 23
(10)

201 + 21
(10)-A

213 + 14
(10)-AB

202 + 18
(10)-AC

7

235 + 22
(10)

235 + 23
(10)

238 + 22
(10)

203 + 23
(10)-A

212 + 14
(10)-AB

198 + 17
(10)-AC

8

238 + 20
(10)

239 + 23
(10)

237 + 23
(10)

201 + 20
(10)-A

211 + 17
(10)-AB

196 + 19
(9) AC

9

242 + 21
(10)

241 + 22
(10)

238 + 23
(10)

204 + 22
(10)-A

211 + 18
(10)-AB

198 + 24
(9) AC

,.....
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TABLE XX.III - continued
Control Animals
Days of
Treatment

II

Restrained Animals

Vehicle

Guanethidine

Reser ine

Vehicle

10

242 + 20
(10)

242 + 23
(10)

240 + 25
(10)

205 + 23
(10)-A

213 + 16
(10)-AB

196 + 23
(9) AC

11

247 + 22
(10)~

247 + 24
(10)

243 + 26
(10)

205 + 20
(10)-A

215 + 20
(10)-AB

203 + 21
(9) AC

12

248 + 20
(10)

247 +
- 23
(10)

237 + 26
(10)

206 + 20
(10)-A

213 + 17
(10)-AB

196 + 22
(9) AC

13

248 + 18
(10)

246 +
- 27
(10)

239 + 24
(10)

204 + 19
(10)-A

212 + 18
(10)-AB

193 + 23
(9) AC

14

255 + 20
(9)

249 + 23
(10)

240 + 26
(10)

204 + 22
(10)-A

212 + 21
(10)-AB

195 + 30
(9) AC

15

256 + 20
(9)

251 + 23
(10)

241 + 26
(10)

203 + 20
(lO)A

211 + 19
(10) AB

193 + 32
(9) AC

16

260 + 20
(9)

251 + 24
(10)

242 + 25
(10)

203 + 16
(10)-A

212 + 19
(10)-AB

201 + 28
(8) AC

17

258 + 20
(9)

253 + 23
(10)

241 + 20
(10)

202 + 17
(10)-A

209 + 18
(10)-AB

197 + 32
(8) AC

18

260 + 22
(9)

254 + 24
(10)

242 + 22
(10)

202 + 18
(10)-A

210 + 20
(10)-AB

197 + 32
(8) AC

19

262 + 21
(9)

254 + 24
(10)

243 + 25
(10)

202 + 18
(10)-A

207 + 20
(10)-AB

202 + 33
(7) AC

Guanethidine

Reser ine

t-'

°'
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TABLE XX.III - continued

II

Control Animals
Days of
Treatment

a:
b:
c:

Vehicle

Restrained Animals

Guanethidine

Reser ine

Vehicle

Guanethidine

Reser i e

20

262 + 22
(9)

254 + 23
(10)

242 + 24
(10)

201 + 20
(10)-A

205 + 22
(10)-AB

194 + 32
(7) AC

21

264 -+ 24
(9)

258 + 25
(10)

243 +
- 26
(10)

202 + 17
(10)-A

208 + 23
(10)-AB

201 + 33
(7) AC

22

266 + 23
(9)

256 + 25
(10)

244 + 34
(10)

205 + 20
(10)-A

213 +
- 18
(9) AB

194 + 39
(7) AC

23

265 + 26
(9)

259 + 26
(10)

245 + 38
(10)

205 + 18
(10)-A

213 + 19
(9) AB

200 + 39
(7) AC

24

268 + 25
(9)

262 + 26
(10)

247 + 31
(10)

204 + 18
(10)-A

215 + 19
(9) AB

215 + 21
(6) AC

mean± S.E., daily weights (grams).
number of rats.
statistical comparison at probability, P< O. 05.

A - significantly different from vehicle-control group.
B - significantly different from guanethidine-control group.
C - significantly different from reserpine-control group.
Drug doses, (i.p.) daily for 24 days: Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.

I-'

0\
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TABLE XXIV
THE EFFECT OF RESTRAINT ON RELATIVE ADRENAL WEIGHT OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Control Animals
Days of
Treatment
1

a:
b:
c:
A
B
C
D

Restrained Animals

II

Vehicle
0.011 + o.001a
(lO)b

Guanethidine
o. 011 + o. 001
(10)

Reser ine
0.011+0.001
(10)

Vehicle
0.011 + 0.001
(9)

Guanethidine
0.011 + 0,001
(10)

Reser ine
0.011 + 0.001
(10)

3

0.011 + 0.001
(10)

o. 011 + o. 000
(10)

0.012 + 0.001
(10)

0.012 + 0.001
(10)

0.012 + 0.001
(10)

0.014 + 0.001
(9) ABDc

6

0.008 + 0.001
(10)

0.007 + 0.001
(10)

0.008 + 0.001
(10)

o. 010 + o. 001
(10) A

0.012 + 0.001
(10) AC

0.011 + 0.001
(10) AD

12

0.010 + 0.001
(10)

o. 011 + o. 000
(10)

0.011 + 0.001
(10)

0.016 + 0.001
(10) A

0.017 + 0.001
(9)
AC

0.016 + 0.001
(9)
AD

24

o. 011 + o. 001
(10)

0.009 + 0.001
(10)

0.010 + 0.001
(10)

0.015 + 0.001
(10) A

0.015 + 0.002
(9)
c

0.016 + 0.002
(6)
A

mean± S.E. (g/100 g of body weight)
number of rats
statistical comparison at probability, P<0.05.
-

significantly
significantly
significantly
significantly

different
different
different
different

from
from
from
from

vehicle-control group.
vehicle-restrained group.
guanethidine-control group,
reserpine-control group.

Drug doses (i.p.) daily: Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0.2 mg/kg.

t-'

°'
°'

TABLE XXV
THE EFFECT OF RESTRAINT ON RELATIVE HEART WEIGHT OF
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Control Ani mals
Days of
Treatment

Restrained Animals

II
Vehicle

Guanethidine

Reser ine

. 004

0 . 314 + . 007
(10)

0.306 + .007
(10) BC

0.309 + .005
(10)

0.357 + .011
(10)
A

0.339 + .007
(10)
c

0.334 + .005
(9)
D

0.324 + .005
(10)

0.343 + . 006
(10) A

0.358 + .007
(10)
A

0.351 + .011
(10)
AC

0 . 347 + .006
(10) A

0.329 + . 014
(10)

0.301 + .005
(10)

0 . 335 + .005
(10)

0.374 + .011
(10)
A

0.372 + .010
(9)
AC

0. 350 + . 006
(9)

0 . 305 + .010
(10)

0.276 + .003
(10)
A

0 . 309 + . 007
(10)

0 . 323 + .006
(10)

0.314 + .005
(9)
c

o. 3-20

Vehicle
0.322 + .008a
(lO)b -

Guanethidine

Reser ine

0.316 + .006
(10)

0.308 + .009
(10)

o. 324 +(9)

3

0 . 325 + . 006
(10)

0.316 + ,002
(10)

6

0.319 + .004
(10)

12
24

1

mean + S.E. (g/100 g of body weight)
number of rats
statistical comparison at probability, P < 0. 05

a:
b:
c:
A
B
C
D

+ . 006

(6)

-

significantly
significantly
significantly
significantly

different
different
different
different

from
from
from
from

vehicle-control group.
vehicle-restrained group.
guanethidine-control group.
reserpine-control group.

Drug doses; (i.p.) daily : Guanethi dine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.

Reserpine, 0 . 2 mg/kg.
I-'

°'
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TABLE XXVI
THE EFFECT OF RESTRAINT ON RELATIVE BRAIN WEIGHT OF MALE
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE
Restrained Animals

II

Control Animals
Days of
Treatment

Guanethid i ne

Reserpine

Vehicle

Guanethidine

Reserpine

1

Vehicle
a
0 . 838 + .025
(1o)b -

0.822 + . 016
(10)

0 . 831 + .012
(10)

0.820 -+ .019
(9)

0.839 + .024
(10)

0.834 + .028
(10)

3

0.813 + .027
(10)

0.806 + .026
(10)

0.802 + .028
(10)

0. 784 + . 023
(10)

0 . 793 + .019
(10)

o. 792 + .024
(9)

6

0 . 740 + .018
(10)

o. 744 + .017
(10)

0 . 799 + .020
(10) -Ac

0.824 + . 015
-A
(10)

0.801 + . 027
(10)

0.827 + .015
(10)
A

12

0 . 672 + .022
(10)

0.698 + .015
(10)

0 . 757 + .024
(10)
A

0 . 847 + .029
(10)
A

o. 802 + . 022
(9)
AC

0.883 + .028
(9)
AD

24

0.643 + .025
(10)

0.641 + .022
(10)

0.663 + .016
(10)

0. 783 + . 018
(10)
A

0.771 + .025
(9)
AC

0.743 + . 048
(6)

a:
b:
c:

mean + S.E. (g/100 g of body weight)
number of rats
statistical comparison at probability, P <o . 05.

A - significantly different from vehicle-control group.
C - significantly different from guanethidine-control group .
D - significantly different from reserpine-control group.
Drug doses, (i . p.) daily: Guanethidine, 1.20 mg/kg.
Vehicle, glass-distilled water, 1 ml/kg.
/

Reserpine, 0.2 mg/kg.
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